

**Participant Summary**  
**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE								NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH				
001 ALAN AMINO	ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 20 %										
2024-001	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	379.000	13.551	3.58	303.000	455.000				
2024-001	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	91	395.852	9.966	2.52	317.000	475.000				
2024-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	370.737	15.382	4.15	297.000	445.000				
2024-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	30	334.833	13.294	3.97	268.000	402.000				
2024-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	417.606	42.043	10.07	334.000	501.000				
2024-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	377.171	13.690	3.63	302.000	453.000				
2024-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	430.571	13.119	3.05	344.000	517.000				
2024-001	12 IFCC witho	203 ROCHE	93 ROCHE	12	377.500	23.164	6.14	302.000	453.000				
2024-001	13 ALA &aKETO	165 VITROS	155 ALTV	129	360.260	10.739	2.98	288.000	432.000				
2024-002	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	16.667	1.643	9.86	13.000	20.000				
2024-002	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	91	21.253	2.457	11.56	17.000	26.000				
2024-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	15.053	1.146	7.61	12.000	18.000				
2024-002	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	30	15.000	1.017	6.78	12.000	18.000				
2024-002	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	19.242	2.147	11.16	15.000	23.000				
2024-002	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	15.610	1.286	8.24	12.000	19.000				
2024-002	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	20.357	1.674	8.22	16.000	24.000				
2024-002	12 IFCC witho	203 ROCHE	93 ROCHE	12	15.833	0.898	5.67	13.000	19.000				
2024-002	13 ALA &aKETO	165 VITROS	155 ALTV	129	15.713	0.882	5.61	13.000	19.000				
2024-003	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	141.667	5.947	4.20	113.000	170.000				
2024-003	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	91	153.789	4.189	2.72	123.000	185.000				
2024-003	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	140.316	4.921	3.51	112.000	168.000				
2024-003	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	30	127.000	4.412	3.47	102.000	152.000				
2024-003	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	161.788	11.294	6.98	129.000	194.000				
2024-003	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	142.300	4.931	3.46	114.000	171.000				
2024-003	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	166.143	4.734	2.85	133.000	199.000				
2024-003	12 IFCC witho	203 ROCHE	93 ROCHE	12	143.250	6.405	4.47	115.000	172.000				
2024-003	13 ALA &aKETO	165 VITROS	155 ALTV	129	144.563	4.364	3.02	116.000	173.000				

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
001	ALAN AMINO ALT/SGPT	CLIA TEST ID #: 255	EVALUATION CRITERIA: TARGET VALUE 20 %									
2024-004	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	265.000	10.095	3.81	212.000	318.000			
2024-004	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	91	279.337	8.035	2.88	223.000	335.000			
2024-004	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	256.947	10.546	4.10	206.000	308.000			
2024-004	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	30	234.700	9.781	4.17	188.000	282.000			
2024-004	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	298.606	21.236	7.11	239.000	358.000			
2024-004	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	264.390	10.345	3.91	212.000	317.000			
2024-004	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	307.308	4.321	1.41	246.000	369.000			
2024-004	12 IFCC witho	203 ROCHE	93 ROCHE	12	263.917	13.684	5.18	211.000	317.000			
2024-004	13 ALA &aKETO	165 VITROS	155 ALTV	129	256.188	7.002	2.73	205.000	307.000			
2024-005	5 ENZ. 37 C	197 ARCHITECT	1 ABBOTT	21	122.524	5.509	4.50	98.000	147.000			
2024-005	11 MOD. IFCC	38 SIEMENS DI	143 SIEMENS	91	133.633	3.900	2.92	107.000	160.000			
2024-005	11 MOD. IFCC	184 INTEGRA	93 ROCHE	19	120.500	2.544	2.11	96.000	145.000			
2024-005	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	30	109.655	3.335	3.04	88.000	132.000			
2024-005	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	140.094	7.108	5.07	112.000	168.000			
2024-005	11 MOD. IFCC	203 ROCHE	93 ROCHE	41	123.488	4.559	3.69	99.000	148.000			
2024-005	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	144.077	1.817	1.26	115.000	173.000			
2024-005	12 IFCC witho	203 ROCHE	93 ROCHE	12	124.167	7.723	6.22	99.000	149.000			
2024-005	13 ALA &aKETO	165 VITROS	155 ALTV	129	125.558	3.982	3.17	100.000	151.000			
002	ALBUMIN	CLIA TEST ID #: 265	EVALUATION CRITERIA: TARGET VALUE 10 %									
2024-001	3 DYE BI-B.G	165 VITROS	63 KODAK	143	5.539	0.181	3.26	5.000	6.100			
2024-001	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	29	5.117	0.176	3.45	4.600	5.600			
2024-001	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	31	5.033	0.140	2.78	4.500	5.500			
2024-001	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	33	5.018	0.177	3.52	4.500	5.500			
2024-001	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	13	4.962	0.127	2.57	4.500	5.500			
2024-001	3 DYE BI-B.G	203 ROCHE	93 ROCHE	52	5.196	0.176	3.39	4.700	5.700			
2024-001	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	12	5.150	0.138	2.69	4.600	5.700			
2024-001	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	95	4.824	0.160	3.32	4.300	5.300			
2024-001	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT	11	4.973	0.121	2.44	4.500	5.500			

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
002	ALBUMIN	CLIA TEST ID #: 265		EVALUATION CRITERIA: TARGET VALUE 10 %								
2024-002	3	DYE BI-B.G	165 VITROS	63	KODAK	143	1.806	0.055	3.03	1.600	2.000	
2024-002	3	DYE BI-B.G	184 INTEGRA	93	ROCHE	29	1.986	0.112	5.66	1.800	2.200	
2024-002	3	DYE BI-B.G	186 BECK. COUL	76	AU-BECKMAN	31	1.897	0.040	2.11	1.700	2.100	
2024-002	3	DYE BI-B.G	191 RX-SERIES	126	RANDOX	33	1.944	0.066	3.39	1.700	2.100	
2024-002	3	DYE BI-B.G	197 ARCHITECT	1	ABBOTT	13	1.800	0.078	4.36	1.600	2.000	
2024-002	3	DYE BI-B.G	203 ROCHE	93	ROCHE	52	2.025	0.098	4.83	1.800	2.200	
2024-002	3	DYE BI-B.G	219 ATELLICA	143	SIEMENS	12	1.892	0.064	3.38	1.700	2.100	
2024-002	4	DYE BI-B.P	38 SIEMENS DI	143	SIEMENS	95	1.602	0.079	4.96	1.400	1.800	
2024-002	5	DYE B-HABA	197 ARCHITECT	1	ABBOTT	11	1.791	0.051	2.87	1.600	2.000	
2024-003	3	DYE BI-B.G	165 VITROS	63	KODAK	143	3.065	0.100	3.27	2.800	3.400	
2024-003	3	DYE BI-B.G	184 INTEGRA	93	ROCHE	29	3.141	0.107	3.40	2.800	3.500	
2024-003	3	DYE BI-B.G	186 BECK. COUL	76	AU-BECKMAN	31	3.023	0.056	1.85	2.700	3.300	
2024-003	3	DYE BI-B.G	191 RX-SERIES	126	RANDOX	33	3.055	0.110	3.61	2.700	3.400	
2024-003	3	DYE BI-B.G	197 ARCHITECT	1	ABBOTT	13	2.938	0.092	3.14	2.600	3.200	
2024-003	3	DYE BI-B.G	203 ROCHE	93	ROCHE	52	3.184	0.073	2.30	2.900	3.500	
2024-003	3	DYE BI-B.G	219 ATELLICA	143	SIEMENS	12	3.050	0.087	2.84	2.700	3.400	
2024-003	4	DYE BI-B.P	38 SIEMENS DI	143	SIEMENS	95	2.703	0.108	4.00	2.400	3.000	
2024-003	5	DYE B-HABA	197 ARCHITECT	1	ABBOTT	11	2.955	0.066	2.22	2.700	3.300	
2024-004	3	DYE BI-B.G	165 VITROS	63	KODAK	143	4.349	0.144	3.32	3.900	4.800	
2024-004	3	DYE BI-B.G	184 INTEGRA	93	ROCHE	29	4.183	0.172	4.12	3.800	4.600	
2024-004	3	DYE BI-B.G	186 BECK. COUL	76	AU-BECKMAN	31	4.084	0.111	2.72	3.700	4.500	
2024-004	3	DYE BI-B.G	191 RX-SERIES	126	RANDOX	33	4.106	0.112	2.72	3.700	4.500	
2024-004	3	DYE BI-B.G	197 ARCHITECT	1	ABBOTT	13	4.023	0.112	2.78	3.600	4.400	
2024-004	3	DYE BI-B.G	203 ROCHE	93	ROCHE	52	4.273	0.119	2.78	3.800	4.700	
2024-004	3	DYE BI-B.G	219 ATELLICA	143	SIEMENS	12	4.142	0.111	2.69	3.700	4.600	
2024-004	4	DYE BI-B.P	38 SIEMENS DI	143	SIEMENS	95	3.793	0.136	3.59	3.400	4.200	
2024-004	5	DYE B-HABA	197 ARCHITECT	1	ABBOTT	11	4.009	0.100	2.48	3.600	4.400	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE								
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH			
002	ALBUMIN	CLIA TEST ID #: 265	EVALUATION CRITERIA: TARGET VALUE 10 %									
2024-005	3 DYE BI-B.G	165 VITROS	63 KODAK	143	2.889	0.091	3.16	2.600	3.200			
2024-005	3 DYE BI-B.G	184 INTEGRA	93 ROCHE	29	2.993	0.111	3.72	2.700	3.300			
2024-005	3 DYE BI-B.G	186 BECK. COUL	76 AU-BECKMAN	31	2.848	0.071	2.50	2.600	3.100			
2024-005	3 DYE BI-B.G	191 RX-SERIES	126 RANDOX	33	2.888	0.109	3.79	2.600	3.200			
2024-005	3 DYE BI-B.G	197 ARCHITECT	1 ABBOTT	13	2.746	0.101	3.67	2.500	3.000			
2024-005	3 DYE BI-B.G	203 ROCHE	93 ROCHE	52	3.010	0.088	2.93	2.700	3.300			
2024-005	3 DYE BI-B.G	219 ATELLICA	143 SIEMENS	12	2.867	0.062	2.18	2.600	3.200			
2024-005	4 DYE BI-B.P	38 SIEMENS DI	143 SIEMENS	95	2.540	0.102	4.01	2.300	2.800			
2024-005	5 DYE B-HABA	197 ARCHITECT	1 ABBOTT	11	2.782	0.039	1.39	2.500	3.100			
003	ALKALINE PHOSPHATE	CLIA TEST ID #: 275	EVALUATION CRITERIA: TARGET VALUE 30 %									
2024-001	3 COLORIMET.	184 INTEGRA	93 ROCHE	24	358.043	17.211	4.81	251.000	465.000			
2024-001	3 COLORIMET.	203 ROCHE	93 ROCHE	36	356.571	12.350	3.46	250.000	464.000			
2024-001	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	340.545	14.234	4.18	238.000	443.000			
2024-001	6 KINETIC 37	165 VITROS	63 KODAK	143	219.521	12.105	5.51	154.000	285.000			
2024-001	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	31	289.968	34.553	11.92	203.000	377.000			
2024-001	10 IFCC	219 ATELLICA	143 SIEMENS	14	346.286	12.674	3.66	242.000	450.000			
2024-001	11 Modified I	38 SIEMENS DI	143 SIEMENS	88	375.057	14.837	3.96	263.000	488.000			
2024-001	11 Modified I	191 RX-SERIES	126 RANDOX	27	303.296	34.799	11.47	212.000	394.000			
2024-001	11 Modified I	191 RX-SERIES	126 RANDOX	27	370.667	8.260	2.23	259.000	482.000			
2024-001	12 P NITRO PH	197 ARCHITECT	1 ABBOTT	12	330.333	32.461	9.83	231.000	429.000			
2024-002	3 COLORIMET.	184 INTEGRA	93 ROCHE	24	25.609	1.661	6.49	18.000	33.000			
2024-002	3 COLORIMET.	203 ROCHE	93 ROCHE	36	25.556	1.279	5.00	18.000	33.000			
2024-002	5 KINETIC 30	197 ARCHITECT	1 ABBOTT	11	25.000	1.477	5.91	18.000	33.000			
2024-002	6 KINETIC 37	165 VITROS	63 KODAK	143	40.373	2.502	6.20	28.000	52.000			
2024-002	8 BOW. MC-37	186 BECK. COUL	76 AU-BECKMAN	31	19.839	2.384	12.02	14.000	26.000			
2024-002	10 IFCC	219 ATELLICA	143 SIEMENS	14	25.786	1.145	4.44	18.000	34.000			
2024-002	11 Modified I	38 SIEMENS DI	143 SIEMENS	88	25.886	2.979	11.51	18.000	34.000			
2024-002	11 Modified I	191 RX-SERIES	126 RANDOX	27	18.000	10.614	58.97	13.000	23.000			

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	11	Modified I	191	RX-SERIES	126	RANDOX	27	22.667	3.991	17.61	16.000	29.000
2024-002	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	22.917	2.660	11.61	16.000	30.000
003	ALKALINE PHOSPHATE		CLIA TEST ID #: 275				EVALUATION CRITERIA: TARGET VALUE 30 %					
2024-003	3	COLORIMET.	184	INTEGRA	93	ROCHE	24	139.250	6.173	4.43	97.000	181.000
2024-003	3	COLORIMET.	203	ROCHE	93	ROCHE	36	138.278	5.305	3.84	97.000	180.000
2024-003	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	132.909	5.485	4.13	93.000	173.000
2024-003	6	KINETIC 37	165	VITROS	63	KODAK	143	141.482	8.251	5.83	99.000	184.000
2024-003	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	31	111.290	12.877	11.57	78.000	145.000
2024-003	10	IFCC	219	ATELLICA	143	SIEMENS	14	136.786	4.663	3.41	96.000	178.000
2024-003	11	Modified I	38	SIEMENS DI	143	SIEMENS	88	144.920	5.987	4.13	101.000	188.000
2024-003	11	Modified I	191	RX-SERIES	126	RANDOX	27	124.148	12.542	10.10	87.000	161.000
2024-003	11	Modified I	191	RX-SERIES	126	RANDOX	27	142.667	3.859	2.70	100.000	185.000
2024-003	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	124.000	9.840	7.94	87.000	161.000
2024-004	3	COLORIMET.	184	INTEGRA	93	ROCHE	24	251.167	13.449	5.35	176.000	327.000
2024-004	3	COLORIMET.	203	ROCHE	93	ROCHE	36	249.500	9.550	3.83	175.000	324.000
2024-004	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	240.000	8.873	3.70	168.000	312.000
2024-004	6	KINETIC 37	165	VITROS	63	KODAK	143	198.129	11.093	5.60	139.000	258.000
2024-004	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	31	201.677	24.802	12.30	141.000	262.000
2024-004	10	IFCC	219	ATELLICA	143	SIEMENS	14	246.571	8.270	3.35	173.000	321.000
2024-004	11	Modified I	38	SIEMENS DI	143	SIEMENS	88	264.161	11.423	4.32	185.000	343.000
2024-004	11	Modified I	191	RX-SERIES	126	RANDOX	27	262.000	5.354	2.04	183.000	341.000
2024-004	11	Modified I	191	RX-SERIES	126	RANDOX	27	217.407	22.170	10.20	152.000	283.000
2024-004	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	223.167	17.511	7.85	156.000	290.000
2024-005	3	COLORIMET.	184	INTEGRA	93	ROCHE	24	122.333	5.444	4.45	86.000	159.000
2024-005	3	COLORIMET.	203	ROCHE	93	ROCHE	36	121.722	4.640	3.81	85.000	158.000
2024-005	5	KINETIC 30	197	ARCHITECT	1	ABBOTT	11	116.636	3.748	3.21	82.000	152.000
2024-005	6	KINETIC 37	165	VITROS	63	KODAK	143	129.255	7.285	5.64	90.000	168.000
2024-005	8	BOW. MC-37	186	BECK. COUL	76	AU-BECKMAN	31	97.419	10.713	11.00	68.000	127.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	10	IFCC	219	ATELLICA	143	SIEMENS	14	119.214	4.693	3.94	83.000	155.000
2024-005	11	Modified I	38	SIEMENS DI	143	SIEMENS	88	127.218	5.584	4.39	89.000	165.000
2024-005	11	Modified I	191	RX-SERIES	126	RANDOX	27	110.185	12.181	11.05	77.000	143.000
2024-005	11	Modified I	191	RX-SERIES	126	RANDOX	27	122.667	2.494	2.03	86.000	159.000
2024-005	12	P NITRO PH	197	ARCHITECT	1	ABBOTT	12	107.917	8.321	7.71	76.000	140.000
004	AMYLASE		CLIA TEST ID #: 285			EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-001	3	ENZYM. 37C	165	VITROS	63	KODAK	83	173.878	7.157	4.12	122.000	226.000
2024-001	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	264.115	6.727	2.55	185.000	343.000
2024-001	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	262.250	2.586	0.99	184.000	341.000
2024-001	9	ENZ/COL.37	184	INTEGRA	93	ROCHE	10	254.000	9.633	3.79	178.000	330.000
2024-001	9	ENZ/COL.37	203	ROCHE	93	ROCHE	25	254.200	6.210	2.44	178.000	330.000
2024-001	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	204.000	10.551	5.17	143.000	265.000
2024-001	11	KINETIC	219	ATELLICA	143	SIEMENS	10	289.200	6.369	2.20	202.000	376.000
2024-002	3	ENZYM. 37C	165	VITROS	63	KODAK	83	30.099	0.337	1.12	21.000	39.000
2024-002	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	20.750	0.829	4.00	15.000	27.000
2024-002	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	21.640	0.742	3.43	15.000	28.000
2024-002	9	ENZ/COL.37	184	INTEGRA	93	ROCHE	10	24.600	0.800	3.25	17.000	32.000
2024-002	9	ENZ/COL.37	203	ROCHE	93	ROCHE	25	23.640	0.794	3.36	17.000	31.000
2024-002	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	16.250	1.392	8.57	11.000	21.000
2024-002	11	KINETIC	219	ATELLICA	143	SIEMENS	10	27.100	0.943	3.48	19.000	35.000
2024-003	3	ENZYM. 37C	165	VITROS	63	KODAK	83	74.181	5.584	7.53	52.000	96.000
2024-003	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	105.560	2.211	2.09	74.000	137.000
2024-003	4	HYDRO ACT.	38	SIEMENS DI	143	SIEMENS	26	103.250	0.829	0.80	72.000	134.000
2024-003	9	ENZ/COL.37	184	INTEGRA	93	ROCHE	10	101.400	3.040	3.00	71.000	132.000
2024-003	9	ENZ/COL.37	203	ROCHE	93	ROCHE	25	100.080	2.697	2.69	70.000	130.000
2024-003	10	CNPG3	186	BECK. COUL	76	AU-BECKMAN	16	81.500	4.444	5.45	57.000	106.000
2024-003	11	KINETIC	219	ATELLICA	143	SIEMENS	10	115.500	2.110	1.83	81.000	150.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
004	AMYLASE	CLIA TEST ID #: 285		EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-004	3 ENZYM. 37C	165 VITROS	63 KODAK	83	126.771	5.842	4.61	89.000	165.000			
2024-004	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	26	184.500	3.905	2.12	129.000	240.000			
2024-004	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	26	186.080	3.136	1.69	130.000	242.000			
2024-004	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	10	177.100	7.905	4.46	124.000	230.000			
2024-004	9 ENZ/COL.37	203 ROCHE	93 ROCHE	25	178.250	5.433	3.05	125.000	232.000			
2024-004	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	16	146.438	10.428	7.12	103.000	190.000			
2024-004	11 KINETIC	219 ATELLICA	143 SIEMENS	10	206.200	3.919	1.90	144.000	268.000			
2024-005	3 ENZYM. 37C	165 VITROS	63 KODAK	83	66.098	5.576	8.44	46.000	86.000			
2024-005	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	26	92.192	2.020	2.19	65.000	120.000			
2024-005	4 HYDRO ACT.	38 SIEMENS DI	143 SIEMENS	26	88.250	1.299	1.47	62.000	115.000			
2024-005	9 ENZ/COL.37	184 INTEGRA	93 ROCHE	10	89.300	3.226	3.61	63.000	116.000			
2024-005	9 ENZ/COL.37	203 ROCHE	93 ROCHE	25	88.240	2.196	2.49	62.000	115.000			
2024-005	10 CNPG3	186 BECK. COUL	76 AU-BECKMAN	16	71.875	4.649	6.47	50.000	93.000			
2024-005	11 KINETIC	219 ATELLICA	143 SIEMENS	10	101.100	2.119	2.10	71.000	131.000			
005	ASP. AMINO AST/SGOT	CLIA TEST ID #: 295		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-001	1 ASPAR&KETO	165 VITROS	63 KODAK	141	538.712	22.311	4.14	431.000	646.000			
2024-001	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	95	389.936	11.446	2.94	312.000	468.000			
2024-001	11 MOD. IFCC	184 INTEGRA	93 ROCHE	21	387.250	14.198	3.67	310.000	465.000			
2024-001	11 MOD. IFCC	186 BECK. COUL	76 AU-BECKMAN	31	337.419	20.175	5.98	270.000	405.000			
2024-001	11 MOD. IFCC	191 RX-SERIES	126 RANDOX	33	440.515	44.576	10.12	352.000	529.000			
2024-001	11 MOD. IFCC	203 ROCHE	93 ROCHE	39	392.615	12.384	3.15	314.000	471.000			
2024-001	11 MOD. IFCC	219 ATELLICA	143 SIEMENS	14	434.929	10.694	2.46	348.000	522.000			
2024-001	12 IFCC witho	203 ROCHE	93 ROCHE	12	394.333	16.311	4.14	315.000	473.000			
2024-001	13 NADH wo P5	197 ARCHITECT	1 ABBOTT	14	377.857	14.086	3.73	302.000	453.000			
2024-002	1 ASPAR&KETO	165 VITROS	63 KODAK	141	47.331	1.833	3.87	38.000	57.000			
2024-002	5 ENZYMA.37C	38 SIEMENS DI	143 SIEMENS	95	41.394	1.985	4.80	33.000	50.000			
2024-002	11 MOD. IFCC	184 INTEGRA	93 ROCHE	21	39.381	2.870	7.29	32.000	47.000			

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	35.767	1.606	4.49	29.000	43.000	
2024-002	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	33	47.515	2.986	6.28	38.000	57.000	
2024-002	11 MOD. IFCC	203	ROCHE	93	ROCHE	39	41.256	1.372	3.33	33.000	50.000	
2024-002	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	14	47.385	1.332	2.81	38.000	57.000	
2024-002	12 IFCC witho	203	ROCHE	93	ROCHE	12	41.583	1.498	3.60	33.000	50.000	
2024-002	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	39.429	1.954	4.95	32.000	47.000	
005 ASP. AMINO AST/SGOT		CLIA TEST ID #: 295	EVALUATION CRITERIA: TARGET VALUE 20 %									
2024-003	1 ASPAR&KETO	165	VITROS	63	KODAK	141	192.071	6.463	3.36	154.000	230.000	
2024-003	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	95	160.394	5.384	3.36	128.000	192.000	
2024-003	11 MOD. IFCC	184	INTEGRA	93	ROCHE	21	162.700	5.711	3.51	130.000	195.000	
2024-003	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	141.367	5.913	4.18	113.000	170.000	
2024-003	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	33	186.455	13.567	7.28	149.000	224.000	
2024-003	11 MOD. IFCC	203	ROCHE	93	ROCHE	39	164.333	4.984	3.03	131.000	197.000	
2024-003	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	14	184.857	3.889	2.10	148.000	222.000	
2024-003	12 IFCC witho	203	ROCHE	93	ROCHE	12	165.667	5.437	3.28	133.000	199.000	
2024-003	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	157.286	6.204	3.94	126.000	189.000	
2024-004	1 ASPAR&KETO	165	VITROS	63	KODAK	141	355.411	13.895	3.91	284.000	426.000	
2024-004	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	95	279.053	9.333	3.34	223.000	335.000	
2024-004	11 MOD. IFCC	184	INTEGRA	93	ROCHE	21	275.429	15.813	5.74	220.000	331.000	
2024-004	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	242.100	11.484	4.74	194.000	291.000	
2024-004	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	33	324.606	24.014	7.40	260.000	390.000	
2024-004	11 MOD. IFCC	203	ROCHE	93	ROCHE	39	283.711	8.013	2.82	227.000	340.000	
2024-004	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	14	316.571	4.866	1.54	253.000	380.000	
2024-004	12 IFCC witho	203	ROCHE	93	ROCHE	12	282.250	12.872	4.56	226.000	339.000	
2024-004	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	271.500	10.480	3.86	217.000	326.000	
2024-005	1 ASPAR&KETO	165	VITROS	63	KODAK	141	168.700	5.774	3.42	135.000	202.000	
2024-005	5 ENZYMA.37C	38	SIEMENS DI	143	SIEMENS	95	142.242	4.765	3.35	114.000	171.000	
2024-005	11 MOD. IFCC	184	INTEGRA	93	ROCHE	21	144.600	5.314	3.68	116.000	174.000	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	11 MOD. IFCC	186	BECK. COUL	76	AU-BECKMAN	31	124.517	3.729	2.99	100.000	149.000	
2024-005	11 MOD. IFCC	191	RX-SERIES	126	RANDOX	33	168.091	10.763	6.40	134.000	202.000	
2024-005	11 MOD. IFCC	203	ROCHE	93	ROCHE	39	146.205	4.077	2.79	117.000	175.000	
2024-005	11 MOD. IFCC	219	ATELLICA	143	SIEMENS	14	163.571	2.993	1.83	131.000	196.000	
2024-005	12 IFCC witho	203	ROCHE	93	ROCHE	12	145.250	4.265	2.94	116.000	174.000	
2024-005	13 NADH wo P5	197	ARCHITECT	1	ABBOTT	14	139.143	5.514	3.96	111.000	167.000	
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-001	4 J-G WITH B	38	SIEMENS DI	143	SIEMENS	93	7.067	0.275	3.90	5.650	8.480	
2024-001	4 J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	29	6.397	0.219	3.43	5.120	7.680	
2024-001	4 J-G WITH B	191	RX-SERIES	126	RANDOX	25	7.075	0.509	7.19	5.660	8.490	
2024-001	4 J-G WITH B	191	RX-SERIES	126	RANDOX	25	7.587	0.367	4.84	6.070	9.100	
2024-001	5 J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	6.386	0.552	8.64	5.110	7.660	
2024-001	7 DIAZO-DYPH	165	VITROS	63	KODAK	140	6.547	0.285	4.35	5.240	7.860	
2024-001	13 AZOBIL.	184	INTEGRA	93	ROCHE	11	6.226	0.369	5.93	4.980	7.470	
2024-001	13 AZOBIL.	203	ROCHE	93	ROCHE	36	6.223	0.348	5.59	4.980	7.470	
2024-001	14 VANADATE	219	ATELLICA	143	SIEMENS	14	7.441	0.488	6.56	5.950	8.930	
2024-001	18 COLORIMETR	184	INTEGRA	93	ROCHE	12	6.088	0.302	4.96	4.870	7.310	
2024-001	18 COLORIMETR	203	ROCHE	93	ROCHE	14	6.085	0.185	3.05	4.870	7.300	
2024-001	19 DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	6.613	0.279	4.23	5.290	7.940	
2024-002	4 J-G WITH B	38	SIEMENS DI	143	SIEMENS	93	0.091	0.033	36.11	0.070	0.110	
2024-002	4 J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	29	0.104	0.010	9.26	0.080	0.130	
2024-002	4 J-G WITH B	191	RX-SERIES	126	RANDOX	25	0.143	0.045	31.37	0.110	0.170	
2024-002	4 J-G WITH B	191	RX-SERIES	126	RANDOX	25	0.116	0.064	54.96	0.090	0.140	
2024-002	5 J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	0.108	0.024	22.22	0.090	0.130	
2024-002	7 DIAZO-DYPH	165	VITROS	63	KODAK	140	0.119	0.038	31.79	0.090	0.140	
2024-002	13 AZOBIL.	184	INTEGRA	93	ROCHE	11	0.095	0.060	63.52	0.080	0.110	
2024-002	13 AZOBIL.	203	ROCHE	93	ROCHE	36	0.157	0.022	13.77	0.130	0.190	
2024-002	14 VANADATE	219	ATELLICA	143	SIEMENS	14	0.171	0.025	14.43	0.140	0.210	
2024-002	18 COLORIMETR	184	INTEGRA	93	ROCHE	12	0.110	0.059	53.78	0.090	0.130	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	18	COLORIMETR	203	ROCHE	93	ROCHE	14	0.107	0.061	56.49	0.090	0.130
2024-002	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	0.100	0.000	0.00	0.080	0.120
006 BILIRUBIN, TOTAL		CLIA TEST ID #: 305				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-003	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	93	2.422	0.104	4.31	1.940	2.910
2024-003	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	29	2.363	0.054	2.30	1.890	2.840
2024-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	2.454	0.188	7.68	1.960	2.950
2024-003	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	2.503	0.078	3.10	2.000	3.000
2024-003	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	2.267	0.146	6.46	1.810	2.720
2024-003	7	DIAZO-DYPH	165	VITROS	63	KODAK	140	2.307	0.114	4.95	1.850	2.770
2024-003	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	2.135	0.145	6.81	1.710	2.560
2024-003	13	AZOBIL.	203	ROCHE	93	ROCHE	36	2.121	0.093	4.39	1.700	2.550
2024-003	14	VANADATE	219	ATELLICA	143	SIEMENS	14	2.605	0.173	6.64	2.080	3.130
2024-003	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	2.095	0.039	1.85	1.680	2.510
2024-003	18	COLORIMETR	203	ROCHE	93	ROCHE	14	2.075	0.074	3.56	1.660	2.490
2024-003	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	2.376	0.162	6.80	1.900	2.850
2024-004	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	93	4.802	0.198	4.12	3.840	5.760
2024-004	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	29	4.457	0.151	3.39	3.570	5.350
2024-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	5.060	0.257	5.07	4.050	6.070
2024-004	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	4.831	0.346	7.16	3.860	5.800
2024-004	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	4.426	0.306	6.90	3.540	5.310
2024-004	7	DIAZO-DYPH	165	VITROS	63	KODAK	140	4.445	0.195	4.40	3.560	5.330
2024-004	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	4.186	0.300	7.16	3.350	5.020
2024-004	13	AZOBIL.	203	ROCHE	93	ROCHE	36	4.256	0.200	4.70	3.400	5.110
2024-004	14	VANADATE	219	ATELLICA	143	SIEMENS	14	5.086	0.327	6.43	4.070	6.100
2024-004	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	4.131	0.204	4.94	3.300	4.960
2024-004	18	COLORIMETR	203	ROCHE	93	ROCHE	14	4.149	0.216	5.19	3.320	4.980
2024-004	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	4.529	0.257	5.68	3.620	5.430
2024-005	4	J-G WITH B	38	SIEMENS DI	143	SIEMENS	93	2.043	0.100	4.87	1.630	2.450

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	4	J-G WITH B	186	BECK. COUL	76	AU-BECKMAN	29	2.010	0.064	3.20	1.610	2.410
2024-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	2.099	0.176	8.40	1.680	2.520
2024-005	4	J-G WITH B	191	RX-SERIES	126	RANDOX	25	2.037	0.082	4.02	1.630	2.440
2024-005	5	J-G NO BK.	197	ARCHITECT	1	ABBOTT	10	1.967	0.125	6.36	1.570	2.360
2024-005	7	DIAZO-DYPH	165	VITROS	63	KODAK	140	1.954	0.107	5.48	1.560	2.340
2024-005	13	AZOBIL.	184	INTEGRA	93	ROCHE	11	1.820	0.113	6.21	1.460	2.180
2024-005	13	AZOBIL.	203	ROCHE	93	ROCHE	36	1.777	0.080	4.51	1.420	2.130
2024-005	14	VANADATE	219	ATELLICA	143	SIEMENS	14	2.160	0.074	3.42	1.730	2.590
2024-005	18	COLORIMETR	184	INTEGRA	93	ROCHE	12	1.803	0.080	4.42	1.440	2.160
2024-005	18	COLORIMETR	203	ROCHE	93	ROCHE	14	1.738	0.054	3.12	1.390	2.090
2024-005	19	DIAZO W BL	197	ARCHITECT	1	ABBOTT	10	2.026	0.179	8.83	1.620	2.430
010	CALCIUM, TOTAL		CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-001	3	ARSEN.-III	165	VITROS	63	KODAK	158	11.572	0.222	1.92	10.600	12.600
2024-001	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	33	11.997	0.355	2.96	11.000	13.000
2024-001	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	33	12.131	0.360	2.97	11.100	13.100
2024-001	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	12.000	0.183	1.52	11.000	13.000
2024-001	3	ARSEN.-III	220	Medica E.	99	STAMBIO	12	11.925	0.631	5.29	10.900	12.900
2024-001	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	11.900	0.355	2.98	10.900	12.900
2024-001	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	96	11.624	0.359	3.09	10.600	12.600
2024-001	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	15	11.887	0.358	3.01	10.900	12.900
2024-001	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	11.780	0.354	3.01	10.800	12.800
2024-001	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	14	11.843	0.272	2.30	10.800	12.800
2024-001	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	16	11.750	0.320	2.72	10.800	12.800
2024-001	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	40	11.885	0.329	2.77	10.900	12.900
2024-002	3	ARSEN.-III	165	VITROS	63	KODAK	158	5.627	0.138	2.46	4.600	6.600
2024-002	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	33	5.727	0.160	2.79	4.700	6.700
2024-002	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	33	6.055	0.287	4.74	5.100	7.100
2024-002	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	5.742	0.193	3.37	4.700	6.700
2024-002	3	ARSEN.-III	220	Medica E.	99	STAMBIO	12	5.617	0.090	1.60	4.600	6.600

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	5.720	0.147	2.57	4.700	6.700
2024-002	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	96	5.803	0.227	3.91	4.800	6.800
2024-002	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	15	5.807	0.149	2.56	4.800	6.800
2024-002	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	5.950	0.191	3.21	5.000	7.000
2024-002	8	CRESOLPHT.	219	APELLICA	143	SIEMENS	14	5.500	0.160	2.92	4.500	6.500
2024-002	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	16	5.700	0.170	2.97	4.700	6.700
2024-002	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	40	5.868	0.140	2.39	4.900	6.900
010	CALCIUM, TOTAL		CLIA TEST ID #: 345			EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-003	3	ARSEN.-III	165	VITROS	63	KODAK	158	7.732	0.184	2.38	6.700	8.700
2024-003	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	33	7.879	0.195	2.48	6.900	8.900
2024-003	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	33	8.191	0.191	2.33	7.200	9.200
2024-003	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	7.833	0.118	1.50	6.800	8.800
2024-003	3	ARSEN.-III	220	Medica E.	99	STAMBIO	12	7.917	0.329	4.15	6.900	8.900
2024-003	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	7.730	0.261	3.38	6.700	8.700
2024-003	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	96	7.747	0.244	3.16	6.700	8.700
2024-003	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	15	7.833	0.196	2.50	6.800	8.800
2024-003	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.910	0.104	1.32	6.900	8.900
2024-003	8	CRESOLPHT.	219	APELLICA	143	SIEMENS	14	7.721	0.174	2.25	6.700	8.700
2024-003	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	16	7.731	0.199	2.58	6.700	8.700
2024-003	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	40	7.900	0.176	2.23	6.900	8.900
2024-004	3	ARSEN.-III	165	VITROS	63	KODAK	158	9.797	0.202	2.06	8.800	10.800
2024-004	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	33	10.042	0.247	2.46	9.000	11.000
2024-004	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	33	10.245	0.308	3.00	9.200	11.200
2024-004	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	9.975	0.183	1.84	9.000	11.000
2024-004	3	ARSEN.-III	220	Medica E.	99	STAMBIO	12	10.075	0.385	3.83	9.100	11.100
2024-004	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	9.870	0.249	2.52	8.900	10.900
2024-004	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	96	9.781	0.273	2.79	8.800	10.800
2024-004	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	15	9.853	0.488	4.96	8.900	10.900
2024-004	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	10.020	0.260	2.59	9.000	11.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-004	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	14	9.957	0.184	1.85	9.000	11.000
2024-004	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	16	9.869	0.282	2.86	8.900	10.900
2024-004	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	40	10.026	0.203	2.03	9.000	11.000
010 CALCIUM, TOTAL		CLIA TEST ID #: 345				EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-005	3	ARSEN.-III	165	VITROS	63	KODAK	158	7.435	0.179	2.40	6.400	8.400
2024-005	3	ARSEN.-III	186	BECK. COUL	76	AU-BECKMAN	33	7.570	0.211	2.79	6.600	8.600
2024-005	3	ARSEN.-III	191	RX-SERIES	126	RANDOX	33	7.939	0.258	3.25	6.900	8.900
2024-005	3	ARSEN.-III	197	ARCHITECT	1	ABBOTT	12	7.475	0.136	1.82	6.500	8.500
2024-005	3	ARSEN.-III	220	Medica E.	99	STAMBIO	12	7.525	0.286	3.80	6.500	8.500
2024-005	5	CALC-NONFL	197	ARCHITECT	1	ABBOTT	10	7.440	0.180	2.42	6.400	8.400
2024-005	8	CRESOLPHT.	38	SIEMENS DI	143	SIEMENS	96	7.440	0.221	2.97	6.400	8.400
2024-005	8	CRESOLPHT.	184	INTEGRA	93	ROCHE	15	7.607	0.232	3.05	6.600	8.600
2024-005	8	CRESOLPHT.	203	ROCHE	93	ROCHE	10	7.740	0.174	2.25	6.700	8.700
2024-005	8	CRESOLPHT.	219	ATELLICA	143	SIEMENS	14	7.400	0.151	2.04	6.400	8.400
2024-005	15	CA-NM-BAPT	184	INTEGRA	93	ROCHE	16	7.450	0.203	2.73	6.500	8.500
2024-005	15	CA-NM-BAPT	203	ROCHE	93	ROCHE	40	7.608	0.159	2.09	6.600	8.600
011 CHLORIDE		CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2024-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	109.813	2.543	2.32	104.000	115.000
2024-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	111.500	1.658	1.49	106.000	117.000
2024-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	31	104.710	2.331	2.23	99.000	110.000
2024-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	108.786	1.567	1.44	103.000	114.000
2024-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	104.778	2.149	2.05	100.000	110.000
2024-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	105.491	2.589	2.45	100.000	111.000
2024-001	4	ISE UND-DI	165	VITROS	63	KODAK	66	107.969	2.053	1.90	103.000	113.000
2024-001	4	ISE UND-DI	165	VITROS	156	Kit 32	90	109.667	2.211	2.02	104.000	115.000
2024-001	4	ISE UND-DI	165	VITROS	156	Kit 32	90	108.225	2.087	1.93	103.000	114.000
2024-001	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	108.788	3.043	2.80	103.000	114.000
2024-001	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	109.667	2.211	2.02	104.000	115.000
2024-001	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	111.846	3.325	2.97	106.000	117.000
2024-001	5	MER NIT/DI	197	ARCHITECT	1	ABBOTT	10	108.700	1.792	1.65	103.000	114.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-001	8	IMT	219	APELLICA	143	SIEMENS	14	111.000	2.299	2.07	105.000	117.000
2024-001	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	110.391	2.032	1.84	105.000	116.000
011	CHLORIDE	CLIA TEST ID #: 355				EVALUATION CRITERIA: TARGET VALUE 5 %						
2024-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	86.750	0.829	0.96	82.000	91.000
2024-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	85.452	1.187	1.39	81.000	90.000
2024-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	31	85.871	1.314	1.53	82.000	90.000
2024-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	89.429	0.979	1.10	85.000	94.000
2024-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	83.519	2.267	2.71	79.000	88.000
2024-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	87.000	1.247	1.43	83.000	91.000
2024-002	4	ISE UND-DI	165	VITROS	63	KODAK	66	87.924	1.570	1.79	84.000	92.000
2024-002	4	ISE UND-DI	165	VITROS	156	Kit 32	90	88.236	1.366	1.55	84.000	93.000
2024-002	4	ISE UND-DI	165	VITROS	156	Kit 32	90	85.667	1.106	1.29	81.000	90.000
2024-002	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	85.667	1.106	1.29	81.000	90.000
2024-002	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	84.606	2.059	2.43	80.000	89.000
2024-002	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	84.214	2.177	2.59	80.000	88.000
2024-002	5	MER NIT/DI	197	ARCHITECT	1	ABBOTT	10	88.900	0.943	1.06	84.000	93.000
2024-002	8	IMT	219	APELLICA	143	SIEMENS	14	89.357	1.797	2.01	85.000	94.000
2024-002	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	83.140	1.349	1.62	79.000	87.000
2024-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	93.097	1.399	1.50	88.000	98.000
2024-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	95.000	0.707	0.74	90.000	100.000
2024-003	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	31	92.065	1.366	1.48	87.000	97.000
2024-003	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	95.929	0.961	1.00	91.000	101.000
2024-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	93.222	1.227	1.32	89.000	98.000
2024-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	90.630	2.163	2.39	86.000	95.000
2024-003	4	ISE UND-DI	165	VITROS	63	KODAK	66	94.106	1.548	1.65	89.000	99.000
2024-003	4	ISE UND-DI	165	VITROS	156	Kit 32	90	92.000	1.732	1.88	87.000	97.000
2024-003	4	ISE UND-DI	165	VITROS	156	Kit 32	90	94.506	1.515	1.60	90.000	99.000
2024-003	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	92.091	2.379	2.58	87.000	97.000
2024-003	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	92.000	1.732	1.88	87.000	97.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-003	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	94.214	2.484	2.64	90.000	99.000
2024-003	5	MER NIT/DI	197	ARCHITECT	1	ABBOTT	10	94.800	1.887	1.99	90.000	100.000
2024-003	8	IMT	219	ATELLICA	143	SIEMENS	14	96.429	1.917	1.99	92.000	101.000
2024-003	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	92.140	1.542	1.67	88.000	97.000
011	CHLORIDE	CLIA TEST ID #: 355		EVALUATION CRITERIA: TARGET VALUE 5 %								
2024-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	103.750	2.278	2.20	99.000	109.000
2024-004	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	102.419	2.587	2.53	97.000	108.000
2024-004	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	31	99.032	2.177	2.20	94.000	104.000
2024-004	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	103.286	1.161	1.12	98.000	108.000
2024-004	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	99.038	2.402	2.42	94.000	104.000
2024-004	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	101.111	3.178	3.14	96.000	106.000
2024-004	4	ISE UND-DI	165	VITROS	63	KODAK	66	101.500	2.069	2.04	96.000	107.000
2024-004	4	ISE UND-DI	165	VITROS	156	Kit 32	90	102.067	1.931	1.89	97.000	107.000
2024-004	4	ISE UND-DI	165	VITROS	156	Kit 32	90	100.833	2.734	2.71	96.000	106.000
2024-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	100.833	2.734	2.71	96.000	106.000
2024-004	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	101.313	1.960	1.93	96.000	106.000
2024-004	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	104.714	3.149	3.01	99.000	110.000
2024-004	5	MER NIT/DI	197	ARCHITECT	1	ABBOTT	10	102.400	1.800	1.76	97.000	108.000
2024-004	8	IMT	219	ATELLICA	143	SIEMENS	14	104.500	1.500	1.44	99.000	110.000
2024-004	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	102.011	1.840	1.80	97.000	107.000
2024-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	92.581	1.642	1.77	88.000	97.000
2024-005	3	ISE DILUTE	184	INTEGRA	93	ROCHE	32	93.500	0.500	0.53	89.000	98.000
2024-005	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	31	91.548	1.603	1.75	87.000	96.000
2024-005	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	14	94.714	1.161	1.23	90.000	99.000
2024-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	92.556	1.832	1.98	88.000	97.000
2024-005	3	ISE DILUTE	203	ROCHE	93	ROCHE	54	89.868	2.181	2.43	85.000	94.000
2024-005	4	ISE UND-DI	165	VITROS	63	KODAK	66	93.773	1.677	1.79	89.000	98.000
2024-005	4	ISE UND-DI	165	VITROS	156	Kit 32	90	91.333	2.867	3.14	87.000	96.000
2024-005	4	ISE UND-DI	165	VITROS	156	Kit 32	90	94.045	1.557	1.66	89.000	99.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	91.394	2.674	2.93	87.000	96.000
2024-005	4	ISE UND-DI	191	RX-SERIES	126	RANDOX	33	91.333	2.867	3.14	87.000	96.000
2024-005	4	ISE UND-DI	220	Medica E.	130	MEDICA	14	92.929	2.374	2.56	88.000	98.000
2024-005	5	MER NIT/DI	197	ARCHITECT	1	ABBOTT	10	94.500	1.628	1.72	90.000	99.000
2024-005	8	IMT	219	ATELLICA	143	SIEMENS	14	95.500	1.955	2.05	91.000	100.000
2024-005	9	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	91.000	1.488	1.64	86.000	96.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-001	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	92	191.429	8.307	4.34	172.000	211.000
2024-001	1	ENZYMATIC	165	VITROS	63	KODAK	145	227.556	7.481	3.29	205.000	250.000
2024-001	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	199.750	5.673	2.84	180.000	220.000
2024-001	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	39	224.282	9.724	4.34	202.000	247.000
2024-001	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	207.727	3.744	1.80	187.000	229.000
2024-001	1	ENZYMATIC	203	ROCHE	93	ROCHE	22	209.773	6.522	3.11	189.000	231.000
2024-001	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	219.000	12.053	5.50	197.000	241.000
2024-001	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	203.583	6.171	3.03	183.000	224.000
2024-001	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	29	201.862	7.099	3.52	182.000	222.000
2024-001	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	210.467	7.003	3.33	189.000	232.000
2024-001	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	210.300	3.926	1.87	189.000	231.000
2024-001	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	14	215.769	7.688	3.56	194.000	237.000
2024-002	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	92	105.424	4.158	3.94	95.000	116.000
2024-002	1	ENZYMATIC	165	VITROS	63	KODAK	145	105.147	3.717	3.54	95.000	116.000
2024-002	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	105.917	6.383	6.03	95.000	117.000
2024-002	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	39	115.795	5.823	5.03	104.000	127.000
2024-002	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	112.182	1.800	1.60	101.000	123.000
2024-002	1	ENZYMATIC	203	ROCHE	93	ROCHE	22	112.364	1.990	1.77	101.000	124.000
2024-002	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	114.818	1.898	1.65	103.000	126.000
2024-002	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	109.667	3.145	2.87	99.000	121.000
2024-002	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	29	108.069	2.288	2.12	97.000	119.000
2024-002	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	112.333	2.599	2.31	101.000	124.000



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	111.200	2.638	2.37	100.000	122.000
2024-002	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	14	110.769	3.445	3.11	100.000	122.000
012 CHOLESTEROL, TOTAL			CLIA TEST ID #: 365				EVALUATION CRITERIA: TARGET VALUE 10 %					
2024-003	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	92	133.554	5.468	4.09	120.000	147.000
2024-003	1	ENZYMATIC	165	VITROS	63	KODAK	145	146.259	4.612	3.15	132.000	161.000
2024-003	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	138.500	4.031	2.91	125.000	152.000
2024-003	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	39	152.256	5.241	3.44	137.000	167.000
2024-003	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	143.091	1.730	1.21	129.000	157.000
2024-003	1	ENZYMATIC	203	ROCHE	93	ROCHE	22	145.091	3.288	2.27	131.000	160.000
2024-003	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	150.000	3.618	2.41	135.000	165.000
2024-003	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	141.167	4.079	2.89	127.000	155.000
2024-003	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	29	140.552	2.919	2.08	126.000	155.000
2024-003	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	144.786	2.144	1.48	130.000	159.000
2024-003	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	142.600	2.800	1.96	128.000	157.000
2024-003	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	14	146.846	4.276	2.91	132.000	162.000
2024-004	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	92	163.451	7.732	4.73	147.000	180.000
2024-004	1	ENZYMATIC	165	VITROS	63	KODAK	145	188.378	6.343	3.37	170.000	207.000
2024-004	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	168.250	8.447	5.02	151.000	185.000
2024-004	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	39	189.026	8.544	4.52	170.000	208.000
2024-004	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	175.636	3.255	1.85	158.000	193.000
2024-004	1	ENZYMATIC	203	ROCHE	93	ROCHE	22	180.091	3.789	2.10	162.000	198.000
2024-004	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	184.364	3.844	2.09	166.000	203.000
2024-004	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	173.583	5.951	3.43	156.000	191.000
2024-004	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	29	172.207	5.235	3.04	155.000	189.000
2024-004	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	179.200	7.405	4.13	161.000	197.000
2024-004	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	176.800	4.214	2.38	159.000	194.000
2024-004	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	14	183.846	5.157	2.80	165.000	202.000
2024-005	1	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	92	129.576	5.102	3.94	117.000	143.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	1	ENZYMATIC	165	VITROS	63	KODAK	145	140.306	4.793	3.42	126.000	154.000
2024-005	1	ENZYMATIC	184	INTEGRA	93	ROCHE	12	133.833	3.891	2.91	120.000	147.000
2024-005	1	ENZYMATIC	191	RX-SERIES	126	RANDOX	39	148.256	6.254	4.22	133.000	163.000
2024-005	1	ENZYMATIC	197	ARCHITECT	1	ABBOTT	11	138.727	2.004	1.44	125.000	153.000
2024-005	1	ENZYMATIC	203	ROCHE	93	ROCHE	22	140.545	5.211	3.71	126.000	155.000
2024-005	1	ENZYMATIC	220	Medica E.	130	MEDICA	11	146.000	2.374	1.63	131.000	161.000
2024-005	5	FE-SALTS-N	197	ARCHITECT	1	ABBOTT	12	136.000	4.163	3.06	122.000	150.000
2024-005	8	ENZYMATIC	186	BECK. COUL	76	AU-BECKMAN	29	135.759	3.255	2.40	122.000	149.000
2024-005	8	ENZYMATIC	203	ROCHE	93	ROCHE	15	141.067	3.043	2.16	127.000	155.000
2024-005	9	ENZYMATIC	203	ROCHE	93	ROCHE	10	138.400	2.615	1.89	125.000	152.000
2024-005	9	ENZYMATIC	219	ATELLICA	143	SIEMENS	14	142.385	4.764	3.35	128.000	157.000
013	CHOLESTEROL, (HDL)		CLIA TEST ID #: 375		EVALUATION CRITERIA: TARGET VALUE 30 %							
2024-001	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	72.040	2.436	3.38	50.400	93.700
2024-001	11	ENC.-COLO.	165	VITROS	63	KODAK	141	64.461	4.341	6.73	45.100	83.800
2024-001	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	30	56.107	3.349	5.97	39.300	72.900
2024-001	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	30	75.470	4.537	6.01	52.800	98.100
2024-001	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	60.849	5.283	8.68	42.600	79.100
2024-001	11	ENC.-COLO.	203	ROCHE	93	ROCHE	42	56.867	2.705	4.76	39.800	73.900
2024-001	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	77.693	3.147	4.05	54.400	101.000
2024-001	11	ENC.-COLO.	220	Medica E.	130	MEDICA	11	70.727	5.118	7.24	49.500	91.900
2024-001	12	HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	71.771	2.922	4.07	50.200	93.300
2024-001	13	AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	89	43.066	2.461	5.72	30.100	56.000
2024-002	5	DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	43.790	1.076	2.46	30.700	56.900
2024-002	11	ENC.-COLO.	165	VITROS	63	KODAK	141	36.609	1.853	5.06	25.600	47.600
2024-002	11	ENC.-COLO.	184	INTEGRA	93	ROCHE	30	42.913	2.621	6.11	30.000	55.800
2024-002	11	ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	30	44.440	2.680	6.03	31.100	57.800
2024-002	11	ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	36.521	3.497	9.57	25.600	47.500
2024-002	11	ENC.-COLO.	203	ROCHE	93	ROCHE	42	43.602	2.269	5.20	30.500	56.700
2024-002	11	ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	46.143	1.836	3.98	32.300	60.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	11 ENC.-COLO.	220	Medica E.	130	MEDICA	11	38.727	2.895	7.47	27.100	50.300	
2024-002	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	42.679	2.296	5.38	29.900	55.500	
2024-002	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	89	41.905	2.097	5.00	29.300	54.500	
013 CHOLESTEROL, (HDL)		CLIA TEST ID #: 375				EVALUATION CRITERIA: TARGET VALUE 30 %						
2024-003	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	53.010	1.342	2.53	37.100	68.900	
2024-003	11 ENC.-COLO.	165	VITROS	63	KODAK	141	43.901	2.233	5.09	30.700	57.100	
2024-003	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	30	48.083	2.938	6.11	33.700	62.500	
2024-003	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	30	55.143	2.919	5.29	38.600	71.700	
2024-003	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	45.187	4.500	9.96	31.600	58.700	
2024-003	11 ENC.-COLO.	203	ROCHE	93	ROCHE	42	48.605	2.544	5.23	34.000	63.200	
2024-003	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	57.400	2.353	4.10	40.200	74.600	
2024-003	11 ENC.-COLO.	220	Medica E.	130	MEDICA	11	49.091	4.399	8.96	34.400	63.800	
2024-003	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	52.386	2.328	4.44	36.700	68.100	
2024-003	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	89	43.315	2.352	5.43	30.300	56.300	
2024-004	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	63.690	1.733	2.72	44.600	82.800	
2024-004	11 ENC.-COLO.	165	VITROS	63	KODAK	141	53.303	3.136	5.88	37.300	69.300	
2024-004	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	30	52.576	3.052	5.80	36.800	68.300	
2024-004	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	30	65.567	3.465	5.28	45.900	85.200	
2024-004	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	53.616	4.975	9.28	37.500	69.700	
2024-004	11 ENC.-COLO.	203	ROCHE	93	ROCHE	42	53.183	2.990	5.62	37.200	69.100	
2024-004	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	68.536	3.017	4.40	48.000	89.100	
2024-004	11 ENC.-COLO.	220	Medica E.	130	MEDICA	11	60.455	3.893	6.44	42.300	78.600	
2024-004	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	62.450	2.750	4.40	43.700	81.200	
2024-004	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	89	43.800	2.669	6.09	30.700	56.900	
2024-005	5 DEX.SUL/Mg	197	ARCHITECT	1	ABBOTT	10	52.110	1.144	2.20	36.500	67.700	
2024-005	11 ENC.-COLO.	165	VITROS	63	KODAK	141	42.922	2.210	5.15	30.000	55.800	
2024-005	11 ENC.-COLO.	184	INTEGRA	93	ROCHE	30	47.610	2.942	6.18	33.300	61.900	
2024-005	11 ENC.-COLO.	186	BECK. COUL	76	AU-BECKMAN	30	53.017	2.911	5.49	37.100	68.900	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	11 ENC.-COLO.	191	RX-SERIES	126	RANDOX	39	44.538	3.895	8.74	31.200	57.900	
2024-005	11 ENC.-COLO.	203	ROCHE	93	ROCHE	42	48.114	2.539	5.28	33.700	62.500	
2024-005	11 ENC.-COLO.	219	ATELLICA	143	SIEMENS	14	55.336	2.199	3.97	38.700	71.900	
2024-005	11 ENC.-COLO.	220	Medica E.	130	MEDICA	11	47.727	3.519	7.37	33.400	62.000	
2024-005	12 HOM-LQ.S.D	197	ARCHITECT	1	ABBOTT	14	50.871	2.734	5.37	35.600	66.100	
2024-005	13 AMIN.W.E.Q	38	SIEMENS DI	143	SIEMENS	89	43.130	2.142	4.97	30.200	56.100	
014	CREATINE KINASE (CK)	CLIA	TEST ID #: 385	EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-001	3 KINETIC 37	165	VITROS	63	KODAK	70	397.086	28.532	7.19	278.000	516.000	
2024-001	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	571.176	32.522	5.69	400.000	743.000	
2024-001	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	12	636.667	15.488	2.43	446.000	828.000	
2024-001	6 ENZYMAT.37	203	ROCHE	93	ROCHE	10	621.200	28.809	4.64	435.000	808.000	
2024-001	8 Hexokinase	203	ROCHE	93	ROCHE	11	618.455	20.246	3.27	433.000	804.000	
2024-001	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	29	616.429	12.508	2.03	432.000	801.000	
2024-001	10 ENZYMATIC-	203	ROCHE	93	ROCHE	10	623.200	12.352	1.98	436.000	810.000	
2024-002	3 KINETIC 37	165	VITROS	63	KODAK	70	24.710	4.090	16.55	17.000	32.000	
2024-002	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	23.059	2.071	8.98	16.000	30.000	
2024-002	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	12	30.667	2.981	9.72	21.000	40.000	
2024-002	6 ENZYMAT.37	203	ROCHE	93	ROCHE	10	49.900	64.063	128.38	35.000	65.000	
2024-002	8 Hexokinase	203	ROCHE	93	ROCHE	11	27.364	2.012	7.35	19.000	36.000	
2024-002	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	29	25.345	1.935	7.63	18.000	33.000	
2024-002	10 ENZYMATIC-	203	ROCHE	93	ROCHE	10	27.900	1.221	4.38	20.000	36.000	
2024-003	3 KINETIC 37	165	VITROS	63	KODAK	70	203.143	16.039	7.90	142.000	264.000	
2024-003	3 KINETIC 37	186	BECK. COUL	76	AU-BECKMAN	17	214.529	9.690	4.52	150.000	279.000	
2024-003	5 SZASZ-MOD.	219	ATELLICA	143	SIEMENS	12	242.917	6.034	2.48	170.000	316.000	
2024-003	6 ENZYMAT.37	203	ROCHE	93	ROCHE	10	234.100	6.992	2.99	164.000	304.000	
2024-003	8 Hexokinase	203	ROCHE	93	ROCHE	11	231.000	7.483	3.24	162.000	300.000	
2024-003	9 SIEMENS	38	SIEMENS DI	143	SIEMENS	29	231.103	5.095	2.20	162.000	300.000	
2024-003	10 ENZYMATIC-	203	ROCHE	93	ROCHE	10	233.700	6.133	2.62	164.000	304.000	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH			
014	CREATINE KINASE (CK)	CLIA TEST ID #: 385		EVALUATION CRITERIA: TARGET VALUE 30 %								
2024-004	3 KINETIC 37	165 VITROS	63 KODAK	70	327.147	19.516	5.97	229.000	425.000			
2024-004	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	17	398.882	20.531	5.15	279.000	519.000			
2024-004	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS	12	447.500	7.963	1.78	313.000	582.000			
2024-004	6 ENZYMAT.37	203 ROCHE	93 ROCHE	10	436.900	19.300	4.42	306.000	568.000			
2024-004	8 Hexokinase	203 ROCHE	93 ROCHE	11	431.909	16.984	3.93	302.000	561.000			
2024-004	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	29	431.621	10.043	2.33	302.000	561.000			
2024-004	10 ENZYMATIC-	203 ROCHE	93 ROCHE	10	436.700	7.643	1.75	306.000	568.000			
2024-005	3 KINETIC 37	165 VITROS	63 KODAK	70	179.057	13.533	7.56	125.000	233.000			
2024-005	3 KINETIC 37	186 BECK. COUL	76 AU-BECKMAN	17	183.529	8.388	4.57	128.000	239.000			
2024-005	5 SZASZ-MOD.	219 ATELLICA	143 SIEMENS	12	208.917	4.112	1.97	146.000	272.000			
2024-005	6 ENZYMAT.37	203 ROCHE	93 ROCHE	10	201.200	6.794	3.38	141.000	262.000			
2024-005	8 Hexokinase	203 ROCHE	93 ROCHE	11	202.455	4.906	2.42	142.000	263.000			
2024-005	9 SIEMENS	38 SIEMENS DI	143 SIEMENS	29	200.103	4.641	2.32	140.000	260.000			
2024-005	10 ENZYMATIC-	203 ROCHE	93 ROCHE	10	199.500	6.021	3.02	140.000	259.000			
016	CREATININE	CLIA TEST ID #: 405		EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2024-001	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	26	5.687	0.311	5.47	5.120	6.260			
2024-001	2 AK. PIC. N	191 RX-SERIES	126 RANDOX	26	5.428	0.307	5.65	4.880	5.970			
2024-001	4 ENZYMATIC	203 ROCHE	93 ROCHE	11	6.345	0.227	3.57	5.710	6.980			
2024-001	4 ENZYMATIC	220 Medica E.	130 MEDICA	13	6.799	0.077	1.14	6.120	7.480			
2024-001	6 KIN. ALK P	184 INTEGRA	93 ROCHE	16	6.233	0.270	4.33	5.610	6.860			
2024-001	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN	33	6.537	0.224	3.43	5.880	7.190			
2024-001	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT	18	7.199	0.191	2.66	6.480	7.920			
2024-001	6 KIN. ALK P	203 ROCHE	93 ROCHE	28	6.158	0.226	3.67	5.540	6.770			
2024-001	8 IDMS-CREA	165 VITROS	63 KODAK	156	5.624	0.164	2.92	5.060	6.190			
2024-001	9 MODIFIED	219 ATELLICA	143 SIEMENS	14	6.439	0.182	2.82	5.800	7.080			
2024-001	10 JAFFE COMP	184 INTEGRA	93 ROCHE	10	6.106	0.307	5.03	5.500	6.720			
2024-001	10 JAFFE COMP	184 INTEGRA	93 ROCHE	10	6.257	0.210	3.36	5.630	6.880			
2024-001	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS	88	6.819	0.170	2.49	6.140	7.500			

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
016 CREATININE		CLIA TEST ID #: 405	EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}								
2024-002	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		26	0.920	0.078	8.47	0.620	1.220	
2024-002	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		26	0.958	0.070	7.31	0.660	1.260	
2024-002	4 ENZYMATIC	203 ROCHE	93 ROCHE		11	0.885	0.049	5.54	0.590	1.190	
2024-002	4 ENZYMATIC	220 Medica E.	130 MEDICA		13	0.942	0.040	4.20	0.640	1.240	
2024-002	6 KIN. ALK P	184 INTEGRA	93 ROCHE		16	0.919	0.066	7.15	0.620	1.220	
2024-002	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN		33	0.872	0.045	5.17	0.570	1.170	
2024-002	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT		18	0.804	0.018	2.26	0.500	1.100	
2024-002	6 KIN. ALK P	203 ROCHE	93 ROCHE		28	0.865	0.039	4.50	0.570	1.170	
2024-002	8 IDMS-CREA	165 VITROS	63 KODAK		156	0.854	0.047	5.53	0.550	1.150	
2024-002	9 MODIFIED	219 ATELLICA	143 SIEMENS		14	0.822	0.046	5.54	0.520	1.120	
2024-002	10 JAFFE COMP	184 INTEGRA	93 ROCHE		10	0.872	0.036	4.07	0.570	1.170	
2024-002	10 JAFFE COMP	184 INTEGRA	93 ROCHE		10	0.903	0.056	6.15	0.600	1.200	
2024-002	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS		88	0.827	0.047	5.71	0.530	1.130	
2024-003	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		26	2.665	0.154	5.78	2.370	2.970	
2024-003	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		26	2.528	0.163	6.44	2.230	2.830	
2024-003	4 ENZYMATIC	203 ROCHE	93 ROCHE		11	2.921	0.095	3.26	2.620	3.220	
2024-003	4 ENZYMATIC	220 Medica E.	130 MEDICA		13	2.942	0.096	3.26	2.640	3.240	
2024-003	6 KIN. ALK P	184 INTEGRA	93 ROCHE		16	2.900	0.095	3.28	2.600	3.200	
2024-003	6 KIN. ALK P	186 BECK. COUL	76 AU-BECKMAN		33	2.888	0.086	2.98	2.590	3.190	
2024-003	6 KIN. ALK P	197 ARCHITECT	1 ABBOTT		18	2.987	0.072	2.41	2.690	3.290	
2024-003	6 KIN. ALK P	203 ROCHE	93 ROCHE		28	2.849	0.097	3.41	2.550	3.150	
2024-003	8 IDMS-CREA	165 VITROS	63 KODAK		156	2.782	0.085	3.06	2.480	3.080	
2024-003	9 MODIFIED	219 ATELLICA	143 SIEMENS		14	2.801	0.128	4.58	2.500	3.100	
2024-003	10 JAFFE COMP	184 INTEGRA	93 ROCHE		10	2.870	0.152	5.30	2.570	3.170	
2024-003	10 JAFFE COMP	184 INTEGRA	93 ROCHE		10	2.880	0.063	2.19	2.580	3.180	
2024-003	11 IDMS Jaffe	38 SIEMENS DI	143 SIEMENS		88	2.976	0.089	2.99	2.680	3.280	
2024-004	2 AK. PIC. N	191 RX-SERIES	126 RANDOX		26	4.043	0.253	6.26	3.640	4.450	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-004	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	26	4.108	0.171	4.17	3.700	4.520
2024-004	4	ENZYMATIC	203	ROCHE	93	ROCHE	11	4.730	0.143	3.03	4.260	5.200
2024-004	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	4.950	0.177	3.57	4.460	5.450
2024-004	6	KIN. ALK P	184	INTEGRA	93	ROCHE	16	4.614	0.221	4.79	4.150	5.080
2024-004	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	33	4.810	0.182	3.78	4.330	5.290
2024-004	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	5.182	0.135	2.61	4.660	5.700
2024-004	6	KIN. ALK P	203	ROCHE	93	ROCHE	28	4.656	0.166	3.57	4.190	5.120
2024-004	8	IDMS-CREA	165	VITROS	63	KODAK	156	4.382	0.137	3.13	3.940	4.820
2024-004	9	MODIFIED	219	ATELLICA	143	SIEMENS	14	4.716	0.175	3.72	4.240	5.190
2024-004	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	4.691	0.155	3.31	4.220	5.160
2024-004	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	4.620	0.212	4.59	4.160	5.080
2024-004	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	88	4.924	0.141	2.87	4.430	5.420
016	CREATININE	CLIA TEST ID #: 405				EVALUATION CRITERIA: TARGET VALUE 10 % OR 0.30 {GREATER}						
2024-005	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	26	2.438	0.134	5.51	2.140	2.740
2024-005	2	AK. PIC. N	191	RX-SERIES	126	RANDOX	26	2.257	0.155	6.86	1.960	2.560
2024-005	4	ENZYMATIC	203	ROCHE	93	ROCHE	11	2.598	0.072	2.77	2.300	2.900
2024-005	4	ENZYMATIC	220	Medica E.	130	MEDICA	13	2.662	0.049	1.85	2.360	2.960
2024-005	6	KIN. ALK P	184	INTEGRA	93	ROCHE	16	2.590	0.098	3.78	2.290	2.890
2024-005	6	KIN. ALK P	186	BECK. COUL	76	AU-BECKMAN	33	2.556	0.100	3.91	2.260	2.860
2024-005	6	KIN. ALK P	197	ARCHITECT	1	ABBOTT	18	2.641	0.093	3.53	2.340	2.940
2024-005	6	KIN. ALK P	203	ROCHE	93	ROCHE	28	2.546	0.085	3.35	2.250	2.850
2024-005	8	IDMS-CREA	165	VITROS	63	KODAK	156	2.501	0.077	3.07	2.200	2.800
2024-005	9	MODIFIED	219	ATELLICA	143	SIEMENS	14	2.509	0.107	4.28	2.210	2.810
2024-005	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	2.580	0.129	5.02	2.280	2.880
2024-005	10	JAFFE COMP	184	INTEGRA	93	ROCHE	10	2.580	0.077	2.98	2.280	2.880
2024-005	11	IDMS Jaffe	38	SIEMENS DI	143	SIEMENS	88	2.687	0.081	3.00	2.390	2.990
017	GLUCOSE	CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2024-001	3	GL. OXI. C	165	VITROS	63	KODAK	159	163.923	3.865	2.36	148.000	180.000
2024-001	3	GL. OXI. C	165	VITROS	63	KODAK	159	148.714	7.535	5.07	134.000	164.000
2024-001	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	96	166.406	5.641	3.39	150.000	183.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-001	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	158.600	3.441	2.17	143.000	174.000
2024-001	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	33	155.909	4.129	2.65	140.000	172.000
2024-001	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	159.484	6.095	3.82	144.000	175.000
2024-001	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	155.100	4.571	2.95	140.000	171.000
2024-001	5	HEXOKINASE	203	ROCHE	93	ROCHE	32	159.133	3.658	2.30	143.000	175.000
2024-001	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	166.231	7.495	4.51	150.000	183.000
2024-001	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	158.095	5.227	3.31	142.000	174.000
2024-001	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	155.071	2.658	1.71	140.000	171.000
2024-001	12	HEXOKINASE	203	ROCHE	93	ROCHE	21	154.857	5.185	3.35	139.000	170.000
2024-001	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	14	155.071	3.474	2.24	140.000	171.000
017 GLUCOSE			CLIA TEST ID #: 415			EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2024-002	3	GL. OXI. C	165	VITROS	63	KODAK	159	37.429	1.178	3.15	31.000	43.000
2024-002	3	GL. OXI. C	165	VITROS	63	KODAK	159	33.968	1.338	3.94	28.000	40.000
2024-002	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	96	41.621	1.760	4.23	36.000	48.000
2024-002	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	38.500	1.204	3.13	33.000	45.000
2024-002	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	33	38.281	0.838	2.19	32.000	44.000
2024-002	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	42.200	1.720	4.08	36.000	48.000
2024-002	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	36.400	0.800	2.20	30.000	42.000
2024-002	5	HEXOKINASE	203	ROCHE	93	ROCHE	32	37.844	1.003	2.65	32.000	44.000
2024-002	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	40.077	2.200	5.49	34.000	46.000
2024-002	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	37.800	0.927	2.45	32.000	44.000
2024-002	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	36.429	0.623	1.71	30.000	42.000
2024-002	12	HEXOKINASE	203	ROCHE	93	ROCHE	21	37.381	0.950	2.54	31.000	43.000
2024-002	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	14	38.500	0.732	1.90	33.000	45.000
2024-003	3	GL. OXI. C	165	VITROS	63	KODAK	159	78.841	1.957	2.48	71.000	87.000
2024-003	3	GL. OXI. C	165	VITROS	63	KODAK	159	77.714	1.385	1.78	70.000	85.000
2024-003	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	96	84.594	2.588	3.06	76.000	93.000
2024-003	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	80.100	2.300	2.87	72.000	88.000
2024-003	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	33	79.727	1.601	2.01	72.000	88.000



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-003	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	82.065	3.663	4.46	74.000	90.000
2024-003	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	77.600	1.800	2.32	70.000	85.000
2024-003	5	HEXOKINASE	203	ROCHE	93	ROCHE	32	79.406	2.119	2.67	71.000	87.000
2024-003	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	84.385	2.949	3.50	76.000	93.000
2024-003	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	79.238	1.900	2.40	71.000	87.000
2024-003	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	77.429	0.904	1.17	70.000	85.000
2024-003	12	HEXOKINASE	203	ROCHE	93	ROCHE	21	78.095	2.068	2.65	70.000	86.000
2024-003	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	14	79.286	1.532	1.93	71.000	87.000
017 GLUCOSE		CLIA TEST ID #: 415				EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}						
2024-004	3	GL. OXI. C	165	VITROS	63	KODAK	159	116.000	2.726	2.35	104.000	128.000
2024-004	3	GL. OXI. C	165	VITROS	63	KODAK	159	120.611	2.951	2.45	109.000	133.000
2024-004	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	96	127.084	3.638	2.86	114.000	140.000
2024-004	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	120.300	3.407	2.83	108.000	132.000
2024-004	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	33	118.939	3.330	2.80	107.000	131.000
2024-004	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	122.452	4.478	3.66	110.000	135.000
2024-004	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	117.700	2.100	1.78	106.000	129.000
2024-004	5	HEXOKINASE	203	ROCHE	93	ROCHE	32	120.625	2.955	2.45	109.000	133.000
2024-004	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	126.923	4.599	3.62	114.000	140.000
2024-004	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	119.650	3.468	2.90	108.000	132.000
2024-004	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	117.643	1.716	1.46	106.000	129.000
2024-004	12	HEXOKINASE	203	ROCHE	93	ROCHE	21	118.429	3.245	2.74	107.000	130.000
2024-004	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	14	118.857	2.416	2.03	107.000	131.000
2024-005	3	GL. OXI. C	165	VITROS	63	KODAK	159	72.551	1.918	2.64	65.000	80.000
2024-005	3	GL. OXI. C	165	VITROS	63	KODAK	159	71.857	2.030	2.83	65.000	79.000
2024-005	5	HEXOKINASE	38	SIEMENS DI	143	SIEMENS	96	78.115	2.419	3.10	70.000	86.000
2024-005	5	HEXOKINASE	184	INTEGRA	93	ROCHE	10	73.400	1.497	2.04	66.000	81.000
2024-005	5	HEXOKINASE	186	BECK. COUL	76	AU-BECKMAN	33	73.094	1.548	2.12	66.000	80.000
2024-005	5	HEXOKINASE	191	RX-SERIES	126	RANDOX	31	77.000	2.874	3.73	69.000	85.000
2024-005	5	HEXOKINASE	197	ARCHITECT	1	ABBOTT	10	71.100	1.758	2.47	64.000	78.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	5	HEXOKINASE	203	ROCHE	93	ROCHE	32	72.813	1.793	2.46	66.000	80.000
2024-005	6	HEXOKI. CO	220	Medica E.	130	MEDICA	13	77.308	2.266	2.93	70.000	85.000
2024-005	12	HEXOKINASE	184	INTEGRA	93	ROCHE	21	73.286	1.931	2.63	66.000	81.000
2024-005	12	HEXOKINASE	197	ARCHITECT	1	ABBOTT	14	71.071	1.334	1.88	64.000	78.000
2024-005	12	HEXOKINASE	203	ROCHE	93	ROCHE	21	72.238	1.509	2.09	65.000	79.000
2024-005	12	HEXOKINASE	219	ATELLICA	143	SIEMENS	14	73.357	1.445	1.97	66.000	81.000
018 IRON, TOTAL			CLIA TEST ID #: 425			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-001	4	COULOMETR.	165	VITROS	63	KODAK	16	366.313	14.136	3.86	293.000	440.000
2024-002	4	COULOMETR.	165	VITROS	63	KODAK	16	46.000	4.975	10.82	37.000	55.000
2024-003	4	COULOMETR.	165	VITROS	63	KODAK	16	140.063	7.587	5.42	112.000	168.000
2024-004	4	COULOMETR.	165	VITROS	63	KODAK	16	248.313	9.459	3.81	199.000	298.000
2024-005	4	COULOMETR.	165	VITROS	63	KODAK	16	125.500	7.272	5.79	100.000	151.000
019 LACTASE DEHY. (LDH)			CLIA TEST ID #: 435									
2024-001	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	566.579	38.970	6.88	453.000	680.000
2024-001	6	NADH	203	ROCHE	93	ROCHE	24	711.958	38.781	5.45	570.000	854.000
2024-001	6	NADH	219	ATELLICA	143	SIEMENS	10	685.000	22.419	3.27	548.000	822.000
2024-001	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	687.500	23.698	3.45	550.000	825.000
2024-001	9	LDH1	165	VITROS	63	KODAK	68	819.897	47.316	5.77	656.000	984.000
2024-002	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	52.053	4.161	7.99	42.000	62.000
2024-002	6	NADH	203	ROCHE	93	ROCHE	24	66.130	3.097	4.68	53.000	79.000
2024-002	6	NADH	219	ATELLICA	143	SIEMENS	10	66.200	2.482	3.75	53.000	79.000
2024-002	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	60.667	6.298	10.38	49.000	73.000
2024-002	9	LDH1	165	VITROS	63	KODAK	68	82.030	4.288	5.23	66.000	98.000
2024-003	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	231.737	14.889	6.42	185.000	278.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-003	6	NADH	203	ROCHE	93	ROCHE	24	291.391	11.522	3.95	233.000	350.000
2024-003	6	NADH	219	ATELLICA	143	SIEMENS	10	294.400	9.069	3.08	236.000	353.000
2024-003	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	277.971	7.405	2.66	222.000	334.000
2024-003	9	LDH1	165	VITROS	63	KODAK	68	349.164	9.475	2.71	279.000	419.000
019	LACTASE DEHY. (LDH)		CLIA TEST ID #: 435			EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-004	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	405.263	26.143	6.45	324.000	486.000
2024-004	6	NADH	203	ROCHE	93	ROCHE	24	511.333	24.617	4.81	409.000	614.000
2024-004	6	NADH	219	ATELLICA	143	SIEMENS	10	501.900	16.920	3.37	402.000	602.000
2024-004	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	490.500	17.103	3.49	392.000	589.000
2024-004	9	LDH1	165	VITROS	63	KODAK	68	593.221	24.379	4.11	475.000	712.000
2024-005	3	KINETIC-37	186	BECK. COUL	76	AU-BECKMAN	19	202.579	13.319	6.57	162.000	243.000
2024-005	6	NADH	203	ROCHE	93	ROCHE	24	259.000	12.878	4.97	207.000	311.000
2024-005	6	NADH	219	ATELLICA	143	SIEMENS	10	260.300	7.695	2.96	208.000	312.000
2024-005	7	SIEMENS 37	38	SIEMENS DI	143	SIEMENS	36	245.167	8.102	3.30	196.000	294.000
2024-005	9	LDH1	165	VITROS	63	KODAK	68	309.691	8.250	2.66	248.000	372.000
021	MAGNESIUM		CLIA TEST ID #: 455			EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-001	5	COLOR./K E	165	VITROS	63	KODAK	25	5.780	0.179	3.09	4.300	7.200
2024-002	5	COLOR./K E	165	VITROS	63	KODAK	25	1.336	0.062	4.68	1.000	1.700
2024-003	5	COLOR./K E	165	VITROS	63	KODAK	25	2.892	0.084	2.92	2.200	3.600
2024-004	5	COLOR./K E	165	VITROS	63	KODAK	25	4.392	0.126	2.87	3.300	5.500
2024-005	5	COLOR./K E	165	VITROS	63	KODAK	25	2.644	0.080	3.04	2.000	3.300
022	POTASSIUM		CLIA TEST ID #: 465			EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-001	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	5.827	0.134	2.30	4.800	6.800
2024-001	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	32	5.719	0.155	2.71	4.700	6.700
2024-001	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	16	5.856	0.106	1.81	4.900	6.900

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-001	3	ISE DILUT.	203	ROCHE	93	ROCHE	55	5.844	0.112	1.91	4.800	6.800
2024-001	4	ISE UNDIL.	165	VITROS	63	KODAK	66	5.895	0.131	2.22	4.900	6.900
2024-001	4	ISE UNDIL.	165	VITROS	156	Kit 32	91	5.884	0.132	2.24	4.900	6.900
2024-001	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	32	5.725	0.171	2.99	4.700	6.700
2024-001	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	5.638	0.150	2.65	4.600	6.600
2024-001	5	IMT	219	ATELLICA	143	SIEMENS	14	5.707	0.116	2.04	4.700	6.700
2024-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	5.769	0.110	1.90	4.800	6.800
022	POTASSIUM	CLIA TEST ID #: 465				EVALUATION CRITERIA: TARGET VALUE 1.00						
2024-002	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	2.021	0.041	2.00	1.000	3.000
2024-002	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	32	2.100	0.043	2.06	1.100	3.100
2024-002	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	16	2.013	0.060	2.98	1.000	3.000
2024-002	3	ISE DILUT.	203	ROCHE	93	ROCHE	55	2.061	0.070	3.42	1.100	3.100
2024-002	4	ISE UNDIL.	165	VITROS	63	KODAK	66	2.006	0.042	2.10	1.000	3.000
2024-002	4	ISE UNDIL.	165	VITROS	156	Kit 32	91	2.000	0.000	0.00	1.000	3.000
2024-002	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	32	2.171	0.140	6.43	1.200	3.200
2024-002	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	1.993	0.070	3.53	1.000	3.000
2024-002	5	IMT	219	ATELLICA	143	SIEMENS	14	1.986	0.074	3.74	1.000	3.000
2024-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	1.942	0.049	2.54	0.900	2.900
2024-003	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	3.300	0.058	1.75	2.300	4.300
2024-003	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	32	3.294	0.056	1.69	2.300	4.300
2024-003	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	16	3.288	0.093	2.82	2.300	4.300
2024-003	3	ISE DILUT.	203	ROCHE	93	ROCHE	55	3.347	0.071	2.12	2.300	4.300
2024-003	4	ISE UNDIL.	165	VITROS	63	KODAK	66	3.314	0.058	1.76	2.300	4.300
2024-003	4	ISE UNDIL.	165	VITROS	156	Kit 32	91	3.285	0.063	1.91	2.300	4.300
2024-003	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	32	3.375	0.112	3.31	2.400	4.400
2024-003	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	3.221	0.086	2.67	2.200	4.200
2024-003	5	IMT	219	ATELLICA	143	SIEMENS	14	3.250	0.073	2.25	2.300	4.300
2024-003	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	3.247	0.070	2.15	2.200	4.200

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST	REAGENTS			NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
022	POTASSIUM	CLIA TEST ID #: 465			EVALUATION CRITERIA: TARGET VALUE 1.00							
2024-004	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	4.583	0.118	2.57	3.600	5.600
2024-004	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	32	4.531	0.110	2.43	3.500	5.500
2024-004	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	16	4.619	0.095	2.06	3.600	5.600
2024-004	3	ISE DILUT.	203	ROCHE	93	ROCHE	55	4.643	0.100	2.15	3.600	5.600
2024-004	4	ISE UNDIL.	165	VITROS	63	KODAK	66	4.632	0.102	2.20	3.600	5.600
2024-004	4	ISE UNDIL.	165	VITROS	156	Kit 32	91	4.610	0.105	2.28	3.600	5.600
2024-004	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	32	4.565	0.093	2.05	3.600	5.600
2024-004	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	4.500	0.146	3.25	3.500	5.500
2024-004	5	IMT	219	ATELLICA	143	SIEMENS	14	4.529	0.070	1.55	3.500	5.500
2024-004	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	4.543	0.095	2.09	3.500	5.500
2024-005	3	ISE DILUT.	184	INTEGRA	93	ROCHE	30	3.113	0.067	2.15	2.100	4.100
2024-005	3	ISE DILUT.	186	BECK. COUL	76	AU-BECKMAN	32	3.109	0.063	2.03	2.100	4.100
2024-005	3	ISE DILUT.	197	ARCHITECT	1	ABBOTT	16	3.100	0.061	1.98	2.100	4.100
2024-005	3	ISE DILUT.	203	ROCHE	93	ROCHE	55	3.149	0.085	2.70	2.100	4.100
2024-005	4	ISE UNDIL.	165	VITROS	63	KODAK	66	3.108	0.061	1.97	2.100	4.100
2024-005	4	ISE UNDIL.	165	VITROS	156	Kit 32	91	3.101	0.055	1.77	2.100	4.100
2024-005	4	ISE UNDIL.	191	RX-SERIES	126	RANDOX	32	3.194	0.117	3.67	2.200	4.200
2024-005	4	ISE UNDIL.	220	Medica E.	130	MEDICA	14	3.021	0.056	1.85	2.000	4.000
2024-005	5	IMT	219	ATELLICA	143	SIEMENS	14	3.057	0.062	2.04	2.100	4.100
2024-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	92	3.044	0.065	2.13	2.000	4.000
023	SODIUM	CLIA TEST ID #: 475			EVALUATION CRITERIA: TARGET VALUE 4.00							
2024-001	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	155.500	2.649	1.70	152.000	160.000
2024-001	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	32	156.094	3.617	2.32	152.000	160.000
2024-001	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	160.250	2.165	1.35	156.000	164.000
2024-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	157.938	2.779	1.76	154.000	162.000
2024-001	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	151.500	2.291	1.51	148.000	156.000
2024-001	4	ISE UNDIL.	165	VITROS	63	KODAK	60	162.100	3.150	1.94	158.000	166.000
2024-001	4	ISE UNDIL.	165	VITROS	156	Kit 32	96	162.305	2.803	1.73	158.000	166.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-001	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	161.000	3.080	1.91	157.000	165.000
2024-001	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	155.500	4.924	3.17	152.000	160.000
2024-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	158.143	7.754	4.90	154.000	162.000
2024-001	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	155.500	4.924	3.17	152.000	160.000
2024-001	5	IMT	197	ARCHITECT	1	ABBOTT	12	160.500	1.803	1.12	157.000	165.000
2024-001	5	IMT	219	ATELLICA	143	SIEMENS	14	155.143	3.204	2.07	151.000	159.000
2024-001	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	156.914	2.734	1.74	153.000	161.000
023 SODIUM		CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00						
2024-002	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	126.077	1.685	1.34	122.000	130.000
2024-002	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	32	127.188	1.991	1.57	123.000	131.000
2024-002	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	127.667	1.546	1.21	124.000	132.000
2024-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	127.250	1.479	1.16	123.000	131.000
2024-002	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	127.396	1.857	1.46	123.000	131.000
2024-002	4	ISE UNLIL.	165	VITROS	63	KODAK	60	125.322	1.692	1.35	121.000	129.000
2024-002	4	ISE UNLIL.	165	VITROS	156	Kit 32	96	125.316	1.656	1.32	121.000	129.000
2024-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	125.500	4.822	3.84	122.000	130.000
2024-002	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	125.733	1.692	1.35	122.000	130.000
2024-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	125.143	2.416	1.93	121.000	129.000
2024-002	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	125.500	4.822	3.84	122.000	130.000
2024-002	5	IMT	197	ARCHITECT	1	ABBOTT	12	126.583	1.847	1.46	123.000	131.000
2024-002	5	IMT	219	ATELLICA	143	SIEMENS	14	128.000	2.360	1.84	124.000	132.000
2024-002	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	128.912	1.628	1.26	125.000	133.000
2024-003	3	ISE DILUTE	184	INTEGRA	93	ROCHE	27	135.667	1.656	1.22	132.000	140.000
2024-003	3	ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	32	137.250	1.904	1.39	133.000	141.000
2024-003	3	ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	138.333	1.599	1.16	134.000	142.000
2024-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	137.245	1.857	1.35	133.000	141.000
2024-003	3	ISE DILUTE	203	ROCHE	93	ROCHE	49	135.250	1.785	1.32	131.000	139.000
2024-003	4	ISE UNLIL.	165	VITROS	63	KODAK	60	136.950	2.093	1.53	133.000	141.000
2024-003	4	ISE UNLIL.	165	VITROS	156	Kit 32	96	136.642	1.722	1.26	133.000	141.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-003	4 ISE UNLIL.	191	RX-SERIES	126	RANLIX	31	136.833	2.130	1.56	133.000	141.000	
2024-003	4 ISE UNLIL.	191	RX-SERIES	126	RANLIX	31	134.750	4.323	3.21	131.000	139.000	
2024-003	4 ISE UNLIL.	220	Medica E.	130	MEDICA	14	136.429	3.201	2.35	132.000	140.000	
2024-003	4 ISE UNLIL.	220	Medica E.	130	MEDICA	14	134.750	4.323	3.21	131.000	139.000	
2024-003	5 IMT	197	ARCHITECT	1	ABBOTT	12	137.250	1.831	1.33	133.000	141.000	
2024-003	5 IMT	219	ATELLICA	143	SIEMENS	14	137.071	2.711	1.98	133.000	141.000	
2024-003	6 QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	138.054	1.969	1.43	134.000	142.000	
023 SODIUM		CLIA TEST ID #: 475				EVALUATION CRITERIA: TARGET VALUE 4.00						
2024-004	3 ISE DILUTE	184	INTEGRA	93	ROCHE	27	146.462	3.177	2.17	142.000	150.000	
2024-004	3 ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	32	147.938	3.142	2.12	144.000	152.000	
2024-004	3 ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	150.500	1.893	1.26	147.000	155.000	
2024-004	3 ISE DILUTE	203	ROCHE	93	ROCHE	49	144.750	1.299	0.90	141.000	149.000	
2024-004	3 ISE DILUTE	203	ROCHE	93	ROCHE	49	148.896	2.468	1.66	145.000	153.000	
2024-004	4 ISE UNLIL.	165	VITROS	63	KODAK	60	150.400	2.899	1.93	146.000	154.000	
2024-004	4 ISE UNLIL.	165	VITROS	156	Kit 32	96	150.188	2.510	1.67	146.000	154.000	
2024-004	4 ISE UNLIL.	191	RX-SERIES	126	RANLIX	31	145.750	4.710	3.23	142.000	150.000	
2024-004	4 ISE UNLIL.	191	RX-SERIES	126	RANLIX	31	149.161	2.749	1.84	145.000	153.000	
2024-004	4 ISE UNLIL.	220	Medica E.	130	MEDICA	14	149.000	4.440	2.98	145.000	153.000	
2024-004	4 ISE UNLIL.	220	Medica E.	130	MEDICA	14	145.750	4.710	3.23	142.000	150.000	
2024-004	5 IMT	197	ARCHITECT	1	ABBOTT	12	149.250	1.920	1.29	145.000	153.000	
2024-004	5 IMT	219	ATELLICA	143	SIEMENS	14	147.357	1.986	1.35	143.000	151.000	
2024-004	6 QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	148.387	2.540	1.71	144.000	152.000	
2024-005	3 ISE DILUTE	184	INTEGRA	93	ROCHE	27	134.444	2.315	1.72	130.000	138.000	
2024-005	3 ISE DILUTE	186	BECK. COUL	76	AU-BECKMAN	32	135.906	2.390	1.76	132.000	140.000	
2024-005	3 ISE DILUTE	197	ARCHITECT	1	ABBOTT	12	136.583	1.977	1.45	133.000	141.000	
2024-005	3 ISE DILUTE	203	ROCHE	93	ROCHE	49	136.122	2.125	1.56	132.000	140.000	
2024-005	3 ISE DILUTE	203	ROCHE	93	ROCHE	49	134.000	1.225	0.91	130.000	138.000	
2024-005	4 ISE UNLIL.	165	VITROS	63	KODAK	60	135.717	1.984	1.46	132.000	140.000	
2024-005	4 ISE UNLIL.	165	VITROS	156	Kit 32	96	135.660	1.831	1.35	132.000	140.000	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	135.800	1.939	1.43	132.000	140.000
2024-005	4	ISE UNLIL.	191	RX-SERIES	126	RANLDOX	31	133.250	4.815	3.61	129.000	137.000
2024-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	135.214	2.512	1.86	131.000	139.000
2024-005	4	ISE UNLIL.	220	Medica E.	130	MEDICA	14	133.250	4.815	3.61	129.000	137.000
2024-005	5	IMT	197	ARCHITECT	1	ABBOTT	12	136.167	1.518	1.12	132.000	140.000
2024-005	5	IMT	219	ATELLICA	143	SIEMENS	14	136.143	2.199	1.62	132.000	140.000
2024-005	6	QUICK LYTE	38	SIEMENS DI	143	SIEMENS	93	137.120	1.977	1.44	133.000	141.000
024 TOTAL PROTEIN			CLIA TEST ID #: 485			EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-001	1	BIURET	38	SIEMENS DI	143	SIEMENS	94	8.294	0.216	2.60	7.500	9.100
2024-001	1	BIURET	165	VITROS	63	KODAK	142	7.883	0.182	2.31	7.100	8.700
2024-001	1	BIURET	184	INTEGRA	93	ROCHE	19	7.542	0.274	3.63	6.800	8.300
2024-001	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	30	7.883	0.278	3.53	7.100	8.700
2024-001	1	BIURET	191	RX-SERIES	126	RANLDOX	33	7.930	0.295	3.72	7.100	8.700
2024-001	1	BIURET	197	ARCHITECT	1	ABBOTT	21	8.167	0.186	2.28	7.400	9.000
2024-001	1	BIURET	203	ROCHE	93	ROCHE	45	7.864	0.240	3.06	7.100	8.700
2024-001	1	BIURET	219	ATELLICA	143	SIEMENS	14	8.100	0.171	2.11	7.300	8.900
2024-001	1	BIURET	220	Medica E.	130	MEDICA	10	7.570	0.456	6.03	6.800	8.300
2024-001	3	BIURET COL	203	ROCHE	93	ROCHE	10	7.880	0.214	2.71	7.100	8.700
2024-002	1	BIURET	38	SIEMENS DI	143	SIEMENS	94	3.003	0.087	2.89	2.700	3.300
2024-002	1	BIURET	165	VITROS	63	KODAK	142	2.994	0.082	2.74	2.700	3.300
2024-002	1	BIURET	184	INTEGRA	93	ROCHE	19	2.806	0.127	4.52	2.500	3.100
2024-002	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	30	2.890	0.106	3.67	2.600	3.200
2024-002	1	BIURET	191	RX-SERIES	126	RANLDOX	33	2.903	0.174	6.00	2.600	3.200
2024-002	1	BIURET	197	ARCHITECT	1	ABBOTT	21	2.824	0.097	3.44	2.500	3.100
2024-002	1	BIURET	203	ROCHE	93	ROCHE	45	2.958	0.077	2.62	2.700	3.300
2024-002	1	BIURET	219	ATELLICA	143	SIEMENS	14	2.886	0.091	3.17	2.600	3.200
2024-002	1	BIURET	220	Medica E.	130	MEDICA	10	2.720	0.160	5.88	2.400	3.000
2024-002	3	BIURET COL	203	ROCHE	93	ROCHE	10	2.940	0.092	3.12	2.600	3.200



**Participant Summary**  
**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH		
024 TOTAL PROTEIN		CLIA TEST ID #: 485				EVALUATION CRITERIA: TARGET VALUE 10 %						
2024-003	1	BIURET	38	SIEMENS DI	143	SIEMENS	94	4.796	0.196	4.09	4.300	5.300
2024-003	1	BIURET	165	VITROS	63	KODAK	142	4.677	0.112	2.40	4.200	5.100
2024-003	1	BIURET	184	INTEGRA	93	ROCHE	19	4.447	0.163	3.67	4.000	4.900
2024-003	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	30	4.607	0.074	1.61	4.100	5.100
2024-003	1	BIURET	191	RX-SERIES	126	RANDOX	33	4.600	0.203	4.42	4.100	5.100
2024-003	1	BIURET	197	ARCHITECT	1	ABBOTT	21	4.590	0.087	1.89	4.100	5.000
2024-003	1	BIURET	203	ROCHE	93	ROCHE	45	4.660	0.114	2.45	4.200	5.100
2024-003	1	BIURET	219	ATELLICA	143	SIEMENS	14	4.707	0.096	2.04	4.200	5.200
2024-003	1	BIURET	220	Medica E.	130	MEDICA	10	4.390	0.207	4.72	4.000	4.800
2024-003	3	BIURET COL	203	ROCHE	93	ROCHE	10	4.610	0.170	3.69	4.100	5.100
2024-004	1	BIURET	38	SIEMENS DI	143	SIEMENS	94	6.614	0.167	2.52	6.000	7.300
2024-004	1	BIURET	165	VITROS	63	KODAK	142	6.316	0.153	2.42	5.700	6.900
2024-004	1	BIURET	184	INTEGRA	93	ROCHE	19	6.042	0.296	4.90	5.400	6.600
2024-004	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	30	6.314	0.200	3.16	5.700	6.900
2024-004	1	BIURET	191	RX-SERIES	126	RANDOX	33	6.344	0.205	3.22	5.700	7.000
2024-004	1	BIURET	197	ARCHITECT	1	ABBOTT	21	6.395	0.080	1.26	5.800	7.000
2024-004	1	BIURET	203	ROCHE	93	ROCHE	45	6.395	0.169	2.65	5.800	7.000
2024-004	1	BIURET	219	ATELLICA	143	SIEMENS	14	6.471	0.122	1.89	5.800	7.100
2024-004	1	BIURET	220	Medica E.	130	MEDICA	10	6.060	0.297	4.91	5.500	6.700
2024-004	3	BIURET COL	203	ROCHE	93	ROCHE	10	6.330	0.142	2.24	5.700	7.000
2024-005	1	BIURET	38	SIEMENS DI	143	SIEMENS	94	4.546	0.102	2.25	4.100	5.000
2024-005	1	BIURET	165	VITROS	63	KODAK	142	4.437	0.098	2.20	4.000	4.900
2024-005	1	BIURET	184	INTEGRA	93	ROCHE	19	4.226	0.148	3.50	3.800	4.600
2024-005	1	BIURET	186	BECK. COUL	76	AU-BECKMAN	30	4.338	0.106	2.45	3.900	4.800
2024-005	1	BIURET	191	RX-SERIES	126	RANDOX	33	4.359	0.171	3.93	3.900	4.800
2024-005	1	BIURET	197	ARCHITECT	1	ABBOTT	21	4.295	0.113	2.64	3.900	4.700
2024-005	1	BIURET	203	ROCHE	93	ROCHE	45	4.431	0.109	2.46	4.000	4.900

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	1	BIURET	219	APELLICA	143	SIEMENS	14	4.421	0.108	2.44	4.000	4.900
2024-005	1	BIURET	220	Medica E.	130	MEDICA	10	4.130	0.155	3.76	3.700	4.500
2024-005	3	BIURET COL	203	ROCHE	93	ROCHE	10	4.350	0.112	2.57	3.900	4.800
025 TRIGLYCERIDES		CLIA TEST ID #: 495				EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-001	2	ENZ. COLO.	165	VITROS	63	KODAK	145	248.097	8.036	3.24	186.000	310.000
2024-001	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	195.769	6.974	3.56	147.000	245.000
2024-001	2	ENZ. COLO.	203	ROCHE	93	ROCHE	27	199.222	6.344	3.18	149.000	249.000
2024-001	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	197.636	23.658	11.97	148.000	247.000
2024-001	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	92	202.934	5.781	2.85	152.000	254.000
2024-001	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	199.500	6.035	3.02	150.000	249.000
2024-001	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	30	213.345	5.148	2.41	160.000	267.000
2024-001	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	32	201.250	7.661	3.81	151.000	252.000
2024-001	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	15	197.733	5.662	2.86	148.000	247.000
2024-001	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	196.880	6.276	3.19	148.000	246.000
2024-001	10	ENZYM. GPO	219	APELLICA	143	SIEMENS	14	212.000	9.434	4.45	159.000	265.000
2024-001	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	199.364	3.392	1.70	150.000	249.000
2024-002	2	ENZ. COLO.	165	VITROS	63	KODAK	145	87.813	3.358	3.82	66.000	110.000
2024-002	2	ENZ. COLO.	184	INTEGRA	93	ROCHE	13	81.462	2.406	2.95	61.000	102.000
2024-002	2	ENZ. COLO.	203	ROCHE	93	ROCHE	27	82.074	2.340	2.85	62.000	103.000
2024-002	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	81.100	1.300	1.60	61.000	101.000
2024-002	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	92	71.176	3.126	4.39	53.000	89.000
2024-002	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	74.667	2.981	3.99	56.000	93.000
2024-002	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	30	81.700	2.923	3.58	61.000	102.000
2024-002	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	32	81.452	3.088	3.79	61.000	102.000
2024-002	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	15	81.333	4.541	5.58	61.000	102.000
2024-002	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	81.800	2.349	2.87	61.000	102.000
2024-002	10	ENZYM. GPO	219	APELLICA	143	SIEMENS	14	85.214	7.272	8.53	64.000	107.000
2024-002	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	75.000	1.348	1.80	56.000	94.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 10 ROUTINE							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
025 TRIGLYCERIDES		CLIA TEST ID #: 495		EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-003	2	ENZ. COLO.	165 VITROS	63	KODAK	145	141.869	5.171	3.64	106.000	177.000
2024-003	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	13	123.385	2.618	2.12	93.000	154.000
2024-003	2	ENZ. COLO.	203 ROCHE	93	ROCHE	27	124.593	3.890	3.12	93.000	156.000
2024-003	2	ENZ. COLO.	220 Medica E.	130	MEDICA	11	118.700	2.648	2.23	89.000	148.000
2024-003	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	92	116.934	3.467	2.96	88.000	146.000
2024-003	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	117.417	3.523	3.00	88.000	147.000
2024-003	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	30	127.724	2.778	2.17	96.000	160.000
2024-003	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	32	122.719	3.659	2.98	92.000	153.000
2024-003	10	ENZYM. GPO	184 INTEGRA	93	ROCHE	15	124.533	3.403	2.73	93.000	156.000
2024-003	10	ENZYM. GPO	203 ROCHE	93	ROCHE	25	123.600	2.638	2.13	93.000	155.000
2024-003	10	ENZYM. GPO	219 ATELLICA	143	SIEMENS	14	128.929	7.186	5.57	97.000	161.000
2024-003	11	GLY PO4 OX	197 ARCHITECT	1	ABBOTT	11	117.727	1.355	1.15	88.000	147.000
2024-004	2	ENZ. COLO.	165 VITROS	63	KODAK	145	196.545	6.450	3.28	147.000	246.000
2024-004	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	13	160.538	5.799	3.61	120.000	201.000
2024-004	2	ENZ. COLO.	203 ROCHE	93	ROCHE	27	164.000	4.315	2.63	123.000	205.000
2024-004	2	ENZ. COLO.	220 Medica E.	130	MEDICA	11	160.091	19.856	12.40	120.000	200.000
2024-004	4	ENZ. (GPD)	38 SIEMENS DI	143	SIEMENS	92	161.670	5.047	3.12	121.000	202.000
2024-004	5	HANTZCH-C)	197 ARCHITECT	1	ABBOTT	12	160.750	4.323	2.69	121.000	201.000
2024-004	9	GPO TRIND.	186 BECK. COUL	76	AU-BECKMAN	30	171.333	5.497	3.21	129.000	214.000
2024-004	9	GPO TRIND.	191 RX-SERIES	126	RANDOX	32	164.250	5.728	3.49	123.000	205.000
2024-004	10	ENZYM. GPO	184 INTEGRA	93	ROCHE	15	162.667	4.949	3.04	122.000	203.000
2024-004	10	ENZYM. GPO	203 ROCHE	93	ROCHE	25	163.583	3.546	2.17	123.000	204.000
2024-004	10	ENZYM. GPO	219 ATELLICA	143	SIEMENS	14	173.786	9.033	5.20	130.000	217.000
2024-004	11	GLY PO4 OX	197 ARCHITECT	1	ABBOTT	11	160.545	1.437	0.90	120.000	201.000
2024-005	2	ENZ. COLO.	165 VITROS	63	KODAK	145	133.806	4.871	3.64	100.000	167.000
2024-005	2	ENZ. COLO.	184 INTEGRA	93	ROCHE	13	117.308	3.360	2.86	88.000	147.000
2024-005	2	ENZ. COLO.	203 ROCHE	93	ROCHE	27	118.074	3.780	3.20	89.000	148.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-005	2	ENZ. COLO.	220	Medica E.	130	MEDICA	11	112.545	3.602	3.20	84.000	141.000
2024-005	4	ENZ. (GPD)	38	SIEMENS DI	143	SIEMENS	92	110.440	3.872	3.51	83.000	138.000
2024-005	5	HANTZCH-C)	197	ARCHITECT	1	ABBOTT	12	111.167	4.525	4.07	83.000	139.000
2024-005	9	GPO TRIND.	186	BECK. COUL	76	AU-BECKMAN	30	120.448	3.223	2.68	90.000	151.000
2024-005	9	GPO TRIND.	191	RX-SERIES	126	RANDOX	32	116.563	4.322	3.71	87.000	146.000
2024-005	10	ENZYM. GPO	184	INTEGRA	93	ROCHE	15	118.533	3.810	3.21	89.000	148.000
2024-005	10	ENZYM. GPO	203	ROCHE	93	ROCHE	25	118.600	3.085	2.60	89.000	148.000
2024-005	10	ENZYM. GPO	219	APELLICA	143	SIEMENS	14	123.143	7.717	6.27	92.000	154.000
2024-005	11	GLY PO4 OX	197	ARCHITECT	1	ABBOTT	11	110.818	1.850	1.67	83.000	139.000
026 UREA NITROGEN (BUN)			CLIA TEST ID #: 505			EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}						
2024-001	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	96	40.484	1.880	4.64	37.000	44.000
2024-001	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	38.727	1.619	4.18	35.000	42.000
2024-001	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	32	39.594	1.783	4.50	36.000	43.000
2024-001	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	37.294	1.690	4.53	34.000	41.000
2024-001	2	UREAS.GLDH	203	ROCHE	93	ROCHE	55	39.185	1.375	3.51	36.000	43.000
2024-001	2	UREAS.GLDH	219	APELLICA	143	SIEMENS	14	38.714	1.221	3.15	35.000	42.000
2024-001	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	40.231	1.310	3.26	37.000	44.000
2024-001	8	UREASE QUI	165	VITROS	63	KODAK	158	37.731	1.009	2.67	34.000	41.000
2024-001	10	UREASE 37	220	Medica E.	130	MEDICA	13	37.231	1.887	5.07	34.000	41.000
2024-002	2	UREAS.GLDH	38	SIEMENS DI	143	SIEMENS	96	11.116	0.819	7.37	9.000	13.000
2024-002	2	UREAS.GLDH	184	INTEGRA	93	ROCHE	33	11.030	0.758	6.87	9.000	13.000
2024-002	2	UREAS.GLDH	186	BECK. COUL	76	AU-BECKMAN	32	11.594	0.655	5.65	10.000	14.000
2024-002	2	UREAS.GLDH	191	RX-SERIES	126	RANDOX	34	11.412	0.691	6.06	9.000	13.000
2024-002	2	UREAS.GLDH	203	ROCHE	93	ROCHE	55	11.074	0.504	4.55	9.000	13.000
2024-002	2	UREAS.GLDH	219	APELLICA	143	SIEMENS	14	12.000	0.000	0.00	10.000	14.000
2024-002	5	CHROMATOG.	197	ARCHITECT	1	ABBOTT	13	10.615	1.003	9.45	9.000	13.000
2024-002	8	UREASE QUI	165	VITROS	63	KODAK	158	9.510	0.560	5.89	8.000	12.000
2024-002	10	UREASE 37	220	Medica E.	130	MEDICA	13	10.923	0.730	6.68	9.000	13.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 10 ROUTINE                      GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
026 UREA NITROGEN (BUN)		CLIA TEST ID #: 505	EVALUATION CRITERIA: TARGET VALUE 9 % OR 2.00 {GREATER}								
2024-003	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		96	20.906	1.071	5.12	19.000	23.000	
2024-003	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		33	20.333	0.841	4.14	18.000	22.000	
2024-003	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		32	21.031	0.847	4.03	19.000	23.000	
2024-003	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX		34	20.676	0.962	4.65	19.000	23.000	
2024-003	2 UREAS.GLDH	203 ROCHE	93 ROCHE		55	20.648	0.724	3.51	19.000	23.000	
2024-003	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS		14	21.286	0.700	3.29	19.000	23.000	
2024-003	5 CHROMATOG.	197 ARCHITECT	1 ABBOTT		13	20.615	0.836	4.05	19.000	23.000	
2024-003	8 UREASE QUI	165 VITROS	63 KODAK		158	18.582	0.668	3.59	17.000	21.000	
2024-003	10 UREASE 37	220 Medica E.	130 MEDICA		13	20.308	0.821	4.04	18.000	22.000	
2024-004	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		96	30.854	1.561	5.06	28.000	34.000	
2024-004	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		33	29.727	1.483	4.99	27.000	32.000	
2024-004	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		32	30.406	1.389	4.57	28.000	33.000	
2024-004	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX		34	29.500	1.194	4.05	27.000	32.000	
2024-004	2 UREAS.GLDH	203 ROCHE	93 ROCHE		55	30.167	1.101	3.65	27.000	33.000	
2024-004	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS		14	30.500	0.824	2.70	28.000	33.000	
2024-004	5 CHROMATOG.	197 ARCHITECT	1 ABBOTT		13	30.769	0.973	3.16	28.000	34.000	
2024-004	8 UREASE QUI	165 VITROS	63 KODAK		158	28.082	0.834	2.97	26.000	31.000	
2024-004	10 UREASE 37	220 Medica E.	130 MEDICA		13	29.231	1.527	5.22	27.000	32.000	
2024-005	2 UREAS.GLDH	38 SIEMENS DI	143 SIEMENS		96	19.421	1.022	5.26	17.000	21.000	
2024-005	2 UREAS.GLDH	184 INTEGRA	93 ROCHE		33	18.758	0.780	4.16	17.000	21.000	
2024-005	2 UREAS.GLDH	186 BECK. COUL	76 AU-BECKMAN		32	19.594	0.824	4.20	18.000	22.000	
2024-005	2 UREAS.GLDH	191 RX-SERIES	126 RANDOX		34	19.294	0.859	4.45	17.000	21.000	
2024-005	2 UREAS.GLDH	203 ROCHE	93 ROCHE		55	19.037	0.816	4.28	17.000	21.000	
2024-005	2 UREAS.GLDH	219 ATELLICA	143 SIEMENS		14	19.929	0.593	2.98	18.000	22.000	
2024-005	5 CHROMATOG.	197 ARCHITECT	1 ABBOTT		13	19.154	1.026	5.36	17.000	21.000	
2024-005	8 UREASE QUI	165 VITROS	63 KODAK		158	17.146	0.666	3.88	15.000	19.000	
2024-005	10 UREASE 37	220 Medica E.	130 MEDICA		13	19.077	0.730	3.83	17.000	21.000	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
027 URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 17 %						
2024-001	2 URICASE	38	SIEMENS DI	143	SIEMENS	51	10.502	0.266	2.54	8.700	12.300	
2024-001	2 URICASE	165	VITROS	63	KODAK	95	10.616	0.257	2.42	8.800	12.400	
2024-001	2 URICASE	184	INTEGRA	93	ROCHE	11	10.755	0.540	5.02	8.900	12.600	
2024-001	2 URICASE	203	ROCHE	93	ROCHE	33	10.270	0.397	3.87	8.500	12.000	
2024-001	2 URICASE	219	ATELLICA	143	SIEMENS	12	10.817	0.172	1.59	9.000	12.700	
2024-001	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	10.258	0.341	3.32	8.500	12.000	
2024-001	6 ENZY. COL	203	ROCHE	93	ROCHE	13	10.475	0.164	1.57	8.700	12.300	
2024-002	2 URICASE	38	SIEMENS DI	143	SIEMENS	51	1.859	0.084	4.54	1.500	2.200	
2024-002	2 URICASE	165	VITROS	63	KODAK	95	1.791	0.052	2.91	1.500	2.100	
2024-002	2 URICASE	184	INTEGRA	93	ROCHE	11	1.827	0.096	5.27	1.500	2.100	
2024-002	2 URICASE	203	ROCHE	93	ROCHE	33	1.719	0.073	4.23	1.400	2.000	
2024-002	2 URICASE	219	ATELLICA	143	SIEMENS	12	1.908	0.076	3.98	1.600	2.200	
2024-002	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	1.863	0.067	3.57	1.500	2.200	
2024-002	6 ENZY. COL	203	ROCHE	93	ROCHE	13	1.723	0.042	2.45	1.400	2.000	
2024-003	2 URICASE	38	SIEMENS DI	143	SIEMENS	51	4.775	0.136	2.84	4.000	5.600	
2024-003	2 URICASE	165	VITROS	63	KODAK	95	4.728	0.115	2.44	3.900	5.500	
2024-003	2 URICASE	184	INTEGRA	93	ROCHE	11	4.864	0.197	4.04	4.000	5.700	
2024-003	2 URICASE	203	ROCHE	93	ROCHE	33	4.703	0.147	3.12	3.900	5.500	
2024-003	2 URICASE	219	ATELLICA	143	SIEMENS	12	4.992	0.111	2.23	4.100	5.800	
2024-003	5 URICASE 37	186	BECK. COUL	76	AU-BECKMAN	19	4.811	0.107	2.23	4.000	5.600	
2024-003	6 ENZY. COL	203	ROCHE	93	ROCHE	13	4.738	0.092	1.95	3.900	5.500	
2024-004	2 URICASE	38	SIEMENS DI	143	SIEMENS	51	7.725	0.224	2.90	6.400	9.000	
2024-004	2 URICASE	165	VITROS	63	KODAK	95	7.692	0.220	2.86	6.400	9.000	
2024-004	2 URICASE	184	INTEGRA	93	ROCHE	11	7.891	0.444	5.63	6.500	9.200	
2024-004	2 URICASE	203	ROCHE	93	ROCHE	33	7.694	0.224	2.91	6.400	9.000	
2024-004	2 URICASE	219	ATELLICA	143	SIEMENS	12	8.042	0.180	2.24	6.700	9.400	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-004	5	URICASE 37		186	BECK. COUL	76	AU-BECKMAN	19	7.658	0.179	2.33	6.400 9.000
2024-004	6	ENZY. COL		203	ROCHE	93	ROCHE	13	7.638	0.178	2.33	6.300 8.900
027	URIC ACID		CLIA TEST ID #: 515				EVALUATION CRITERIA: TARGET VALUE 17 %					
2024-005	2	URICASE		38	SIEMENS DI	143	SIEMENS	51	4.328	0.122	2.81	3.600 5.100
2024-005	2	URICASE		165	VITROS	63	KODAK	95	4.261	0.114	2.67	3.500 5.000
2024-005	2	URICASE		184	INTEGRA	93	ROCHE	11	4.382	0.185	4.22	3.600 5.100
2024-005	2	URICASE		203	ROCHE	93	ROCHE	33	4.236	0.161	3.80	3.500 5.000
2024-005	2	URICASE		219	ATELLICA	143	SIEMENS	12	4.517	0.107	2.36	3.700 5.300
2024-005	5	URICASE 37		186	BECK. COUL	76	AU-BECKMAN	19	4.379	0.115	2.63	3.600 5.100
2024-005	6	ENZY. COL		203	ROCHE	93	ROCHE	13	4.262	0.084	1.96	3.500 5.000
135	GGT (GAMMA GLU. TRA)		CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %					
2024-001	5	KINETIC 37		165	VITROS	63	KODAK	24	534.833	13.350	2.50	428.000 642.000
2024-002	5	KINETIC 37		165	VITROS	63	KODAK	24	20.333	1.312	6.45	16.000 24.000
2024-003	5	KINETIC 37		165	VITROS	63	KODAK	24	239.458	6.545	2.73	192.000 287.000
2024-004	5	KINETIC 37		165	VITROS	63	KODAK	24	406.000	11.380	2.80	325.000 487.000
2024-005	5	KINETIC 37		165	VITROS	63	KODAK	24	208.833	5.528	2.65	167.000 251.000
136	LACTIC ACID											
2024-001	1	LACTATE-P.		165	VITROS	63	KODAK	22	5.810	0.102	1.75	4.600 7.000
2024-002	1	LACTATE-P.		165	VITROS	63	KODAK	22	0.500	0.000	0.00	0.400 0.600
2024-003	1	LACTATE-P.		165	VITROS	63	KODAK	22	2.064	0.064	3.12	1.700 2.500
2024-004	1	LACTATE-P.		165	VITROS	63	KODAK	22	4.073	0.091	2.24	3.300 4.900

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
136	LACTIC ACID	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-005	1 LACTATE-P.	165	VITROS	63	KODAK	22	1.705	0.047	2.78	1.400	2.000	
137	LIPASE											
2024-001	1 COLORIMET.	203	ROCHE	93	ROCHE	18	78.059	4.235	5.43	62.000	94.000	
2024-001	1 COLORIMET.	219	ATELLICA	143	SIEMENS	10	90.100	4.134	4.59	72.000	108.000	
2024-001	2 ENZIMATIC	165	VITROS	63	KODAK	81	618.654	27.632	4.47	495.000	742.000	
2024-001	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	74.500	7.256	9.74	60.000	89.000	
2024-001	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	85.467	5.290	6.19	68.000	103.000	
2024-001	4 ENZ/COLOR	203	ROCHE	93	ROCHE	12	78.500	3.948	5.03	63.000	94.000	
2024-001	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	77.938	3.132	4.02	62.000	94.000	
2024-001	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	85.000	2.449	2.88	68.000	102.000	
2024-002	1 COLORIMET.	203	ROCHE	93	ROCHE	18	15.889	0.994	6.25	13.000	19.000	
2024-002	1 COLORIMET.	219	ATELLICA	143	SIEMENS	10	18.700	1.269	6.79	15.000	22.000	
2024-002	2 ENZIMATIC	165	VITROS	63	KODAK	81	57.222	2.611	4.56	46.000	69.000	
2024-002	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	16.600	1.428	8.60	13.000	20.000	
2024-002	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	14.500	1.592	10.98	12.000	17.000	
2024-002	4 ENZ/COLOR	203	ROCHE	93	ROCHE	12	16.250	1.090	6.71	13.000	20.000	
2024-002	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	16.000	0.816	5.10	13.000	19.000	
2024-002	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	16.938	1.088	6.42	14.000	20.000	
2024-003	1 COLORIMET.	203	ROCHE	93	ROCHE	18	37.706	1.807	4.79	30.000	45.000	
2024-003	1 COLORIMET.	219	ATELLICA	143	SIEMENS	10	44.200	2.482	5.62	35.000	53.000	
2024-003	2 ENZIMATIC	165	VITROS	63	KODAK	81	273.975	11.109	4.05	219.000	329.000	
2024-003	4 ENZ/COLOR	184	INTEGRA	93	ROCHE	10	37.500	3.557	9.48	30.000	45.000	
2024-003	4 ENZ/COLOR	186	BECK. COUL	76	AU-BECKMAN	15	38.933	2.380	6.11	31.000	47.000	
2024-003	4 ENZ/COLOR	203	ROCHE	93	ROCHE	12	37.917	1.656	4.37	30.000	46.000	
2024-003	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	38.375	1.317	3.43	31.000	46.000	
2024-003	5 SIEMENS 37	38	SIEMENS DI	143	SIEMENS	16	40.000	1.414	3.54	32.000	48.000	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY

SUB: 10 ROUTINE

GRP: 10 ROUTINE

ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH	
137	LIPASE	CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 20 %					
2024-004	1	COLORIMET.	203 ROCHE	93	18	59.941	4.505	7.51	48.000	72.000	
2024-004	1	COLORIMET.	219 ATELLICA	143	10	68.600	2.615	3.81	55.000	82.000	
2024-004	2	ENZIMATIC	165 VITROS	63	81	460.062	19.599	4.26	368.000	552.000	
2024-004	4	ENZ/COLOR	184 INTEGRA	93	10	56.800	5.618	9.89	45.000	68.000	
2024-004	4	ENZ/COLOR	186 BECK. COUL	76	15	63.467	3.243	5.11	51.000	76.000	
2024-004	4	ENZ/COLOR	203 ROCHE	93	12	58.667	2.055	3.50	47.000	70.000	
2024-004	5	SIEMENS 37	38 SIEMENS DI	143	16	63.667	3.300	5.18	51.000	76.000	
2024-004	5	SIEMENS 37	38 SIEMENS DI	143	16	59.063	1.713	2.90	47.000	71.000	
2024-005	1	COLORIMET.	203 ROCHE	93	18	34.647	1.643	4.74	28.000	42.000	
2024-005	1	COLORIMET.	219 ATELLICA	143	10	41.300	1.187	2.88	33.000	50.000	
2024-005	2	ENZIMATIC	165 VITROS	63	81	242.222	9.977	4.12	194.000	291.000	
2024-005	4	ENZ/COLOR	184 INTEGRA	93	10	33.900	3.048	8.99	27.000	41.000	
2024-005	4	ENZ/COLOR	186 BECK. COUL	76	15	34.857	1.726	4.95	28.000	42.000	
2024-005	4	ENZ/COLOR	203 ROCHE	93	12	34.667	1.546	4.46	28.000	42.000	
2024-005	5	SIEMENS 37	38 SIEMENS DI	143	16	35.200	1.681	4.78	28.000	42.000	
2024-005	5	SIEMENS 37	38 SIEMENS DI	143	16	37.333	2.494	6.68	30.000	45.000	
138	PHOSPHORUS										
2024-001	1	PHOSPHOMO.	38 SIEMENS DI	143	52	6.457	0.174	2.70	5.200	7.700	
2024-001	1	PHOSPHOMO.	165 VITROS	63	92	5.897	0.189	3.20	4.700	7.100	
2024-001	1	PHOSPHOMO.	184 INTEGRA	93	15	6.013	0.206	3.43	4.800	7.200	
2024-001	1	PHOSPHOMO.	186 BECK. COUL	76	20	6.070	0.217	3.58	4.900	7.300	
2024-001	1	PHOSPHOMO.	203 ROCHE	93	43	6.143	0.151	2.46	4.900	7.400	
2024-001	1	PHOSPHOMO.	219 ATELLICA	143	12	6.333	0.189	2.98	5.100	7.600	
2024-002	1	PHOSPHOMO.	38 SIEMENS DI	143	52	1.687	0.096	5.70	1.300	2.000	
2024-002	1	PHOSPHOMO.	165 VITROS	63	92	1.837	0.112	6.07	1.500	2.200	
2024-002	1	PHOSPHOMO.	184 INTEGRA	93	15	1.600	0.126	7.91	1.300	1.900	
2024-002	1	PHOSPHOMO.	186 BECK. COUL	76	20	1.555	0.080	5.17	1.200	1.900	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-002	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	43	1.557	0.069	4.46	1.200	1.900
2024-002	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	12	1.583	0.090	5.67	1.300	1.900
138	PHOSPHORUS	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-003	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	52	3.373	0.114	3.38	2.700	4.000
2024-003	1	PHOSPHOMO.	165	VITROS	63	KODAK	92	3.336	0.113	3.38	2.700	4.000
2024-003	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	15	3.160	0.193	6.09	2.500	3.800
2024-003	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	3.170	0.084	2.66	2.500	3.800
2024-003	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	43	3.174	0.082	2.58	2.500	3.800
2024-003	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	12	3.308	0.104	3.14	2.600	4.000
2024-004	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	52	4.958	0.159	3.20	4.000	5.900
2024-004	1	PHOSPHOMO.	165	VITROS	63	KODAK	92	4.638	0.150	3.24	3.700	5.600
2024-004	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	15	4.593	0.208	4.53	3.700	5.500
2024-004	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	4.655	0.150	3.22	3.700	5.600
2024-004	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	43	4.700	0.140	2.97	3.800	5.600
2024-004	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	12	4.883	0.099	2.02	3.900	5.900
2024-005	1	PHOSPHOMO.	38	SIEMENS DI	143	SIEMENS	52	3.138	0.121	3.86	2.500	3.800
2024-005	1	PHOSPHOMO.	165	VITROS	63	KODAK	92	3.137	0.118	3.76	2.500	3.800
2024-005	1	PHOSPHOMO.	184	INTEGRA	93	ROCHE	15	2.947	0.163	5.52	2.400	3.500
2024-005	1	PHOSPHOMO.	186	BECK. COUL	76	AU-BECKMAN	20	2.890	0.141	4.88	2.300	3.500
2024-005	1	PHOSPHOMO.	203	ROCHE	93	ROCHE	43	2.940	0.099	3.37	2.400	3.500
2024-005	1	PHOSPHOMO.	219	ATELLICA	143	SIEMENS	12	3.042	0.086	2.83	2.400	3.700
169	CO2			EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-001	1	Generic Me	165	VITROS	63	KODAK	10	22.400	1.428	6.38	18.000	27.000
2024-001	1	Generic Me	184	INTEGRA	93	ROCHE	10	24.500	2.579	10.53	17.000	32.000
2024-001	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	27	25.037	2.252	9.00	18.000	32.000
2024-001	1	Generic Me	203	ROCHE	93	ROCHE	21	22.857	3.152	13.79	13.000	32.000
2024-001	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	78	26.026	2.207	8.48	19.000	33.000
2024-001	2	ENZYMATIC	165	VITROS	63	KODAK	58	22.228	1.892	8.51	17.000	28.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-001	2	ENZYMATIC	165	VITROS	156	Kit 32	82	22.866	2.140	9.36	16.000	29.000
2024-001	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	23.231	2.750	11.84	15.000	31.000
2024-001	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	12	25.500	1.893	7.42	20.000	31.000
169	CO2	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-002	1	Generic Me	165	VITROS	63	KODAK	10	9.300	1.616	17.37	4.000	14.000
2024-002	1	Generic Me	184	INTEGRA	93	ROCHE	10	12.200	6.096	49.97	0	30.000
2024-002	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	27	10.815	1.334	12.34	7.000	15.000
2024-002	1	Generic Me	203	ROCHE	93	ROCHE	21	10.429	2.382	22.84	3.000	18.000
2024-002	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	78	12.429	1.882	15.15	7.000	18.000
2024-002	2	ENZYMATIC	165	VITROS	63	KODAK	58	8.879	1.301	14.65	5.000	13.000
2024-002	2	ENZYMATIC	165	VITROS	156	Kit 32	82	9.383	1.301	13.87	5.000	13.000
2024-002	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	10.923	1.492	13.66	6.000	15.000
2024-002	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	12	11.833	1.624	13.73	7.000	17.000
2024-003	1	Generic Me	165	VITROS	63	KODAK	10	13.000	1.342	10.32	9.000	17.000
2024-003	1	Generic Me	184	INTEGRA	93	ROCHE	10	14.800	3.250	21.96	5.000	25.000
2024-003	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	27	14.556	1.950	13.40	9.000	20.000
2024-003	1	Generic Me	203	ROCHE	93	ROCHE	21	14.190	2.872	20.24	6.000	23.000
2024-003	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	78	16.312	2.002	12.27	10.000	22.000
2024-003	2	ENZYMATIC	165	VITROS	63	KODAK	58	12.983	1.537	11.84	8.000	18.000
2024-003	2	ENZYMATIC	165	VITROS	156	Kit 32	82	13.415	1.767	13.17	8.000	19.000
2024-003	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	14.769	1.928	13.05	9.000	21.000
2024-003	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	12	16.167	2.303	14.25	9.000	23.000
2024-004	1	Generic Me	165	VITROS	63	KODAK	10	17.100	1.446	8.45	13.000	21.000
2024-004	1	Generic Me	184	INTEGRA	93	ROCHE	10	18.300	3.848	21.03	7.000	30.000
2024-004	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	27	19.074	1.844	9.67	14.000	25.000
2024-004	1	Generic Me	203	ROCHE	93	ROCHE	21	18.429	3.216	17.45	9.000	28.000
2024-004	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	78	21.221	2.479	11.68	14.000	29.000
2024-004	2	ENZYMATIC	165	VITROS	63	KODAK	58	17.466	1.967	11.26	12.000	23.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-004	2	ENZYMATIC	165	VITROS	156	Kit 32	82	17.561	1.888	10.75	12.000	23.000
2024-004	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	19.154	2.413	12.60	12.000	26.000
2024-004	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	12	20.917	1.891	9.04	15.000	27.000
169	CO2	CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-005	1	Generic Me	165	VITROS	63	KODAK	10	12.100	1.300	10.74	8.000	16.000
2024-005	1	Generic Me	184	INTEGRA	93	ROCHE	10	14.100	3.113	22.08	5.000	23.000
2024-005	1	Generic Me	186	BECK. COUL	76	AU-BECKMAN	27	14.185	1.467	10.34	10.000	19.000
2024-005	1	Generic Me	203	ROCHE	93	ROCHE	21	13.571	3.332	24.55	4.000	24.000
2024-005	2	ENZYMATIC	38	SIEMENS DI	143	SIEMENS	78	15.603	2.078	13.32	9.000	22.000
2024-005	2	ENZYMATIC	165	VITROS	63	KODAK	58	11.966	1.618	13.53	7.000	17.000
2024-005	2	ENZYMATIC	165	VITROS	156	Kit 32	82	12.427	1.601	12.88	8.000	17.000
2024-005	2	ENZYMATIC	203	ROCHE	93	ROCHE	13	14.077	2.093	14.86	8.000	20.000
2024-005	2	ENZYMATIC	219	ATELLICA	143	SIEMENS	12	15.583	1.977	12.69	10.000	22.000
170	DIRECT BILIRUBIN	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}										
2024-001	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	1.429	0.090	6.32	1.100	1.700
2024-001	11	SPECT. WIT	165	VITROS	63	KODAK	69	0.817	0.175	21.48	0.300	1.300
2024-001	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	1.243	0.184	14.81	0.700	1.800
2024-001	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	2.140	0.242	11.29	1.400	2.900
2024-001	14	VANADATE O	219	ATELLICA	143	SIEMENS	13	2.662	0.133	5.01	2.100	3.200
2024-001	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	2.120	0.312	14.74	1.200	3.100
2024-002	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	0.073	0.044	60.94	0	0.200
2024-002	11	SPECT. WIT	165	VITROS	63	KODAK	69	0.007	0.026	354.96	0	0.100
2024-002	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.140	0.080	57.14	0	0.400
2024-002	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.200	0.000	0.00	0.200	0.200
2024-002	14	VANADATE O	219	ATELLICA	143	SIEMENS	13	0.100	0.000	0.00	0.100	0.100
2024-002	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	0.050	0.067	134.16	0	0.300
2024-003	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	0.602	0.038	6.27	0.500	0.700
2024-003	11	SPECT. WIT	165	VITROS	63	KODAK	69	0.122	0.167	136.93	0	0.600

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 10 ROUTINE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-003	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.585	0.048	8.15	0.400	0.700
2024-003	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.920	0.117	12.68	0.600	1.300
2024-003	14	VANADATE O	219	ATELLICA	143	SIEMENS	13	1.146	0.063	5.53	0.900	1.400
2024-003	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	0.830	0.090	10.84	0.600	1.100
170 DIRECT BILIRUBIN			CLIA TEST ID #: 0				EVALUATION CRITERIA: TARGET VALUE 3 SD OR 20 % {GREATER}					
2024-004	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	1.067	0.074	6.93	0.800	1.300
2024-004	11	SPECT. WIT	165	VITROS	63	KODAK	69	0.509	0.143	28.14	0.100	0.900
2024-004	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	1.580	0.204	12.91	1.000	2.200
2024-004	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.995	0.067	6.72	0.800	1.200
2024-004	14	VANADATE O	219	ATELLICA	143	SIEMENS	13	2.023	0.105	5.19	1.600	2.400
2024-004	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	1.550	0.225	14.50	0.900	2.200
2024-005	4	JEND.-GROG	38	SIEMENS DI	143	SIEMENS	49	0.508	0.044	8.74	0.400	0.600
2024-005	11	SPECT. WIT	165	VITROS	63	KODAK	69	0.078	0.148	189.49	0	0.500
2024-005	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.880	0.075	8.50	0.700	1.100
2024-005	13	AZOBIL.W/D	203	ROCHE	93	ROCHE	21	0.495	0.038	7.76	0.400	0.600
2024-005	14	VANADATE O	219	ATELLICA	143	SIEMENS	13	0.977	0.058	5.89	0.800	1.200
2024-005	18	DIAZ. SULF	191	RX-SERIES	126	RANDOX	10	0.720	0.060	8.33	0.500	0.900

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE				GRP: 15 WHOLE BLOOD GLUCOSE						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
157 WHOLE BLOOD GLUCOSE							EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2024-101	23	ABBOTT PRE					27	142.731	5.821	4.08	128.000	157.000
2024-101	27	STAT SRIP.					75	111.773	7.000	6.26	101.000	123.000
2024-101	33	AC.CHEK II					33	126.152	4.762	3.77	114.000	139.000
2024-101	34	FREE STYL					45	155.178	11.995	7.73	140.000	171.000
2024-102	23	ABBOTT PRE					27	229.370	9.844	4.29	206.000	252.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 10 ROUTINE		GRP: 15 WHOLE BLOOD GLUCOSE					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-102	27	STAT SRIP.		75	158.573	13.525	8.53	143.000	174.000
2024-102	33	AC.CHEK II		33	204.455	8.425	4.12	184.000	225.000
2024-102	34	FREE STYL		45	254.867	19.297	7.57	229.000	280.000
157 WHOLE BLOOD GLUCOSE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 10 % OR 6.00 {GREATER}					
2024-103	23	ABBOTT PRE		27	460.370	27.828	6.04	414.000	506.000
2024-103	27	STAT SRIP.		75	303.467	26.735	8.81	273.000	334.000
2024-103	33	AC.CHEK II		33	458.788	19.510	4.25	413.000	505.000
2024-103	34	FREE STYL		45	497.182	7.315	1.47	447.000	547.000
2024-104	23	ABBOTT PRE		27	462.889	24.504	5.29	417.000	509.000
2024-104	27	STAT SRIP.		75	302.067	26.254	8.69	272.000	332.000
2024-104	33	AC.CHEK II		33	459.545	19.912	4.33	414.000	506.000
2024-104	34	FREE STYL		45	493.659	16.483	3.34	444.000	543.000
2024-105	23	ABBOTT PRE		27	231.222	12.891	5.58	208.000	254.000
2024-105	27	STAT SRIP.		75	161.200	13.602	8.44	145.000	177.000
2024-105	33	AC.CHEK II		33	204.485	9.126	4.46	184.000	225.000
2024-105	34	FREE STYL		45	253.267	19.732	7.79	228.000	279.000

SPEC: 10 CHEMISTRY		SUB: 20 BLOOD GASES		GRP: 30 BLOOD GASES					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
007 BLOOD GASES-pCO2		CLIA TEST ID #: 335		EVALUATION CRITERIA: TARGET VALUE 8 % OR 5.00 {GREATER}					
2024-051	265	ROCHE COBA		32	65.588	1.338	2.04	60.300	70.800
2024-052	265	ROCHE COBA		32	43.009	0.692	1.61	38.000	48.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD		SYST/INST	REAGENTS		LABS	VALUE	DEVIATION	CV	LOW	HIGH
007	BLOOD GASES-pCO2		CLIA TEST ID #: 335	EVALUATION CRITERIA: TARGET VALUE	8 % OR		5.00	{GREATER}			
2024-053	265 ROCHE COBA					32	22.328	0.583	2.61	17.300	27.300
2024-054	265 ROCHE COBA					32	66.738	1.094	1.64	61.400	72.100
2024-055	265 ROCHE COBA					32	22.200	0.515	2.32	17.200	27.200
008	BLOOD GASES-pH		CLIA TEST ID #: 315	EVALUATION CRITERIA: TARGET VALUE	0.04						
2024-051	265 ROCHE COBA					32	7.183	0.008	0.11	7.143	7.223
2024-052	265 ROCHE COBA					32	7.412	0.005	0.07	7.372	7.452
2024-053	265 ROCHE COBA					32	7.584	0.006	0.08	7.544	7.624
2024-054	265 ROCHE COBA					32	7.179	0.006	0.08	7.139	7.219
2024-055	265 ROCHE COBA					32	7.586	0.006	0.08	7.546	7.626
009	BLOOD GASES-pO2		CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE	3 SD						
2024-051	265 ROCHE COBA					32	51.083	5.158	10.10	35.600	66.600
2024-051	265 ROCHE COBA					32	57.914	3.081	5.32	48.700	67.200
2024-052	265 ROCHE COBA					32	113.543	5.359	4.72	97.500	129.600
2024-052	265 ROCHE COBA					32	113.441	6.855	6.04	92.900	134.000
2024-053	265 ROCHE COBA					32	182.572	5.652	3.10	165.600	199.500
2024-053	265 ROCHE COBA					32	188.729	7.208	3.82	167.100	210.400
2024-054	265 ROCHE COBA					32	57.000	5.046	8.85	41.900	72.100
2024-054	265 ROCHE COBA					32	50.043	4.558	9.11	36.400	63.700

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 20 BLOOD GASES			GRP: 30 BLOOD GASES					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
009	BLOOD GASES-pO2	CLIA TEST ID #: 325	EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-055	265 ROCHE COBA			32	181.890	5.772	3.17	164.600	199.200		
2024-055	265 ROCHE COBA			32	187.743	8.390	4.47	162.600	212.900		

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
029	FOLL. STIM. HOR.-FSH	CLIA TEST ID #: 0								
2024-031	116 ROCHE COBA			14	36.721	1.856	5.05	31.200	42.300	
2024-031	125 B.C.ACCESS			10	40.900	3.285	8.03	31.000	50.800	
2024-031	149 ARC i2000s			11	37.982	2.296	6.04	31.100	44.900	
2024-032	116 ROCHE COBA			14	7.014	0.336	4.79	6.000	8.000	
2024-032	125 B.C.ACCESS			10	7.520	0.464	6.17	6.100	8.900	
2024-032	149 ARC i2000s			11	6.545	0.373	5.69	5.400	7.700	
2024-033	116 ROCHE COBA			14	17.664	0.872	4.94	15.000	20.300	
2024-033	125 B.C.ACCESS			10	18.450	1.231	6.67	14.800	22.100	
2024-033	149 ARC i2000s			11	17.073	1.324	7.75	13.100	21.000	
2024-034	116 ROCHE COBA			14	27.657	1.394	5.04	23.500	31.800	
2024-034	125 B.C.ACCESS			10	28.960	1.382	4.77	24.800	33.100	
2024-034	149 ARC i2000s			11	26.955	1.576	5.85	22.200	31.700	
2024-035	116 ROCHE COBA			14	15.879	0.726	4.57	13.700	18.100	
2024-035	125 B.C.ACCESS			10	16.840	0.880	5.23	14.200	19.500	
2024-035	149 ARC i2000s			11	15.327	0.947	6.18	12.500	18.200	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
030	FREE THYROXINE	CLIA TEST ID #: 545	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-031	115 VITROS ECI			47	6.971	0.062	0.89	6.800	7.200	
2024-031	116 ROCHE COBA			47	3.247	0.198	6.09	2.700	3.800	
2024-031	125 B.C.ACCESS			48	2.519	0.112	4.46	2.200	2.900	
2024-031	149 ARC i2000s			23	2.270	0.163	7.17	1.800	2.800	
2024-031	160 SIEMENS EX			50	2.959	0.107	3.61	2.600	3.300	
2024-031	169 ATELLICA			10	2.550	0.081	3.16	2.300	2.800	
2024-032	115 VITROS ECI			47	1.687	0.136	8.07	1.300	2.100	
2024-032	116 ROCHE COBA			47	0.894	0.076	8.45	0.700	1.100	
2024-032	125 B.C.ACCESS			48	0.904	0.065	7.20	0.700	1.100	
2024-032	149 ARC i2000s			23	0.787	0.054	6.81	0.600	0.900	
2024-032	160 SIEMENS EX			50	0.890	0.061	6.83	0.700	1.100	
2024-032	169 ATELLICA			10	0.780	0.040	5.13	0.700	0.900	
2024-033	115 VITROS ECI			47	4.465	0.263	5.89	3.700	5.300	
2024-033	116 ROCHE COBA			47	1.851	0.122	6.58	1.500	2.200	
2024-033	125 B.C.ACCESS			48	1.623	0.082	5.07	1.400	1.900	
2024-033	149 ARC i2000s			23	1.517	0.092	6.04	1.200	1.800	
2024-033	160 SIEMENS EX			50	1.706	0.086	5.03	1.400	2.000	
2024-033	169 ATELLICA			10	1.530	0.078	5.10	1.300	1.800	
2024-034	115 VITROS ECI			47	6.206	0.335	5.40	5.200	7.200	
2024-034	116 ROCHE COBA			47	2.602	0.176	6.75	2.100	3.100	
2024-034	125 B.C.ACCESS			48	2.138	0.096	4.48	1.900	2.400	
2024-034	149 ARC i2000s			23	1.941	0.111	5.74	1.600	2.300	
2024-034	160 SIEMENS EX			50	2.366	0.103	4.36	2.100	2.700	
2024-034	169 ATELLICA			10	2.080	0.075	3.60	1.900	2.300	
2024-035	115 VITROS ECI			47	4.074	0.304	7.46	3.200	5.000	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-035	116	ROCHE COBA		47	1.721	0.118	6.88	1.400	2.100
2024-035	125	B.C.ACCESS		48	1.525	0.085	5.60	1.300	1.800
2024-035	149	ARC i2000s		23	1.370	0.086	6.25	1.100	1.600
2024-035	160	SIEMENS EX		50	1.576	0.074	4.72	1.400	1.800
2024-035	169	ATELLICA		10	1.410	0.083	5.89	1.200	1.700
032 hCG-QUANTITATIVE		CLIA TEST ID #: 555		EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-031	115	VITROS ECI		20	940.635	40.860	4.34	818.100	1063.200
2024-031	116	ROCHE COBA		17	760.006	35.732	4.70	652.800	867.200
2024-031	125	B.C.ACCESS		12	706.642	33.860	4.79	605.100	808.200
2024-032	115	VITROS ECI		20	2.390	0.030	1.26	2.300	2.500
2024-032	116	ROCHE COBA		17	0.376	0.094	25.00	0.100	0.700
2024-032	125	B.C.ACCESS		12	0.908	0.064	7.05	0.700	1.100
2024-033	115	VITROS ECI		20	325.220	12.944	3.98	286.400	364.100
2024-033	116	ROCHE COBA		17	258.682	12.039	4.65	222.600	294.800
2024-033	125	B.C.ACCESS		12	262.492	7.662	2.92	239.500	285.500
2024-034	115	VITROS ECI		20	641.060	28.677	4.47	555.000	727.100
2024-034	116	ROCHE COBA		17	514.369	26.816	5.21	433.900	594.800
2024-034	125	B.C.ACCESS		12	496.408	12.527	2.52	458.800	534.000
2024-035	115	VITROS ECI		20	274.350	10.402	3.79	243.100	305.600
2024-035	116	ROCHE COBA		17	214.575	10.275	4.79	183.700	245.400
2024-035	125	B.C.ACCESS		12	222.992	8.542	3.83	197.400	248.600
035 PROLACTIN		CLIA TEST ID #: 0							
2024-031	116	ROCHE COBA		15	39.407	2.104	5.34	33.100	45.700
2024-031	125	B.C.ACCESS		11	35.000	1.723	4.92	29.800	40.200
2024-032	116	ROCHE COBA		15	3.547	0.167	4.70	3.000	4.000

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY			GRP: 40 ENDOCRINOLOGY (GEN.)				
ANALYTE										
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-032	125 B.C.ACCESS			11	3.118	0.180	5.77	2.600	3.700	
035 PROLACTIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD							
2024-033	116 ROCHE COBA			15	15.700	0.985	6.28	12.700	18.700	
2024-033	125 B.C.ACCESS			11	15.036	0.849	5.65	12.500	17.600	
2024-034	116 ROCHE COBA			15	27.980	1.679	6.00	22.900	33.000	
2024-034	125 B.C.ACCESS			11	25.755	1.392	5.40	21.600	29.900	
2024-035	116 ROCHE COBA			15	13.660	0.826	6.05	11.200	16.100	
2024-035	125 B.C.ACCESS			11	13.218	0.624	4.72	11.300	15.100	
037 TESTOSTERONE										
2024-031	149 ARC i2000s			10	13.890	1.604	11.55	9.100	18.700	
2024-032	149 ARC i2000s			10	0.950	0.120	12.68	0.600	1.300	
2024-033	149 ARC i2000s			10	5.500	0.465	8.45	4.100	6.900	
2024-034	149 ARC i2000s			10	10.180	0.834	8.19	7.700	12.700	
2024-035	149 ARC i2000s			10	4.760	0.415	8.72	3.500	6.000	
039 THYRO. STI. HOR.-TSH		CLIA TEST ID #: 585								
2024-031	106 TOSOH AIA			11	8.291	0.649	7.82	6.300	10.200	
2024-031	115 VITROS ECI			54	7.749	0.221	2.85	7.100	8.400	
2024-031	116 ROCHE COBA			53	6.917	0.361	5.22	5.800	8.000	
2024-031	125 B.C.ACCESS			56	6.752	0.430	6.37	5.500	8.000	
2024-031	149 ARC i2000s			25	6.376	0.358	5.62	5.300	7.500	
2024-031	160 SIEMENS EX			81	5.862	0.313	5.34	4.900	6.800	
2024-031	169 ATELLICA			11	7.191	0.385	5.35	6.000	8.300	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 30 ENDOCRINOLOGY                      GRP: 40 ENDOCRINOLOGY (GEN.)

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
039	THYRO. STI. HOR.-TSH	CLIA TEST ID #: 585	EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-032	106 TOSOH AIA			11	0.791	0.079	10.02	0.600	1.000
2024-032	115 VITROS ECI			54	0.643	0.049	7.70	0.500	0.800
2024-032	116 ROCHE COBA			53	0.881	0.067	7.66	0.700	1.100
2024-032	125 B.C.ACCESS			56	0.691	0.058	8.40	0.500	0.900
2024-032	149 ARC i2000s			25	0.632	0.047	7.38	0.500	0.800
2024-032	160 SIEMENS EX			81	0.676	0.053	7.84	0.500	0.800
2024-032	169 ATELLICA			11	0.718	0.057	8.01	0.500	0.900
2024-033	106 TOSOH AIA			11	3.536	0.284	8.02	2.700	4.400
2024-033	115 VITROS ECI			54	3.334	0.087	2.60	3.100	3.600
2024-033	116 ROCHE COBA			53	3.185	0.181	5.69	2.600	3.700
2024-033	125 B.C.ACCESS			56	2.734	0.182	6.64	2.200	3.300
2024-033	149 ARC i2000s			25	2.600	0.188	7.22	2.000	3.200
2024-033	160 SIEMENS EX			81	2.558	0.145	5.66	2.100	3.000
2024-033	169 ATELLICA			11	3.127	0.160	5.12	2.600	3.600
2024-034	106 TOSOH AIA			11	6.018	0.539	8.96	4.400	7.600
2024-034	115 VITROS ECI			54	5.707	0.168	2.94	5.200	6.200
2024-034	116 ROCHE COBA			53	5.183	0.291	5.62	4.300	6.100
2024-034	125 B.C.ACCESS			56	4.775	0.333	6.97	3.800	5.800
2024-034	149 ARC i2000s			25	4.560	0.243	5.34	3.800	5.300
2024-034	160 SIEMENS EX			81	4.313	0.259	6.01	3.500	5.100
2024-034	169 ATELLICA			11	5.300	0.241	4.55	4.600	6.000
2024-035	106 TOSOH AIA			11	3.127	0.176	5.64	2.600	3.700
2024-035	115 VITROS ECI			54	2.969	0.096	3.23	2.700	3.300
2024-035	116 ROCHE COBA			53	2.823	0.159	5.63	2.300	3.300
2024-035	125 B.C.ACCESS			56	2.434	0.157	6.46	2.000	2.900
2024-035	149 ARC i2000s			25	2.304	0.134	5.82	1.900	2.700

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-035	160	SIEMENS EX		81	2.262	0.142	6.27	1.800	2.700	
2024-035	169	ATELLICA		11	2.745	0.116	4.21	2.400	3.100	
040	THYROXINE (T4)		CLIA TEST ID #: 595							
								EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}		
2024-031	32	SIEM DIME.		49	15.940	0.961	6.03	12.800	19.100	
2024-031	32	SIEM DIME.		49	15.644	0.609	3.90	12.500	18.800	
2024-031	115	VITROS ECI		43	12.986	0.590	4.54	10.400	15.600	
2024-031	116	ROCHE COBA		47	14.767	1.481	10.03	11.800	17.700	
2024-031	116	ROCHE COBA		47	13.613	0.855	6.28	10.900	16.300	
2024-031	125	B.C.ACCESS		45	14.193	1.022	7.20	11.400	17.000	
2024-031	125	B.C.ACCESS		45	17.867	0.704	3.94	14.300	21.400	
2024-031	149	ARC i2000s		23	13.795	1.106	8.01	11.000	16.600	
2024-031	169	ATELLICA		11	13.155	1.011	7.69	10.500	15.800	
2024-032	32	SIEM DIME.		49	3.778	0.586	15.52	2.800	4.800	
2024-032	32	SIEM DIME.		49	3.731	0.565	15.14	2.700	4.700	
2024-032	115	VITROS ECI		43	3.281	0.143	4.37	2.300	4.300	
2024-032	116	ROCHE COBA		47	3.133	0.812	25.91	2.100	4.100	
2024-032	116	ROCHE COBA		47	3.407	0.251	7.36	2.400	4.400	
2024-032	125	B.C.ACCESS		45	4.133	0.806	19.49	3.100	5.100	
2024-032	125	B.C.ACCESS		45	3.044	0.301	9.90	2.000	4.000	
2024-032	149	ARC i2000s		23	2.691	0.422	15.68	1.700	3.700	
2024-032	169	ATELLICA		11	3.918	0.338	8.63	2.900	4.900	
2024-033	32	SIEM DIME.		49	7.810	0.558	7.14	6.200	9.400	
2024-033	32	SIEM DIME.		49	7.789	0.656	8.42	6.200	9.300	
2024-033	115	VITROS ECI		43	6.888	0.342	4.96	5.500	8.300	
2024-033	116	ROCHE COBA		47	7.002	0.391	5.58	5.600	8.400	
2024-033	116	ROCHE COBA		47	7.767	1.132	14.58	6.200	9.300	
2024-033	125	B.C.ACCESS		45	7.507	0.553	7.37	6.000	9.000	
2024-033	125	B.C.ACCESS		45	8.400	0.883	10.51	6.700	10.100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-033	149	ARC i2000s		23	6.641	0.451	6.79	5.300	8.000	
2024-033	169	APELLICA		11	7.736	0.571	7.38	6.200	9.300	
040	THYROXINE (T4)		CLIA TEST ID #: 595		EVALUATION CRITERIA: TARGET VALUE 20 % OR 1.00 {GREATER}					
2024-034	32	SIEM DIME.		49	11.922	0.987	8.28	9.500	14.300	
2024-034	32	SIEM DIME.		49	11.904	0.805	6.76	9.500	14.300	
2024-034	115	VITROS ECI		43	10.084	0.435	4.31	8.100	12.100	
2024-034	116	ROCHE COBA		47	11.500	1.290	11.21	9.200	13.800	
2024-034	116	ROCHE COBA		47	10.498	0.631	6.01	8.400	12.600	
2024-034	125	B.C.ACCESS		45	13.467	0.544	4.04	10.800	16.200	
2024-034	125	B.C.ACCESS		45	11.150	0.896	8.04	8.900	13.400	
2024-034	149	ARC i2000s		23	10.345	0.566	5.47	8.300	12.400	
2024-034	169	APELLICA		11	10.845	0.926	8.54	8.700	13.000	
2024-035	32	SIEM DIME.		49	7.141	0.581	8.14	5.700	8.600	
2024-035	32	SIEM DIME.		49	7.078	0.537	7.59	5.700	8.500	
2024-035	115	VITROS ECI		43	6.274	0.278	4.43	5.000	7.500	
2024-035	116	ROCHE COBA		47	6.433	0.388	6.02	5.100	7.700	
2024-035	116	ROCHE COBA		47	7.317	0.863	11.79	5.900	8.800	
2024-035	125	B.C.ACCESS		45	6.748	0.512	7.59	5.400	8.100	
2024-035	125	B.C.ACCESS		45	7.900	0.374	4.74	6.300	9.500	
2024-035	149	ARC i2000s		23	6.041	0.427	7.07	4.800	7.200	
2024-035	169	APELLICA		11	7.191	0.509	7.08	5.800	8.600	
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %					
2024-031	115	VITROS ECI		14	11.107	0.919	8.28	8.300	13.900	
2024-031	116	ROCHE COBA		22	9.795	0.824	8.42	7.300	12.200	
2024-031	125	B.C.ACCESS		11	12.236	1.207	9.86	9.200	15.300	
2024-031	149	ARC i2000s		13	13.323	1.303	9.78	10.000	16.700	
2024-032	115	VITROS ECI		14	1.007	0.128	12.71	0.800	1.300	
2024-032	116	ROCHE COBA		22	2.000	0.000	0.00	1.500	2.500	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-032	125	B.C.ACCESS		11	1.045	0.183	17.48	0.800	1.300
2024-032	149	ARC i2000s		13	1.254	0.687	54.78	0.900	1.600
141	FOLATE		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %				
2024-033	115	VITROS ECI		14	3.650	0.299	8.20	2.700	4.600
2024-033	116	ROCHE COBA		22	2.923	0.492	16.82	2.200	3.700
2024-033	125	B.C.ACCESS		11	4.845	0.389	8.03	3.600	6.100
2024-033	149	ARC i2000s		13	4.508	0.407	9.02	3.400	5.600
2024-034	115	VITROS ECI		14	7.743	0.991	12.80	5.800	9.700
2024-034	116	ROCHE COBA		22	6.423	0.813	12.66	4.800	8.000
2024-034	125	B.C.ACCESS		11	8.809	0.584	6.63	6.600	11.000
2024-034	149	ARC i2000s		13	9.238	0.905	9.80	6.900	11.500
2024-035	115	VITROS ECI		14	3.129	0.276	8.83	2.300	3.900
2024-035	116	ROCHE COBA		22	2.555	0.422	16.51	1.900	3.200
2024-035	125	B.C.ACCESS		11	4.273	0.256	6.00	3.200	5.300
2024-035	149	ARC i2000s		13	4.138	0.514	12.41	3.100	5.200
142	hLH (HUMAN LUT. HOR)								
2024-031	116	ROCHE COBA		12	36.517	2.366	6.48	27.400	45.600
2024-031	125	B.C.ACCESS		10	32.240	1.838	5.70	24.200	40.300
2024-031	149	ARC i2000s		10	25.600	1.772	6.92	19.200	32.000
2024-032	116	ROCHE COBA		12	4.933	0.357	7.23	3.700	6.200
2024-032	125	B.C.ACCESS		10	3.680	0.271	7.37	2.800	4.600
2024-032	149	ARC i2000s		10	2.940	0.180	6.12	2.200	3.700
2024-033	116	ROCHE COBA		12	16.883	0.900	5.33	12.700	21.100
2024-033	125	B.C.ACCESS		10	14.640	1.029	7.03	11.000	18.300
2024-033	149	ARC i2000s		10	10.660	0.692	6.49	8.000	13.300

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)						
ANALYTE	SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
142 hLH (HUMAN LUT. HOR)		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %						
	2024-034	116	ROCHE COBA		12	27.475	1.558	5.67	20.600	34.300
	2024-034	125	B.C.ACCESS		10	24.420	1.344	5.51	18.300	30.500
	2024-034	149	ARC i2000s		10	18.240	1.163	6.38	13.700	22.800
	2024-035	116	ROCHE COBA		12	15.092	0.859	5.69	11.300	18.900
	2024-035	125	B.C.ACCESS		10	13.110	0.709	5.41	9.800	16.400
	2024-035	149	ARC i2000s		10	9.580	0.534	5.58	7.200	12.000

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY		GRP: 40 ENDOCRINOLOGY (GEN.)							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART # LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE											
2024-031	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-031	142	INSTANT VI		002 002	002 002		002 - POSITIVE	33	33	33	100
2024-031	150	AIM STEP		002 002	002 002		002 - POSITIVE	99	99	99	100
2024-031	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100
2024-031	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100
2024-031	166	FaStep		002 002	002 002		002 - POSITIVE	18	18	18	100
2024-031	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100
2024-032	113	BIO-SIGN		001 001	001 001		001 - NEGATIVE	23	22	22	100
2024-032	113	BIO-SIGN		001 001	001 001		002 - POSITIVE	23	1	22	0
2024-032	142	INSTANT VI		001 001	001 001		001 - NEGATIVE	33	33	33	100
2024-032	150	AIM STEP		001 001	001 001		001 - NEGATIVE	99	99	99	100
2024-032	164	HCG Alere		001 001	001 001		001 - NEGATIVE	70	70	70	100
2024-032	165	Osom HCG C		001 001	001 001		001 - NEGATIVE	22	22	22	100
2024-032	166	FaStep		001 001	001 001		001 - NEGATIVE	18	18	18	100
2024-032	168	STANBIO 20		001 001	001 001		001 - NEGATIVE	14	14	14	100



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY SUB: 30 ENDOCRINOLOGY GRP: 40 ENDOCRINOLOGY (GEN.)

TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
031 hCG-QUALITATIVE											
2024-033	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-033	142	INSTANT VI		002 002	002 002		002 - POSITIVE	33	33	33	100
2024-033	150	AIM STEP		002 002	002 002		002 - POSITIVE	99	99	99	100
2024-033	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100
2024-033	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100
2024-033	166	FaStep		002 002	002 002		002 - POSITIVE	18	18	18	100
2024-033	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100
2024-034	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-034	142	INSTANT VI		002 002	002 002		002 - POSITIVE	33	33	33	100
2024-034	150	AIM STEP		002 002	002 002		002 - POSITIVE	99	99	99	100
2024-034	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100
2024-034	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100
2024-034	166	FaStep		002 002	002 002		002 - POSITIVE	18	18	18	100
2024-034	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100
2024-035	113	BIO-SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100
2024-035	142	INSTANT VI		002 002	002 002		002 - POSITIVE	33	33	33	100
2024-035	150	AIM STEP		002 002	002 002		002 - POSITIVE	99	99	99	100
2024-035	164	HCG Alere		002 002	002 002		002 - POSITIVE	70	70	70	100
2024-035	165	Osom HCG C		002 002	002 002		002 - POSITIVE	22	22	22	100
2024-035	166	FaStep		002 002	002 002		002 - POSITIVE	18	18	18	100
2024-035	168	STANBIO 20		002 002	002 002		002 - POSITIVE	14	14	14	100

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
151 hCG ONLY QUALITATIVE													
2024-021	018	BIO SIGN		001 001	001 001		001 - NEGATIVE	23	23	23	100		
2024-021	114	INSTANT VI		001 001	001 001		002 - POSITIVE	75	1	74	0		
2024-021	114	INSTANT VI		001 001	001 001		001 - NEGATIVE	75	74	74	100		
2024-021	118	AIM STEP		001 001	001 001		001 - NEGATIVE	207	207	207	100		
2024-021	130	ALERE HCG		001 001	001 001		001 - NEGATIVE	94	94	94	100		
2024-021	131	OSOM HCG		001 001	001 001		001 - NEGATIVE	30	30	30	100		
2024-021	133	FaStep		001 001	001 001		001 - NEGATIVE	34	34	34	100		
2024-021	134	Tanner Sc.		001 001	001 001		001 - NEGATIVE	50	50	50	100		
2024-021	136	CLARITY		001 001	001 001		001 - NEGATIVE	18	18	18	100		
2024-022	018	BIO SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100		
2024-022	114	INSTANT VI		002 002	002 002		002 - POSITIVE	75	74	74	100		
2024-022	114	INSTANT VI		002 002	002 002		001 - NEGATIVE	75	1	74	0		
2024-022	118	AIM STEP		002 002	002 002		002 - POSITIVE	207	207	207	100		
2024-022	130	ALERE HCG		002 002	002 002		002 - POSITIVE	94	94	94	100		
2024-022	131	OSOM HCG		002 002	002 002		002 - POSITIVE	30	30	30	100		
2024-022	133	FaStep		002 002	002 002		002 - POSITIVE	34	34	34	100		
2024-022	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	50	50	50	100		
2024-022	136	CLARITY		002 002	002 002		002 - POSITIVE	18	18	18	100		
2024-023	018	BIO SIGN		002 002	002 002		002 - POSITIVE	23	23	23	100		
2024-023	114	INSTANT VI		002 002	002 002		002 - POSITIVE	75	75	75	100		
2024-023	118	AIM STEP		002 002	002 002		002 - POSITIVE	207	207	207	100		
2024-023	130	ALERE HCG		002 002	002 002		002 - POSITIVE	94	94	94	100		
2024-023	131	OSOM HCG		002 002	002 002		002 - POSITIVE	30	30	30	100		
2024-023	133	FaStep		002 002	002 002		002 - POSITIVE	34	34	34	100		
2024-023	134	Tanner Sc.		002 002	002 002		002 - POSITIVE	50	50	50	100		
2024-023	136	CLARITY		002 002	002 002		002 - POSITIVE	18	18	18	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 45 ENDOCRINOL.-hCG ONLY					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
151 hCG ONLY QUALITATIVE												
2024-024	018	BIO SIGN		002	002	002	002	002 - POSITIVE	23	23	23	100
2024-024	114	INSTANT VI		002	002	002	002	002 - POSITIVE	75	75	75	100
2024-024	118	AIM STEP		002	002	002	002	002 - POSITIVE	207	207	207	100
2024-024	130	ALERE HCG		002	002	002	002	002 - POSITIVE	94	94	94	100
2024-024	131	OSOM HCG		002	002	002	002	002 - POSITIVE	30	30	30	100
2024-024	133	FaStep		002	002	002	002	002 - POSITIVE	34	34	34	100
2024-024	134	Tanner Sc.		002	002	002	002	002 - POSITIVE	50	50	50	100
2024-024	136	CLARITY		002	002	002	002	002 - POSITIVE	18	18	18	100
2024-025	018	BIO SIGN		001	001	001	001	001 - NEGATIVE	23	23	23	100
2024-025	114	INSTANT VI		001	001	001	001	002 - POSITIVE	75	2	73	0
2024-025	114	INSTANT VI		001	001	001	001	001 - NEGATIVE	75	73	73	100
2024-025	118	AIM STEP		001	001	001	001	002 - POSITIVE	207	1	206	0
2024-025	118	AIM STEP		001	001	001	001	001 - NEGATIVE	207	206	206	100
2024-025	130	ALERE HCG		001	001	001	001	001 - NEGATIVE	94	94	94	100
2024-025	131	OSOM HCG		001	001	001	001	001 - NEGATIVE	30	30	30	100
2024-025	133	FaStep		001	001	001	001	001 - NEGATIVE	34	34	34	100
2024-025	134	Tanner Sc.		001	001	001	001	001 - NEGATIVE	50	49	49	100
2024-025	134	Tanner Sc.		001	001	001	001	002 - POSITIVE	50	1	49	0
2024-025	136	CLARITY		001	001	001	001	001 - NEGATIVE	18	18	18	100

SPEC: 10 CHEMISTRY			SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)					
ANALYTE												
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
173 T3 UPTAKE												
CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD								
2024-031	1	%U	84	VITROS ECI	1	25-35	39	47.826	1.720	3.60	42.670	52.990
2024-031	1	%U	91	B.C.ACCESS	2	35-45	31	45.547	2.963	6.50	36.660	54.440

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 30 ENDOCRINOLOGY				GRP: 55 ENDO.(T3 UPTAKE)						
ANALYTE												
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH	
2024-031	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.149	0.078	6.75	0.920	1.380	
2024-031	4 %	32	DIMENSION	2	35-45	56	39.767	1.425	3.58	35.490	44.040	
2024-031	4 %	91	B.C.ACCESS	2	35-45	12	45.608	1.788	3.92	40.240	50.970	
2024-031	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.619	0.062	9.95	0.430	0.800	
173	T3 UPTAKE	CLIA TEST ID #: 565				EVALUATION CRITERIA: TARGET VALUE 3 SD						
2024-032	1 %U	84	VITROS ECI	1	25-35	39	60.371	2.182	3.61	53.830	66.920	
2024-032	1 %U	91	B.C.ACCESS	2	35-45	31	51.909	2.433	4.69	44.610	59.210	
2024-032	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.624	0.047	7.46	0.480	0.760	
2024-032	4 %	32	DIMENSION	2	35-45	56	38.187	1.320	3.46	34.230	42.150	
2024-032	4 %	91	B.C.ACCESS	2	35-45	12	52.592	2.217	4.22	45.940	59.240	
2024-032	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.878	0.055	6.26	0.710	1.040	
2024-033	1 %U	84	VITROS ECI	1	25-35	39	55.429	1.739	3.14	50.210	60.650	
2024-033	1 %U	91	B.C.ACCESS	2	35-45	31	49.888	2.960	5.93	41.010	58.770	
2024-033	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.858	0.060	6.98	0.680	1.040	
2024-033	4 %	32	DIMENSION	2	35-45	56	38.586	1.268	3.29	34.780	42.390	
2024-033	4 %	91	B.C.ACCESS	2	35-45	12	50.600	1.292	2.55	46.730	54.470	
2024-033	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.772	0.056	7.31	0.600	0.940	
2024-034	1 %U	84	VITROS ECI	1	25-35	39	50.924	1.801	3.54	45.520	56.330	
2024-034	1 %U	91	B.C.ACCESS	2	35-45	31	48.539	3.031	6.24	39.450	57.630	
2024-034	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	1.018	0.068	6.72	0.810	1.220	
2024-034	4 %	32	DIMENSION	2	35-45	56	39.380	1.569	3.98	34.670	44.090	
2024-034	4 %	91	B.C.ACCESS	2	35-45	12	47.658	2.042	4.29	41.530	53.790	
2024-034	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.692	0.063	9.09	0.500	0.880	
2024-035	1 %U	84	VITROS ECI	1	25-35	39	56.247	1.888	3.36	50.580	61.910	
2024-035	1 %U	91	B.C.ACCESS	2	35-45	31	50.161	3.174	6.33	40.640	59.680	
2024-035	2 TUV	95	Arc i2000s	3	0.7 - 1.2	17	0.824	0.063	7.67	0.630	1.010	
2024-035	4 %	32	DIMENSION	2	35-45	56	38.959	1.445	3.71	34.630	43.290	

**Participant Summary**  
**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 30 ENDOCRINOLOGY                      GRP: 55 ENDO.(T3 UPTAKE)

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-035	4 %	91	B.C.ACCESS	2	35-45	12	50.267	1.382	2.75	46.120	54.410		
2024-035	5 TBI	98	ROCHE COBA	4	0.8-1.3	42	0.787	0.056	7.10	0.620	0.950		

SPEC: 10 CHEMISTRY                      SUB: 40 TOXICOLOGY                      GRP: 60 TOXICOLOGY

ANALYTE													
SAMPLE	METHOD	SYST/INST		REAGENTS		NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
043 DIGOXIN		CLIA TEST ID #: 645		EVALUATION CRITERIA: TARGET VALUE 20 % OR 0.20 {GREATER}									
2024-031	50 VITROS					15	1.667	0.178	10.66	1.300	2.000		
2024-032	50 VITROS					15	0.467	0.060	12.78	0.300	0.700		
2024-033	50 VITROS					15	0.773	0.077	9.98	0.600	1.000		
2024-034	50 VITROS					15	1.160	0.102	8.79	0.900	1.400		
2024-035	50 VITROS					15	0.707	0.124	17.50	0.500	0.900		
045 FERRITIN		CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %									
2024-031	50 VITROS					18	145.778	8.522	5.85	109.300	182.200		
2024-031	90 ROCHE COBA					14	237.443	10.467	4.41	178.100	296.800		
2024-031	98 ARC i200sr					10	242.040	15.503	6.41	181.500	302.600		
2024-031	105 ATELLICA					10	168.890	6.788	4.02	126.700	211.100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 40 TOXICOLOGY		GRP: 60 TOXICOLOGY						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
045	FERRITIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 %							
2024-032	50 VITROS			18	17.372	0.801	4.61	13.000	21.700	
2024-032	90 ROCHE COBA			14	30.564	1.223	4.00	22.900	38.200	
2024-032	98 ARC i200sr			10	25.280	2.312	9.15	19.000	31.600	
2024-032	105 ATELLICA			10	18.240	0.919	5.04	13.700	22.800	
2024-033	50 VITROS			18	57.933	3.763	6.50	43.500	72.400	
2024-033	90 ROCHE COBA			14	100.121	3.801	3.80	75.100	125.200	
2024-033	98 ARC i200sr			10	97.080	9.904	10.20	72.800	121.400	
2024-033	105 ATELLICA			10	65.560	3.360	5.13	49.200	82.000	
2024-034	50 VITROS			18	102.217	5.503	5.38	76.700	127.800	
2024-034	90 ROCHE COBA			14	171.236	7.040	4.11	128.400	214.000	
2024-034	98 ARC i200sr			10	171.230	13.370	7.81	128.400	214.000	
2024-034	105 ATELLICA			10	118.330	5.692	4.81	88.700	147.900	
2024-035	50 VITROS			18	52.272	2.509	4.80	39.200	65.300	
2024-035	90 ROCHE COBA			14	88.043	3.940	4.47	66.000	110.100	
2024-035	98 ARC i200sr			10	84.950	5.280	6.22	63.700	106.200	
2024-035	105 ATELLICA			10	58.080	3.793	6.53	43.600	72.600	
046	GENTAMICIN	CLIA TEST ID #: 665								
2024-031	50 VITROS			15	13.853	0.855	6.18	10.400	17.300	
2024-032	50 VITROS			15	0.600	0.000	0.00	0.500	0.800	
2024-033	50 VITROS			15	4.627	0.188	4.06	3.500	5.800	
2024-034	50 VITROS			15	9.087	0.490	5.39	6.800	11.400	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 40 TOXICOLOGY			GRP: 60 TOXICOLOGY				
ANALYTE										
SAMPLE	METHOD		SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
046 GENTAMICIN			CLIA TEST ID #: 665	EVALUATION CRITERIA: TARGET VALUE 25 %						
2024-035	50 VITROS				15	3.840	0.136	3.53	2.900	4.800
050 PHENYTOIN			CLIA TEST ID #: 695							
2024-031	50 VITROS				15	28.313	1.333	4.71	21.200	35.400
2024-031	92 ROCHE COBA				10	23.250	1.968	8.47	17.400	29.100
2024-032	50 VITROS				15	2.200	1.720	78.20	1.700	2.800
2024-032	92 ROCHE COBA				10	0.720	0.240	33.33	0.500	0.900
2024-033	50 VITROS				15	8.879	0.298	3.36	6.700	11.100
2024-033	92 ROCHE COBA				10	8.170	0.564	6.90	6.100	10.200
2024-034	50 VITROS				15	19.214	0.407	2.12	14.400	24.000
2024-034	92 ROCHE COBA				10	16.720	0.939	5.62	12.500	20.900
2024-035	50 VITROS				15	7.357	0.232	3.15	5.500	9.200
2024-035	92 ROCHE COBA				10	6.820	0.593	8.69	5.100	8.500
054 THEOPHYLLINE			CLIA TEST ID #: 735							
2024-031	50 VITROS				12	47.892	2.595	5.42	35.900	59.900
2024-032	50 VITROS				12	2.417	0.339	14.02	1.800	3.000
2024-033	50 VITROS				12	19.200	0.727	3.79	14.400	24.000
2024-034	50 VITROS				12	34.508	1.141	3.31	25.900	43.100
2024-035	50 VITROS				12	16.533	0.571	3.45	12.400	20.700
127 VANCOMYCIN			CLIA TEST ID #: 0							
2024-031	50 VITROS				19	46.958	2.366	5.04	35.200	58.700

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 40 TOXICOLOGY                      GRP: 60 TOXICOLOGY

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-031	92	ROCHE COBA		11	44.473	2.063	4.64	33.400	55.600
127 VANCOMYCIN			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 25 %				
2024-032	50	VITROS		19	5.000	0.000	0.00	3.800	6.300
2024-032	92	ROCHE COBA		11	4.000	0.000	0.00	3.000	5.000
2024-033	50	VITROS		19	14.726	0.664	4.51	11.000	18.400
2024-033	92	ROCHE COBA		11	15.236	0.803	5.27	11.400	19.000
2024-034	50	VITROS		19	29.453	1.512	5.13	22.100	36.800
2024-034	92	ROCHE COBA		11	29.800	1.749	5.87	22.400	37.300
2024-035	50	VITROS		19	12.547	0.557	4.44	9.400	15.700
2024-035	92	ROCHE COBA		11	12.809	1.030	8.04	9.600	16.000

SPEC: 10 CHEMISTRY                      SUB: 50 URINALYSIS                      GRP: 70 URINALYSIS

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
065 URINA-PROTEIN QUANT.					EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}				
2024-061	58	VITROS		39	160.816	10.460	6.50	120.600	201.000
2024-061	62	SIEM DIM.		49	115.036	2.752	2.39	86.300	143.800
2024-061	79	BECK. COUL		20	102.220	5.378	5.26	76.700	127.800
2024-061	93	ARCHITECT		18	94.744	2.223	2.35	71.100	118.400
2024-061	93	ARCHITECT		18	107.400	3.878	3.61	80.600	134.300
2024-061	113	ROCHE COBA		35	89.109	2.504	2.81	66.800	111.400
2024-061	146	ATELLICA		11	111.064	2.833	2.55	83.300	138.800
2024-062	58	VITROS		39	133.658	9.235	6.91	100.200	167.100
2024-062	62	SIEM DIM.		49	107.684	2.126	1.97	80.800	134.600



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 50 URINALYSIS                      GRP: 70 URINALYSIS

ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-062	79	BECK. COUL		20	99.510	4.984	5.01	74.600	124.400	
2024-062	93	ARCHITECT		18	99.000	3.521	3.56	74.300	123.800	
2024-062	93	ARCHITECT		18	96.306	3.311	3.44	72.200	120.400	
2024-062	113	ROCHE COBA		35	88.917	2.206	2.48	66.700	111.100	
2024-062	146	APELLICA		11	103.950	7.220	6.95	78.000	129.900	
065	URINA-PROTEIN QUANT.	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}							
2024-063	58	VITROS		39	172.184	8.757	5.09	129.100	215.200	
2024-063	62	SIEM DIM.		49	112.342	1.807	1.61	84.300	140.400	
2024-063	79	BECK. COUL		20	98.400	5.230	5.32	73.800	123.000	
2024-063	93	ARCHITECT		18	96.550	2.617	2.71	72.400	120.700	
2024-063	93	ARCHITECT		18	104.800	3.370	3.22	78.600	131.000	
2024-063	113	ROCHE COBA		35	92.297	2.345	2.54	69.200	115.400	
2024-063	146	APELLICA		11	109.173	2.525	2.31	81.900	136.500	
2024-064	58	VITROS		39	4.974	0.160	3.22	0.000	10.000	
2024-064	62	SIEM DIM.		49	13.952	1.083	7.77	9.000	19.000	
2024-064	79	BECK. COUL		20	3.905	0.932	23.88	0	8.900	
2024-064	93	ARCHITECT		18	4.800	1.166	24.30	0	9.800	
2024-064	93	ARCHITECT		18	6.812	0.058	0.85	1.800	11.800	
2024-064	113	ROCHE COBA		35	3.912	0.351	8.98	0	8.900	
2024-064	146	APELLICA		11	14.309	2.393	16.72	9.300	19.300	
2024-065	58	VITROS		39	5.000	0.000	0.00	0.000	10.000	
2024-065	62	SIEM DIM.		49	19.541	1.673	8.56	14.500	24.500	
2024-065	79	BECK. COUL		20	4.316	0.590	13.66	0	9.300	
2024-065	93	ARCHITECT		18	7.047	0.965	13.69	2.000	12.000	
2024-065	93	ARCHITECT		18	6.800	0.980	14.41	1.800	11.800	
2024-065	113	ROCHE COBA		35	3.779	0.501	13.26	0	8.800	
2024-065	146	APELLICA		11	18.218	4.423	24.28	13.200	23.200	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
067	URI-SPECIFIC GRAVITY	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD					
2024-061	11 AMES NM10S			39	1.023	0.003	0.33	1.012	1.033	
2024-061	13 BAYER CLI			24	1.022	0.003	0.31	1.012	1.031	
2024-061	67 URISCAN			57	1.019	0.003	0.29	1.011	1.028	
2024-061	72 URS-9-TECO			60	1.022	0.004	0.35	1.012	1.033	
2024-061	80 ROCHE (CHE			37	1.014	0.002	0.23	1.007	1.020	
2024-061	89 AIMSTRIP			145	1.020	0.002	0.23	1.014	1.027	
2024-061	94 CLINITEK			104	1.025	0.018	1.72	0.972	1.077	
2024-061	102 ACON LAB			129	1.020	0.002	0.22	1.013	1.027	
2024-061	131 iCHEM VELO			30	1.026	0.001	0.09	1.023	1.029	
2024-061	138 URS-10T			12	1.020	0.003	0.28	1.011	1.029	
2024-061	140 MISSION A			42	1.020	0.003	0.31	1.010	1.029	
2024-061	145 CLINITEK			36	1.028	0.001	0.07	1.026	1.030	
2024-061	147 Mission120			42	1.022	0.002	0.23	1.015	1.029	
2024-061	148 Mission500			112	1.020	0.000	0.00	1.020	1.020	
2024-061	151 Clari. Uro			20	1.019	0.003	0.25	1.011	1.027	
2024-062	11 AMES NM10S			39	1.025	0.003	0.27	1.017	1.033	
2024-062	13 BAYER CLI			24	1.023	0.003	0.31	1.014	1.033	
2024-062	67 URISCAN			57	1.023	0.004	0.35	1.012	1.034	
2024-062	72 URS-9-TECO			60	1.023	0.004	0.36	1.012	1.035	
2024-062	80 ROCHE (CHE			37	1.016	0.002	0.20	1.010	1.022	
2024-062	89 AIMSTRIP			145	1.024	0.002	0.22	1.017	1.031	
2024-062	94 CLINITEK			104	1.026	0.017	1.69	0.974	1.078	
2024-062	102 ACON LAB			129	1.023	0.003	0.27	1.015	1.031	
2024-062	131 iCHEM VELO			30	1.025	0.001	0.10	1.022	1.028	
2024-062	138 URS-10T			12	1.023	0.003	0.31	1.013	1.033	
2024-062	140 MISSION A			42	1.023	0.002	0.24	1.015	1.030	
2024-062	145 CLINITEK			36	1.030	0.001	0.06	1.029	1.032	
2024-062	147 Mission120			42	1.024	0.003	0.31	1.014	1.033	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS				
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-062	148	Mission500		112	1.022	0.002	0.24	1.014	1.029	
2024-062	151	Clari. Uro		20	1.024	0.002	0.17	1.019	1.030	
067 URI-SPECIFIC GRAVITY		CLIA TEST ID #: 0			EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-063	11	AMES NM10S		39	1.021	0.003	0.32	1.011	1.030	
2024-063	13	BAYER CLI		24	1.020	0.003	0.26	1.012	1.028	
2024-063	67	URISCAN		57	1.016	0.003	0.26	1.008	1.024	
2024-063	72	URS-9-TECO		60	1.020	0.004	0.36	1.009	1.031	
2024-063	80	ROCHE (CHE		37	1.011	0.002	0.24	1.004	1.018	
2024-063	89	AIMSTRIP		145	1.018	0.003	0.27	1.010	1.027	
2024-063	94	CLINITEK		104	1.022	0.018	1.73	0.969	1.075	
2024-063	102	ACON LAB		129	1.018	0.003	0.29	1.009	1.027	
2024-063	131	iCHEM VELO		30	1.028	0.001	0.12	1.024	1.031	
2024-063	138	URS-10T		12	1.019	0.004	0.35	1.008	1.030	
2024-063	140	MISSION A		42	1.017	0.003	0.31	1.008	1.027	
2024-063	145	CLINITEK		36	1.030	0.001	0.06	1.029	1.032	
2024-063	147	Mission120		42	1.020	0.002	0.19	1.014	1.026	
2024-063	148	Mission500		112	1.017	0.003	0.25	1.010	1.025	
2024-063	151	Clari. Uro		20	1.016	0.002	0.21	1.010	1.023	
2024-064	11	AMES NM10S		39	1.022	0.004	0.35	1.012	1.033	
2024-064	13	BAYER CLI		24	1.020	0.005	0.51	1.004	1.035	
2024-064	67	URISCAN		57	1.022	0.003	0.32	1.012	1.032	
2024-064	72	URS-9-TECO		60	1.021	0.005	0.49	1.006	1.036	
2024-064	80	ROCHE (CHE		37	1.017	0.002	0.23	1.010	1.024	
2024-064	89	AIMSTRIP		145	1.021	0.003	0.28	1.012	1.029	
2024-064	94	CLINITEK		104	1.024	0.018	1.74	0.970	1.077	
2024-064	102	ACON LAB		129	1.021	0.003	0.28	1.013	1.030	
2024-064	131	iCHEM VELO		30	1.027	0.001	0.11	1.024	1.030	
2024-064	138	URS-10T		12	1.022	0.005	0.50	1.006	1.037	
2024-064	140	MISSION A		42	1.022	0.003	0.30	1.013	1.031	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-064	145	CLINITEK		36	1.033	0.001	0.06	1.031	1.035
2024-064	147	Mission120		42	1.022	0.002	0.23	1.015	1.029
2024-064	148	Mission500		112	1.021	0.002	0.22	1.014	1.028
2024-064	151	Clari. Uro		20	1.023	0.003	0.29	1.014	1.032
067 URI-SPECIFIC GRAVITY			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD					
2024-065	11	AMES NM10S		39	1.018	0.004	0.38	1.006	1.030
2024-065	13	BAYER CLI		24	1.016	0.004	0.41	1.004	1.029
2024-065	67	URISCAN		57	1.015	0.002	0.25	1.007	1.022
2024-065	72	URS-9-TECO		60	1.018	0.004	0.36	1.007	1.029
2024-065	80	ROCHE (CHE		37	1.012	0.002	0.23	1.005	1.019
2024-065	89	AIMSTRIP		145	1.016	0.002	0.23	1.009	1.023
2024-065	94	CLINITEK		104	1.021	0.025	2.49	0.945	1.097
2024-065	102	ACON LAB		129	1.016	0.003	0.29	1.007	1.025
2024-065	131	iCHEM VELO		30	1.026	0.001	0.09	1.023	1.028
2024-065	138	URS-10T		12	1.018	0.004	0.43	1.005	1.031
2024-065	140	MISSION A		42	1.017	0.003	0.30	1.008	1.026
2024-065	145	CLINITEK		36	1.031	0.001	0.07	1.029	1.033
2024-065	147	Mission120		42	1.019	0.003	0.26	1.011	1.027
2024-065	148	Mission500		112	1.016	0.002	0.24	1.008	1.023
2024-065	151	Clari. Uro		20	1.016	0.002	0.23	1.009	1.023
166 MICROALBUMIN				EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-061	58	VITROS		52	860.548	42.564	4.95	645.400	1075.700
2024-061	62	SIEM DIM.		82	846.517	44.795	5.29	634.900	1058.100
2024-061	62	SIEM DIM.		82	810.967	87.996	10.85	608.200	1013.700
2024-061	79	BECK. COUL		20	769.160	109.147	14.19	576.900	961.500
2024-061	85	Rx DAYTONA		14	803.193	102.012	12.70	602.400	1004.000
2024-061	93	ARCHITECT		22	844.590	52.721	6.24	633.400	1055.700
2024-061	95	INTEGRA		19	831.747	28.911	3.48	623.800	1039.700
2024-061	113	ROCHE COBA		42	819.324	37.375	4.56	614.500	1024.200
2024-061	146	ATELLICA		13	722.723	25.299	3.50	542.000	903.400

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	%	OR	5.00	{GREATER}		
2024-062	58	VITROS		52	852.958	43.036	5.05	639.700	1066.200	
2024-062	62	SIEM DIM.		82	756.867	34.010	4.49	567.700	946.100	
2024-062	62	SIEM DIM.		82	841.879	40.163	4.77	631.400	1052.300	
2024-062	79	BECK. COUL		20	774.720	120.227	15.52	581.000	968.400	
2024-062	85	Rx DAYTONA		14	789.029	86.573	10.97	591.800	986.300	
2024-062	93	ARCHITECT		22	853.700	36.170	4.24	640.300	1067.100	
2024-062	95	INTEGRA		19	821.842	32.675	3.98	616.400	1027.300	
2024-062	113	ROCHE COBA		42	809.305	41.786	5.16	607.000	1011.600	
2024-062	146	APELLICA		13	700.577	26.770	3.82	525.400	875.700	
2024-063	58	VITROS		52	838.035	40.584	4.84	628.500	1047.500	
2024-063	62	SIEM DIM.		82	830.930	42.064	5.06	623.200	1038.700	
2024-063	62	SIEM DIM.		82	769.300	72.867	9.47	577.000	961.600	
2024-063	79	BECK. COUL		20	755.655	106.114	14.04	566.700	944.600	
2024-063	85	Rx DAYTONA		14	766.100	81.861	10.69	574.600	957.600	
2024-063	93	ARCHITECT		22	838.529	46.052	5.49	628.900	1048.200	
2024-063	95	INTEGRA		19	809.058	30.343	3.75	606.800	1011.300	
2024-063	113	ROCHE COBA		42	798.427	39.310	4.92	598.800	998.000	
2024-063	146	APELLICA		13	692.992	21.370	3.08	519.700	866.200	
2024-064	58	VITROS		52	6.000	0.000	0.00	1.000	11.000	
2024-064	62	SIEM DIM.		82	3.400	2.404	70.71	0	8.400	
2024-064	62	SIEM DIM.		82	2.706	1.081	39.96	0	7.700	
2024-064	79	BECK. COUL		20	2.655	2.883	108.59	0	7.700	
2024-064	85	Rx DAYTONA		14	1.693	2.292	135.41	0	6.700	
2024-064	93	ARCHITECT		22	4.995	0.021	0.43	0.000	10.000	
2024-064	95	INTEGRA		19	3.172	1.238	39.03	0	8.200	
2024-064	113	ROCHE COBA		42	11.718	1.739	14.84	6.700	16.700	
2024-064	146	APELLICA		13	3.000	0.000	0.00	0	8.000	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 50 URINALYSIS		GRP: 70 URINALYSIS						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
166	MICROALBUMIN	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	25	% OR 5.00	{GREATER}				
2024-065	58	VITROS		52	6.000	0.000	0.00	1.000	11.000	
2024-065	62	SIEM DIM.		82	1.919	0.832	43.37	0	6.900	
2024-065	62	SIEM DIM.		82	3.400	2.404	70.71	0	8.400	
2024-065	79	BECK. COUL		20	2.640	2.888	109.41	0	7.600	
2024-065	85	Rx DAYTONA		14	1.979	2.430	122.80	0	7.000	
2024-065	93	ARCHITECT		22	5.424	1.531	28.23	0.400	10.400	
2024-065	95	INTEGRA		19	3.256	1.290	39.62	0	8.300	
2024-065	113	ROCHE COBA		42	11.718	1.739	14.84	6.700	16.700	
2024-065	146	APELLICA		13	3.000	0.000	0.00	0	8.000	
167	CREATININE									
2024-061	58	VITROS		53	244.637	8.595	3.51	183.500	305.800	
2024-061	62	SIEM DIM.		78	246.764	8.741	3.54	185.100	308.500	
2024-061	79	BECK. COUL		20	218.800	14.343	6.56	164.100	273.500	
2024-061	85	Rx DAYTONA		10	226.120	22.889	10.12	169.600	282.700	
2024-061	93	ARCHITECT		20	241.260	6.511	2.70	180.900	301.600	
2024-061	95	INTEGRA		18	257.067	11.274	4.39	192.800	321.300	
2024-061	113	ROCHE COBA		43	251.412	8.749	3.48	188.600	314.300	
2024-061	146	APELLICA		13	229.677	6.337	2.76	172.300	287.100	
2024-062	58	VITROS		53	3.276	0.434	13.24	0	8.300	
2024-062	62	SIEM DIM.		78	8.809	5.815	66.02	3.800	13.800	
2024-062	79	BECK. COUL		20	1.058	1.523	143.99	0	6.100	
2024-062	85	Rx DAYTONA		10	0.770	1.037	134.72	0	5.800	
2024-062	93	ARCHITECT		20	5.000	0.000	0.00	0.000	10.000	
2024-062	95	INTEGRA		18	0.512	0.509	99.38	0	5.500	
2024-062	113	ROCHE COBA		43	3.609	1.182	32.75	0	8.600	
2024-062	146	APELLICA		13	3.000	0.000	0.00	0	8.000	
2024-063	58	VITROS		53	244.232	7.280	2.98	183.200	305.300	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			
ANALYTE									
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH
2024-063	62	SIEM DIM.		78	236.118	8.016	3.40	177.100	295.100
2024-063	79	BECK. COUL		20	200.590	16.257	8.10	150.400	250.700
2024-063	85	Rx DAYTONA		10	217.870	21.676	9.95	163.400	272.300
2024-063	93	ARCHITECT		20	234.700	5.639	2.40	176.000	293.400
2024-063	95	INTEGRA		18	245.589	11.597	4.72	184.200	307.000
2024-063	113	ROCHE COBA		43	240.477	10.333	4.30	180.400	300.600
2024-063	146	APELLICA		13	221.823	6.500	2.93	166.400	277.300
167	CREATININE		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 25 % OR 5.00 {GREATER}					
2024-064	58	VITROS		53	3.252	0.400	12.29	0	8.300
2024-064	62	SIEM DIM.		78	8.815	5.835	66.19	3.800	13.800
2024-064	79	BECK. COUL		20	0.811	1.526	188.30	0	5.800
2024-064	85	Rx DAYTONA		10	1.340	1.570	117.20	0	6.300
2024-064	93	ARCHITECT		20	4.995	0.022	0.45	0.000	10.000
2024-064	95	INTEGRA		18	0.400	0.484	120.96	0	5.400
2024-064	113	ROCHE COBA		43	3.660	1.049	28.67	0	8.700
2024-064	146	APELLICA		13	3.000	0.000	0.00	0	8.000
2024-065	58	VITROS		53	248.420	14.139	5.69	186.300	310.500
2024-065	62	SIEM DIM.		78	241.253	7.903	3.28	180.900	301.600
2024-065	79	BECK. COUL		20	215.990	14.725	6.82	162.000	270.000
2024-065	85	Rx DAYTONA		10	220.580	22.220	10.07	165.400	275.700
2024-065	93	ARCHITECT		20	238.300	6.399	2.69	178.700	297.900
2024-065	95	INTEGRA		18	248.844	9.883	3.97	186.600	311.100
2024-065	113	ROCHE COBA		43	244.430	9.785	4.00	183.300	305.500
2024-065	146	APELLICA		13	225.377	7.578	3.36	169.000	281.700
SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS			GRP: 70 URINALYSIS			

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
057 URINALYSIS-BILIRUBIN													
2024-061	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	39	39	39	100	
2024-061	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	24	24	24	100	
2024-061	067	URISCAN		057	057	057	057	057 - NEGATIVE	56	56	56	100	
2024-061	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	60	60	60	100	
2024-061	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2024-061	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	144	144	144	100	
2024-061	094	CLINITEK		057	057	057	057	057 - NEGATIVE	104	104	104	100	
2024-061	102	ACON LAB		057	057	057	057	057 - NEGATIVE	124	124	124	100	
2024-061	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	30	30	30	100	
2024-061	138	URS-10T		057	057	057	057	057 - NEGATIVE	14	14	14	100	
2024-061	140	MISSION A		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-061	145	CLINITEK		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2024-061	147	Mission120		057	057	057	057	057 - NEGATIVE	43	43	43	100	
2024-061	148	Mission500		057	057	057	057	057 - NEGATIVE	116	116	116	100	
2024-061	151	Clari. Uro		057	057	057	057	057 - NEGATIVE	20	20	20	100	
2024-062	011	AMES NM10S		057	057	057	057	057 - NEGATIVE	39	39	39	100	
2024-062	013	BAYER CLI		057	057	057	057	057 - NEGATIVE	24	24	24	100	
2024-062	067	URISCAN		057	057	057	057	057 - NEGATIVE	56	56	56	100	
2024-062	072	URS-9-TECO		057	057	057	057	057 - NEGATIVE	60	60	60	100	
2024-062	080	ROCHE (CHE		057	057	057	057	057 - NEGATIVE	36	36	36	100	
2024-062	089	AIMSTRIP		057	057	057	057	057 - NEGATIVE	144	144	144	100	
2024-062	094	CLINITEK		057	057	057	057	057 - NEGATIVE	104	104	104	100	
2024-062	102	ACON LAB		057	057	057	057	057 - NEGATIVE	124	124	124	100	
2024-062	131	iCHEM VELO		057	057	057	057	057 - NEGATIVE	30	30	30	100	
2024-062	138	URS-10T		057	057	057	057	057 - NEGATIVE	14	14	14	100	
2024-062	140	MISSION A		057	057	057	057	057 - NEGATIVE	40	40	40	100	
2024-062	145	CLINITEK		057	057	057	057	057 - NEGATIVE	36	36	36	100	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-062	147	Mission120		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2024-062	148	Mission500		057 057	057 057		057 - NEGATIVE	116	115	115	100	
2024-062	148	Mission500		057 057	057 057		058 - TRACES,1+	116	1	115	0	
2024-062	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	20	20	20	100	
057 URINALYSIS-BILIRUBIN												
2024-063	011	AMES NM10S		058 060	057 059		060 - 3+	39	4	39	100	
2024-063	011	AMES NM10S		058 060	057 059		059 - 2+	39	31	39	100	
2024-063	011	AMES NM10S		058 060	057 059		058 - TRACES,1+	39	4	39	100	
2024-063	013	BAYER CLI		058 060	057 059		058 - TRACES,1+	24	1	24	100	
2024-063	013	BAYER CLI		058 060	057 059		059 - 2+	24	23	24	100	
2024-063	067	URISCAN		057 059	057 059		059 - 2+	56	7	56	100	
2024-063	067	URISCAN		057 059	057 059		058 - TRACES,1+	56	40	56	100	
2024-063	067	URISCAN		057 059	057 059		057 - NEGATIVE	56	9	56	100	
2024-063	072	URS-9-TECO		058 060	057 059		058 - TRACES,1+	60	16	60	100	
2024-063	072	URS-9-TECO		058 060	057 059		059 - 2+	60	29	60	100	
2024-063	072	URS-9-TECO		058 060	057 059		060 - 3+	60	14	60	100	
2024-063	072	URS-9-TECO		058 060	057 059		057 - NEGATIVE	60	1	60	100	
2024-063	080	ROCHE (CHE		057 059	057 059		059 - 2+	36	9	34	100	
2024-063	080	ROCHE (CHE		057 059	057 059		058 - TRACES,1+	36	25	34	100	
2024-063	080	ROCHE (CHE		057 059	057 059		060 - 3+	36	2	34	0	
2024-063	089	AIMSTRIP		057 059	057 059		057 - NEGATIVE	144	5	130	100	
2024-063	089	AIMSTRIP		057 059	057 059		058 - TRACES,1+	144	93	130	100	
2024-063	089	AIMSTRIP		057 059	057 059		059 - 2+	144	32	130	100	
2024-063	089	AIMSTRIP		057 059	057 059		060 - 3+	144	14	130	0	
2024-063	094	CLINITEK		058 060	057 059		058 - TRACES,1+	104	5	104	100	
2024-063	094	CLINITEK		058 060	057 059		060 - 3+	104	3	104	100	
2024-063	094	CLINITEK		058 060	057 059		059 - 2+	104	96	104	100	
2024-063	102	ACON LAB		057 059	057 059		058 - TRACES,1+	124	81	119	100	
2024-063	102	ACON LAB		057 059	057 059		059 - 2+	124	37	119	100	
2024-063	102	ACON LAB		057 059	057 059		060 - 3+	124	5	119	0	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	102	ACON LAB		057 059	057 059		057 - NEGATIVE	124	1	119	100	
2024-063	131	iCHEM VELO		057 057	057 059		057 - NEGATIVE	30	30	30	100	
2024-063	138	URS-10T		058 060	057 059		060 - 3+	14	3	14	100	
2024-063	138	URS-10T		058 060	057 059		059 - 2+	14	9	14	100	
2024-063	138	URS-10T		058 060	057 059		058 - TRACES,1+	14	2	14	100	
2024-063	140	MISSION A		057 059	057 059		057 - NEGATIVE	40	1	39	100	
2024-063	140	MISSION A		057 059	057 059		060 - 3+	40	1	39	0	
2024-063	140	MISSION A		057 059	057 059		058 - TRACES,1+	40	26	39	100	
2024-063	140	MISSION A		057 059	057 059		059 - 2+	40	12	39	100	
2024-063	145	CLINITEK		057 057	057 059		057 - NEGATIVE	36	36	36	100	
2024-063	147	Mission120		057 059	057 059		057 - NEGATIVE	43	1	43	100	
2024-063	147	Mission120		057 059	057 059		059 - 2+	43	9	43	100	
2024-063	147	Mission120		057 059	057 059		058 - TRACES,1+	43	33	43	100	
2024-063	148	Mission500		057 059	057 059		058 - TRACES,1+	116	104	116	100	
2024-063	148	Mission500		057 059	057 059		059 - 2+	116	10	116	100	
2024-063	148	Mission500		057 059	057 059		057 - NEGATIVE	116	2	116	100	
2024-063	151	Clari. Uro		057 059	057 059		060 - 3+	20	1	19	0	
2024-063	151	Clari. Uro		057 059	057 059		059 - 2+	20	6	19	100	
2024-063	151	Clari. Uro		057 059	057 059		058 - TRACES,1+	20	13	19	100	
057 URINALYSIS-BILIRUBIN												
2024-064	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2024-064	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	24	24	24	100	
2024-064	067	URISCAN		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2024-064	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	60	60	60	100	
2024-064	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-064	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	144	144	144	100	
2024-064	094	CLINITEK		057 057	057 057		057 - NEGATIVE	104	104	104	100	
2024-064	102	ACON LAB		057 057	057 057		057 - NEGATIVE	124	124	124	100	
2024-064	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2024-064	138	URS-10T		057 057	057 057		057 - NEGATIVE	14	14	14	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	140	MISSION A		057 057	057 057		057 - NEGATIVE	40	40	40	100	
2024-064	145	CLINITEK		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-064	147	Mission120		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2024-064	148	Mission500		057 057	057 057		057 - NEGATIVE	116	116	116	100	
2024-064	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	20	20	20	100	
057 URINALYSIS-BILIRUBIN												
2024-065	011	AMES NM10S		057 057	057 057		057 - NEGATIVE	39	39	39	100	
2024-065	013	BAYER CLI		057 057	057 057		057 - NEGATIVE	24	24	24	100	
2024-065	067	URISCAN		057 057	057 057		057 - NEGATIVE	56	56	56	100	
2024-065	072	URS-9-TECO		057 057	057 057		057 - NEGATIVE	60	60	60	100	
2024-065	080	ROCHE (CHE		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-065	089	AIMSTRIP		057 057	057 057		057 - NEGATIVE	144	144	144	100	
2024-065	094	CLINITEK		057 057	057 057		057 - NEGATIVE	104	104	104	100	
2024-065	102	ACON LAB		057 057	057 057		057 - NEGATIVE	124	124	124	100	
2024-065	131	iCHEM VELO		057 057	057 057		057 - NEGATIVE	30	30	30	100	
2024-065	138	URS-10T		057 057	057 057		057 - NEGATIVE	14	14	14	100	
2024-065	140	MISSION A		057 057	057 057		057 - NEGATIVE	40	40	40	100	
2024-065	145	CLINITEK		057 057	057 057		057 - NEGATIVE	36	36	36	100	
2024-065	147	Mission120		057 057	057 057		057 - NEGATIVE	43	43	43	100	
2024-065	148	Mission500		057 057	057 057		057 - NEGATIVE	116	116	116	100	
2024-065	151	Clari. Uro		057 057	057 057		057 - NEGATIVE	20	20	20	100	
058 URINALYSIS-GLUCOSE												
2024-061	011	AMES NM10S		073 073	073 073		073 - NEGATIVE	40	40	40	100	
2024-061	013	BAYER CLI		073 073	073 073		074 - TRACES	24	1	23	0	
2024-061	013	BAYER CLI		073 073	073 073		073 - NEGATIVE	24	23	23	100	
2024-061	067	URISCAN		073 073	073 073		073 - NEGATIVE	56	56	56	100	
2024-061	072	URS-9-TECO		073 073	073 073		073 - NEGATIVE	59	59	59	100	
2024-061	080	ROCHE (CHE		073 073	073 073		073 - NEGATIVE	37	37	37	100	
2024-061	089	AIMSTRIP		073 073	073 073		073 - NEGATIVE	144	144	144	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	094 CLINITEK			073 073	073 073		073 - NEGATIVE	104	104	104	100	
2024-061	102 ACON LAB			073 073	073 073		074 - TRACES	128	1	127	0	
2024-061	102 ACON LAB			073 073	073 073		073 - NEGATIVE	128	127	127	100	
2024-061	131 iCHEM VELO			073 073	073 073		073 - NEGATIVE	30	30	30	100	
2024-061	138 URS-10T			073 073	073 073		073 - NEGATIVE	13	12	12	100	
2024-061	138 URS-10T			073 073	073 073		074 - TRACES	13	1	12	0	
2024-061	140 MISSION A			073 073	073 073		073 - NEGATIVE	42	42	42	100	
2024-061	145 CLINITEK			073 073	073 073		073 - NEGATIVE	36	36	36	100	
2024-061	147 Mission120			073 073	073 073		073 - NEGATIVE	42	42	42	100	
2024-061	148 Mission500			073 073	073 073		073 - NEGATIVE	114	114	114	100	
2024-061	151 Clari. Uro			073 073	073 073		073 - NEGATIVE	20	20	20	100	
058 URINALYSIS-GLUCOSE												
2024-062	011 AMES NM10S			076 078	075 077		077 - 1000mg/dl	40	27	40	100	
2024-062	011 AMES NM10S			076 078	075 077		076 - 500mg/dl2+	40	13	40	100	
2024-062	013 BAYER CLI			076 078	075 077		077 - 1000mg/dl	24	12	24	100	
2024-062	013 BAYER CLI			076 078	075 077		076 - 500mg/dl2+	24	12	24	100	
2024-062	067 URISCAN			077 078	075 077		076 - 500mg/dl2+	56	2	56	100	
2024-062	067 URISCAN			077 078	075 077		078 - 2000mg/dl	56	40	56	100	
2024-062	067 URISCAN			077 078	075 077		077 - 1000mg/dl	56	14	56	100	
2024-062	072 URS-9-TECO			076 078	075 077		076 - 500mg/dl2+	59	17	59	100	
2024-062	072 URS-9-TECO			076 078	075 077		077 - 1000mg/dl	59	36	59	100	
2024-062	072 URS-9-TECO			076 078	075 077		078 - 2000mg/dl	59	6	59	100	
2024-062	080 ROCHE (CHE			076 078	075 077		078 - 2000mg/dl	37	3	37	100	
2024-062	080 ROCHE (CHE			076 078	075 077		077 - 1000mg/dl	37	34	37	100	
2024-062	089 AIMSTRIP			076 078	075 077		077 - 1000mg/dl	144	83	144	100	
2024-062	089 AIMSTRIP			076 078	075 077		075 - 250mg/dl-+	144	2	144	100	
2024-062	089 AIMSTRIP			076 078	075 077		078 - 2000mg/dl	144	1	144	100	
2024-062	089 AIMSTRIP			076 078	075 077		076 - 500mg/dl2+	144	58	144	100	
2024-062	094 CLINITEK			076 078	075 077		077 - 1000mg/dl	104	74	104	100	
2024-062	094 CLINITEK			076 078	075 077		075 - 250mg/dl-+	104	1	104	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-062	094	CLINITEK		076 078	075 077		078 - 2000mg/dl	104	2	104	100		
2024-062	094	CLINITEK		076 078	075 077		076 - 500mg/dl2+	104	27	104	100		
2024-062	102	ACON LAB		076 078	075 077		077 - 1000mg/dl	128	62	127	100		
2024-062	102	ACON LAB		076 078	075 077		073 - NEGATIVE	128	1	127	0		
2024-062	102	ACON LAB		076 078	075 077		076 - 500mg/dl2+	128	59	127	100		
2024-062	102	ACON LAB		076 078	075 077		075 - 250mg/dl-+	128	1	127	100		
2024-062	102	ACON LAB		076 078	075 077		078 - 2000mg/dl	128	5	127	100		
2024-062	131	iCHEM VELO		075 077	075 077		077 - 1000mg/dl	30	3	30	100		
2024-062	131	iCHEM VELO		075 077	075 077		076 - 500mg/dl2+	30	27	30	100		
2024-062	138	URS-10T		076 078	075 077		078 - 2000mg/dl	13	1	13	100		
2024-062	138	URS-10T		076 078	075 077		077 - 1000mg/dl	13	7	13	100		
2024-062	138	URS-10T		076 078	075 077		076 - 500mg/dl2+	13	5	13	100		
2024-062	140	MISSION A		076 078	075 077		078 - 2000mg/dl	42	6	42	100		
2024-062	140	MISSION A		076 078	075 077		077 - 1000mg/dl	42	25	42	100		
2024-062	140	MISSION A		076 078	075 077		076 - 500mg/dl2+	42	11	42	100		
2024-062	145	CLINITEK		076 078	075 077		078 - 2000mg/dl	36	4	36	100		
2024-062	145	CLINITEK		076 078	075 077		075 - 250mg/dl-+	36	1	36	100		
2024-062	145	CLINITEK		076 078	075 077		076 - 500mg/dl2+	36	1	36	100		
2024-062	145	CLINITEK		076 078	075 077		077 - 1000mg/dl	36	30	36	100		
2024-062	147	Mission120		076 078	075 077		075 - 250mg/dl-+	42	1	42	100		
2024-062	147	Mission120		076 078	075 077		077 - 1000mg/dl	42	27	42	100		
2024-062	147	Mission120		076 078	075 077		076 - 500mg/dl2+	42	4	42	100		
2024-062	147	Mission120		076 078	075 077		078 - 2000mg/dl	42	10	42	100		
2024-062	148	Mission500		076 078	075 077		076 - 500mg/dl2+	114	42	113	100		
2024-062	148	Mission500		076 078	075 077		073 - NEGATIVE	114	1	113	0		
2024-062	148	Mission500		076 078	075 077		077 - 1000mg/dl	114	59	113	100		
2024-062	148	Mission500		076 078	075 077		078 - 2000mg/dl	114	12	113	100		
2024-062	151	Clari. Uro		076 078	075 077		075 - 250mg/dl-+	20	1	20	100		
2024-062	151	Clari. Uro		076 078	075 077		076 - 500mg/dl2+	20	6	20	100		
2024-062	151	Clari. Uro		076 078	075 077		077 - 1000mg/dl	20	13	20	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
058 URINALYSIS-GLUCOSE												
2024-063	011 AMES NM10S			073 073	073 073		073 - NEGATIVE	40	40	40	100	
2024-063	013 BAYER CLI			073 073	073 073		073 - NEGATIVE	24	24	24	100	
2024-063	067 URISCAN			073 073	073 073		073 - NEGATIVE	56	56	56	100	
2024-063	072 URS-9-TECO			073 073	073 073		073 - NEGATIVE	59	59	59	100	
2024-063	080 ROCHE (CHE			073 073	073 073		074 - TRACES	37	2	35	0	
2024-063	080 ROCHE (CHE			073 073	073 073		073 - NEGATIVE	37	35	35	100	
2024-063	089 AIMSTRIP			073 073	073 073		073 - NEGATIVE	144	144	144	100	
2024-063	094 CLINITEK			073 073	073 073		073 - NEGATIVE	104	104	104	100	
2024-063	102 ACON LAB			073 073	073 073		073 - NEGATIVE	128	128	128	100	
2024-063	131 icHEM VELO			073 073	073 073		073 - NEGATIVE	30	30	30	100	
2024-063	138 URS-10T			073 073	073 073		073 - NEGATIVE	13	13	13	100	
2024-063	140 MISSION A			073 073	073 073		073 - NEGATIVE	42	42	42	100	
2024-063	145 CLINITEK			073 073	073 073		073 - NEGATIVE	36	36	36	100	
2024-063	147 Mission120			073 073	073 073		073 - NEGATIVE	42	42	42	100	
2024-063	148 Mission500			073 073	073 073		076 - 500mg/dl2+	114	1	113	0	
2024-063	148 Mission500			073 073	073 073		073 - NEGATIVE	114	113	113	100	
2024-063	151 Clari. Uro			073 073	073 073		073 - NEGATIVE	20	20	20	100	
2024-064	011 AMES NM10S			074 076	074 076		075 - 250mg/dl-+	40	29	38	100	
2024-064	011 AMES NM10S			074 076	074 076		076 - 500mg/dl2+	40	2	38	100	
2024-064	011 AMES NM10S			074 076	074 076		074 - TRACES	40	7	38	100	
2024-064	011 AMES NM10S			074 076	074 076		073 - NEGATIVE	40	2	38	0	
2024-064	013 BAYER CLI			074 076	074 076		075 - 250mg/dl-+	24	17	24	100	
2024-064	013 BAYER CLI			074 076	074 076		074 - TRACES	24	7	24	100	
2024-064	067 URISCAN			075 077	074 076		075 - 250mg/dl-+	56	16	55	100	
2024-064	067 URISCAN			075 077	074 076		078 - 2000mg/dl	56	1	55	0	
2024-064	067 URISCAN			075 077	074 076		076 - 500mg/dl2+	56	24	55	100	
2024-064	067 URISCAN			075 077	074 076		074 - TRACES	56	1	55	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	067	URISCAN		075 077	074 076		077 - 1000mg/dl	56	14	55	100	
2024-064	072	URS-9-TECO		074 076	074 076		075 - 250mg/dl-+	59	36	57	100	
2024-064	072	URS-9-TECO		074 076	074 076		074 - TRACES	59	16	57	100	
2024-064	072	URS-9-TECO		074 076	074 076		076 - 500mg/dl2+	59	5	57	100	
2024-064	072	URS-9-TECO		074 076	074 076		073 - NEGATIVE	59	2	57	0	
2024-064	080	ROCHE (CHE		076 078	074 076		077 - 1000mg/dl	37	32	37	100	
2024-064	080	ROCHE (CHE		076 078	074 076		075 - 250mg/dl-+	37	2	37	100	
2024-064	080	ROCHE (CHE		076 078	074 076		078 - 2000mg/dl	37	3	37	100	
2024-064	089	AIMSTRIP		074 076	074 076		076 - 500mg/dl2+	144	5	138	100	
2024-064	089	AIMSTRIP		074 076	074 076		074 - TRACES	144	15	138	100	
2024-064	089	AIMSTRIP		074 076	074 076		073 - NEGATIVE	144	6	138	0	
2024-064	089	AIMSTRIP		074 076	074 076		075 - 250mg/dl-+	144	118	138	100	
2024-064	094	CLINITEK		074 076	074 076		075 - 250mg/dl-+	104	69	104	100	
2024-064	094	CLINITEK		074 076	074 076		076 - 500mg/dl2+	104	1	104	100	
2024-064	094	CLINITEK		074 076	074 076		074 - TRACES	104	34	104	100	
2024-064	102	ACON LAB		074 076	074 076		076 - 500mg/dl2+	128	1	124	100	
2024-064	102	ACON LAB		074 076	074 076		073 - NEGATIVE	128	4	124	0	
2024-064	102	ACON LAB		074 076	074 076		074 - TRACES	128	19	124	100	
2024-064	102	ACON LAB		074 076	074 076		075 - 250mg/dl-+	128	104	124	100	
2024-064	131	iCHEM VELO		075 077	074 076		077 - 1000mg/dl	30	3	30	100	
2024-064	131	iCHEM VELO		075 077	074 076		076 - 500mg/dl2+	30	27	30	100	
2024-064	138	URS-10T		073 075	074 076		074 - TRACES	13	8	13	100	
2024-064	138	URS-10T		073 075	074 076		075 - 250mg/dl-+	13	5	13	100	
2024-064	140	MISSION A		074 076	074 076		074 - TRACES	42	1	40	100	
2024-064	140	MISSION A		074 076	074 076		073 - NEGATIVE	42	2	40	0	
2024-064	140	MISSION A		074 076	074 076		075 - 250mg/dl-+	42	39	40	100	
2024-064	145	CLINITEK		076 078	074 076		077 - 1000mg/dl	36	31	36	100	
2024-064	145	CLINITEK		076 078	074 076		076 - 500mg/dl2+	36	1	36	100	
2024-064	145	CLINITEK		076 078	074 076		078 - 2000mg/dl	36	4	36	100	
2024-064	147	Mission120		074 076	074 076		075 - 250mg/dl-+	42	40	42	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	147	Mission120		074 076	074 076		074 - TRACES	42	2	42	100	
2024-064	148	Mission500		074 076	074 076		073 - NEGATIVE	114	1	113	0	
2024-064	148	Mission500		074 076	074 076		076 - 500mg/dl2+	114	1	113	100	
2024-064	148	Mission500		074 076	074 076		074 - TRACES	114	4	113	100	
2024-064	148	Mission500		074 076	074 076		075 - 250mg/dl-+	114	108	113	100	
2024-064	151	Clari. Uro		074 076	074 076		075 - 250mg/dl-+	20	19	20	100	
2024-064	151	Clari. Uro		074 076	074 076		074 - TRACES	20	1	20	100	
058 URINALYSIS-GLUCOSE												
2024-065	011	AMES NM10S		076 078	076 078		077 - 1000mg/dl	40	30	40	100	
2024-065	011	AMES NM10S		076 078	076 078		076 - 500mg/dl2+	40	9	40	100	
2024-065	011	AMES NM10S		076 078	076 078		078 - 2000mg/dl	40	1	40	100	
2024-065	013	BAYER CLI		076 078	076 078		077 - 1000mg/dl	24	13	23	100	
2024-065	013	BAYER CLI		076 078	076 078		076 - 500mg/dl2+	24	10	23	100	
2024-065	013	BAYER CLI		076 078	076 078		075 - 250mg/dl-+	24	1	23	0	
2024-065	067	URISCAN		077 078	076 078		078 - 2000mg/dl	56	36	56	100	
2024-065	067	URISCAN		077 078	076 078		076 - 500mg/dl2+	56	4	56	100	
2024-065	067	URISCAN		077 078	076 078		077 - 1000mg/dl	56	16	56	100	
2024-065	072	URS-9-TECO		076 078	076 078		078 - 2000mg/dl	59	9	59	100	
2024-065	072	URS-9-TECO		076 078	076 078		076 - 500mg/dl2+	59	16	59	100	
2024-065	072	URS-9-TECO		076 078	076 078		077 - 1000mg/dl	59	34	59	100	
2024-065	080	ROCHE (CHE		076 078	076 078		075 - 250mg/dl-+	37	1	36	0	
2024-065	080	ROCHE (CHE		076 078	076 078		077 - 1000mg/dl	37	33	36	100	
2024-065	080	ROCHE (CHE		076 078	076 078		078 - 2000mg/dl	37	3	36	100	
2024-065	089	AIMSTRIP		076 078	076 078		075 - 250mg/dl-+	144	4	140	0	
2024-065	089	AIMSTRIP		076 078	076 078		078 - 2000mg/dl	144	2	140	100	
2024-065	089	AIMSTRIP		076 078	076 078		077 - 1000mg/dl	144	89	140	100	
2024-065	089	AIMSTRIP		076 078	076 078		076 - 500mg/dl2+	144	49	140	100	
2024-065	094	CLINITEK		076 078	076 078		077 - 1000mg/dl	104	70	102	100	
2024-065	094	CLINITEK		076 078	076 078		078 - 2000mg/dl	104	3	102	100	
2024-065	094	CLINITEK		076 078	076 078		075 - 250mg/dl-+	104	2	102	0	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-065	094	CLINITEK		076 078	076 078		076 - 500mg/dl2+	104	29	102	100		
2024-065	102	ACON LAB		076 078	076 078		076 - 500mg/dl2+	128	53	121	100		
2024-065	102	ACON LAB		076 078	076 078		073 - NEGATIVE	128	2	121	0		
2024-065	102	ACON LAB		076 078	076 078		077 - 1000mg/dl	128	61	121	100		
2024-065	102	ACON LAB		076 078	076 078		078 - 2000mg/dl	128	7	121	100		
2024-065	102	ACON LAB		076 078	076 078		075 - 250mg/dl-+	128	5	121	0		
2024-065	131	iCHEM VELO		075 077	076 078		076 - 500mg/dl2+	30	26	30	100		
2024-065	131	iCHEM VELO		075 077	076 078		077 - 1000mg/dl	30	4	30	100		
2024-065	138	URS-10T		075 077	076 078		077 - 1000mg/dl	13	5	13	100		
2024-065	138	URS-10T		075 077	076 078		078 - 2000mg/dl	13	1	13	100		
2024-065	138	URS-10T		075 077	076 078		076 - 500mg/dl2+	13	7	13	100		
2024-065	140	MISSION A		076 078	076 078		077 - 1000mg/dl	42	23	42	100		
2024-065	140	MISSION A		076 078	076 078		076 - 500mg/dl2+	42	11	42	100		
2024-065	140	MISSION A		076 078	076 078		078 - 2000mg/dl	42	8	42	100		
2024-065	145	CLINITEK		076 078	076 078		075 - 250mg/dl-+	36	2	34	0		
2024-065	145	CLINITEK		076 078	076 078		078 - 2000mg/dl	36	4	34	100		
2024-065	145	CLINITEK		076 078	076 078		076 - 500mg/dl2+	36	2	34	100		
2024-065	145	CLINITEK		076 078	076 078		077 - 1000mg/dl	36	28	34	100		
2024-065	147	Mission120		076 078	076 078		077 - 1000mg/dl	42	22	42	100		
2024-065	147	Mission120		076 078	076 078		076 - 500mg/dl2+	42	6	42	100		
2024-065	147	Mission120		076 078	076 078		078 - 2000mg/dl	42	14	42	100		
2024-065	148	Mission500		076 078	076 078		073 - NEGATIVE	114	2	108	0		
2024-065	148	Mission500		076 078	076 078		076 - 500mg/dl2+	114	27	108	100		
2024-065	148	Mission500		076 078	076 078		075 - 250mg/dl-+	114	4	108	0		
2024-065	148	Mission500		076 078	076 078		078 - 2000mg/dl	114	21	108	100		
2024-065	148	Mission500		076 078	076 078		077 - 1000mg/dl	114	60	108	100		
2024-065	151	Clari. Uro		076 078	076 078		074 - TRACES	20	1	18	0		
2024-065	151	Clari. Uro		076 078	076 078		077 - 1000mg/dl	20	13	18	100		
2024-065	151	Clari. Uro		076 078	076 078		075 - 250mg/dl-+	20	1	18	0		
2024-065	151	Clari. Uro		076 078	076 078		076 - 500mg/dl2+	20	5	18	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
059 URINALYS.HG.OR BLOOD													
2024-061	011 AMES NM10S			068 069	068 069		069 - POS.(3+) )	40	38	40	100		
2024-061	011 AMES NM10S			068 069	068 069		068 - POS.(1-2+)	40	2	40	100		
2024-061	013 BAYER CLI			068 069	068 069		069 - POS.(3+) )	24	24	24	100		
2024-061	067 URISCAN			068 069	068 069		069 - POS.(3+) )	56	50	56	100		
2024-061	067 URISCAN			068 069	068 069		068 - POS.(1-2+)	56	6	56	100		
2024-061	072 URS-9-TECO			068 069	068 069		069 - POS.(3+) )	59	58	59	100		
2024-061	072 URS-9-TECO			068 069	068 069		068 - POS.(1-2+)	59	1	59	100		
2024-061	080 ROCHE (CHE			068 069	068 069		069 - POS.(3+) )	37	36	37	100		
2024-061	080 ROCHE (CHE			068 069	068 069		068 - POS.(1-2+)	37	1	37	100		
2024-061	089 AIMSTRIP			068 069	068 069		068 - POS.(1-2+)	143	5	143	100		
2024-061	089 AIMSTRIP			068 069	068 069		069 - POS.(3+) )	143	138	143	100		
2024-061	094 CLINITEK			068 069	068 069		068 - POS.(1-2+)	104	2	104	100		
2024-061	094 CLINITEK			068 069	068 069		069 - POS.(3+) )	104	102	104	100		
2024-061	102 ACON LAB			068 069	068 069		068 - POS.(1-2+)	130	3	130	100		
2024-061	102 ACON LAB			068 069	068 069		069 - POS.(3+) )	130	127	130	100		
2024-061	131 iCHEM VELO			068 069	068 069		068 - POS.(1-2+)	30	3	30	100		
2024-061	131 iCHEM VELO			068 069	068 069		069 - POS.(3+) )	30	27	30	100		
2024-061	138 URS-10T			068 069	068 069		069 - POS.(3+) )	13	13	13	100		
2024-061	140 MISSION A			068 069	068 069		069 - POS.(3+) )	40	39	40	100		
2024-061	140 MISSION A			068 069	068 069		068 - POS.(1-2+)	40	1	40	100		
2024-061	145 CLINITEK			068 069	068 069		069 - POS.(3+) )	36	33	36	100		
2024-061	145 CLINITEK			068 069	068 069		068 - POS.(1-2+)	36	3	36	100		
2024-061	147 Mission120			068 069	068 069		069 - POS.(3+) )	43	42	43	100		
2024-061	147 Mission120			068 069	068 069		068 - POS.(1-2+)	43	1	43	100		
2024-061	148 Mission500			068 069	068 069		069 - POS.(3+) )	114	114	114	100		
2024-061	151 Clari. Uro			068 069	068 069		069 - POS.(3+) )	20	20	20	100		
2024-062	011 AMES NM10S			068 069	068 069		069 - POS.(3+) )	40	36	40	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-062	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	40	4	40	100	
2024-062	013	BAYER CLI		068 069	068 069		069 - POS.(3+) )	24	24	24	100	
2024-062	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	56	9	56	100	
2024-062	067	URISCAN		068 069	068 069		069 - POS.(3+) )	56	47	56	100	
2024-062	072	URS-9-TECO		068 069	068 069		069 - POS.(3+) )	59	53	59	100	
2024-062	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	59	6	59	100	
2024-062	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+) )	37	33	37	100	
2024-062	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	4	37	100	
2024-062	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	143	7	142	100	
2024-062	089	AIMSTRIP		068 069	068 069		067 - TRACES	143	1	142	0	
2024-062	089	AIMSTRIP		068 069	068 069		069 - POS.(3+) )	143	135	142	100	
2024-062	094	CLINITEK		068 069	068 069		069 - POS.(3+) )	104	101	104	100	
2024-062	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	104	3	104	100	
2024-062	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	130	2	130	100	
2024-062	102	ACON LAB		068 069	068 069		069 - POS.(3+) )	130	128	130	100	
2024-062	131	iCHEM VELO		068 069	068 069		069 - POS.(3+) )	30	27	30	100	
2024-062	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	30	3	30	100	
2024-062	138	URS-10T		068 069	068 069		069 - POS.(3+) )	13	12	13	100	
2024-062	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	13	1	13	100	
2024-062	140	MISSION A		068 069	068 069		069 - POS.(3+) )	40	38	40	100	
2024-062	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	2	40	100	
2024-062	145	CLINITEK		068 069	068 069		069 - POS.(3+) )	36	34	36	100	
2024-062	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	36	2	36	100	
2024-062	147	Mission120		068 069	068 069		069 - POS.(3+) )	43	43	43	100	
2024-062	148	Mission500		068 069	068 069		068 - POS.(1-2+)	114	1	114	100	
2024-062	148	Mission500		068 069	068 069		069 - POS.(3+) )	114	113	114	100	
2024-062	151	Clari. Uro		068 069	068 069		069 - POS.(3+) )	20	20	20	100	
059 URINALYS.HG.OR BLOOD												
2024-063	011	AMES NM10S		068 069	068 069		068 - POS.(1-2+)	40	10	40	100	
2024-063	011	AMES NM10S		068 069	068 069		069 - POS.(3+) )	40	30	40	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	013	BAYER CLI		068 069	068 069		069 - POS.(3+) )	24	22	24	100	
2024-063	013	BAYER CLI		068 069	068 069		068 - POS.(1-2+)	24	2	24	100	
2024-063	067	URISCAN		068 069	068 069		069 - POS.(3+) )	56	48	56	100	
2024-063	067	URISCAN		068 069	068 069		068 - POS.(1-2+)	56	8	56	100	
2024-063	072	URS-9-TECO		068 069	068 069		069 - POS.(3+) )	59	47	59	100	
2024-063	072	URS-9-TECO		068 069	068 069		068 - POS.(1-2+)	59	12	59	100	
2024-063	080	ROCHE (CHE		068 069	068 069		068 - POS.(1-2+)	37	2	37	100	
2024-063	080	ROCHE (CHE		068 069	068 069		069 - POS.(3+) )	37	35	37	100	
2024-063	089	AIMSTRIP		068 069	068 069		068 - POS.(1-2+)	143	4	143	100	
2024-063	089	AIMSTRIP		068 069	068 069		069 - POS.(3+) )	143	139	143	100	
2024-063	094	CLINITEK		068 069	068 069		068 - POS.(1-2+)	104	14	104	100	
2024-063	094	CLINITEK		068 069	068 069		069 - POS.(3+) )	104	90	104	100	
2024-063	102	ACON LAB		068 069	068 069		069 - POS.(3+) )	130	127	130	100	
2024-063	102	ACON LAB		068 069	068 069		068 - POS.(1-2+)	130	3	130	100	
2024-063	131	iCHEM VELO		068 069	068 069		069 - POS.(3+) )	30	16	28	100	
2024-063	131	iCHEM VELO		068 069	068 069		067 - TRACES	30	2	28	0	
2024-063	131	iCHEM VELO		068 069	068 069		068 - POS.(1-2+)	30	12	28	100	
2024-063	138	URS-10T		068 069	068 069		068 - POS.(1-2+)	13	3	13	100	
2024-063	138	URS-10T		068 069	068 069		069 - POS.(3+) )	13	10	13	100	
2024-063	140	MISSION A		068 069	068 069		068 - POS.(1-2+)	40	1	40	100	
2024-063	140	MISSION A		068 069	068 069		069 - POS.(3+) )	40	39	40	100	
2024-063	145	CLINITEK		068 069	068 069		068 - POS.(1-2+)	36	16	36	100	
2024-063	145	CLINITEK		068 069	068 069		069 - POS.(3+) )	36	20	36	100	
2024-063	147	Mission120		068 069	068 069		069 - POS.(3+) )	43	42	43	100	
2024-063	147	Mission120		068 069	068 069		068 - POS.(1-2+)	43	1	43	100	
2024-063	148	Mission500		068 069	068 069		068 - POS.(1-2+)	114	1	114	100	
2024-063	148	Mission500		068 069	068 069		069 - POS.(3+) )	114	113	114	100	
2024-063	151	Clari. Uro		068 069	068 069		069 - POS.(3+) )	20	20	20	100	
059 URINALYS.HG.OR BLOOD												
2024-064	011	AMES NM10S		066 066	066 066		066 - NEGATIVE	40	40	40	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	013	BAYER CLI		066	066	066	066	066 - NEGATIVE	24	24	24	100
2024-064	067	URISCAN		066	066	066	066	066 - NEGATIVE	56	56	56	100
2024-064	072	URS-9-TECO		066	066	066	066	066 - NEGATIVE	59	59	59	100
2024-064	080	ROCHE (CHE		066	066	066	066	066 - NEGATIVE	37	37	37	100
2024-064	089	AIMSTRIP		066	066	066	066	066 - NEGATIVE	143	143	143	100
2024-064	094	CLINITEK		066	066	066	066	066 - NEGATIVE	104	104	104	100
2024-064	102	ACON LAB		066	066	066	066	066 - NEGATIVE	130	130	130	100
2024-064	131	iCHEM VELO		066	066	066	066	066 - NEGATIVE	30	29	29	100
2024-064	131	iCHEM VELO		066	066	066	066	067 - TRACES	30	1	29	0
2024-064	138	URS-10T		066	066	066	066	066 - NEGATIVE	13	13	13	100
2024-064	140	MISSION A		066	066	066	066	067 - TRACES	40	1	39	0
2024-064	140	MISSION A		066	066	066	066	066 - NEGATIVE	40	39	39	100
2024-064	145	CLINITEK		066	066	066	066	066 - NEGATIVE	36	36	36	100
2024-064	147	Mission120		066	066	066	066	066 - NEGATIVE	43	43	43	100
2024-064	148	Mission500		066	066	066	066	066 - NEGATIVE	114	113	113	100
2024-064	148	Mission500		066	066	066	066	067 - TRACES	114	1	113	0
2024-064	151	Clari. Uro		066	066	066	066	066 - NEGATIVE	20	20	20	100
059 URINALYS.HG.OR BLOOD												
2024-065	011	AMES NM10S		066	066	066	066	066 - NEGATIVE	40	40	40	100
2024-065	013	BAYER CLI		066	066	066	066	066 - NEGATIVE	24	24	24	100
2024-065	067	URISCAN		066	066	066	066	066 - NEGATIVE	56	56	56	100
2024-065	072	URS-9-TECO		066	066	066	066	066 - NEGATIVE	59	59	59	100
2024-065	080	ROCHE (CHE		066	066	066	066	066 - NEGATIVE	37	36	36	100
2024-065	080	ROCHE (CHE		066	066	066	066	067 - TRACES	37	1	36	0
2024-065	089	AIMSTRIP		066	066	066	066	067 - TRACES	143	1	142	0
2024-065	089	AIMSTRIP		066	066	066	066	066 - NEGATIVE	143	142	142	100
2024-065	094	CLINITEK		066	066	066	066	066 - NEGATIVE	104	104	104	100
2024-065	102	ACON LAB		066	066	066	066	066 - NEGATIVE	130	130	130	100
2024-065	131	iCHEM VELO		066	066	066	066	066 - NEGATIVE	30	30	30	100
2024-065	138	URS-10T		066	066	066	066	066 - NEGATIVE	13	13	13	100

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY				SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-065	140	MISSION A		066 066	066 066		066 - NEGATIVE	40	40	40	100	
2024-065	145	CLINITEK		066 066	066 066		066 - NEGATIVE	36	36	36	100	
2024-065	147	Mission120		066 066	066 066		066 - NEGATIVE	43	43	43	100	
2024-065	148	Mission500		066 066	066 066		066 - NEGATIVE	114	114	114	100	
2024-065	151	Clari. Uro		066 066	066 066		066 - NEGATIVE	20	20	20	100	
060 URINALYSIS-KETONES												
2024-061	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	40	40	40	100	
2024-061	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	24	24	24	100	
2024-061	067	URISCAN		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2024-061	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	59	58	58	100	
2024-061	072	URS-9-TECO		090 090	090 090		091 - TRACE	59	1	58	0	
2024-061	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-061	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	144	144	144	100	
2024-061	094	CLINITEK		090 090	090 090		090 - NEGATIVE	104	104	104	100	
2024-061	102	ACON LAB		090 090	090 090		090 - NEGATIVE	128	128	128	100	
2024-061	131	iCHEM VELO		090 090	090 090		090 - NEGATIVE	30	30	30	100	
2024-061	138	URS-10T		090 090	090 090		090 - NEGATIVE	13	13	13	100	
2024-061	140	MISSION A		090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-061	145	CLINITEK		090 090	090 090		090 - NEGATIVE	36	36	36	100	
2024-061	147	Mission120		090 090	090 090		090 - NEGATIVE	42	42	42	100	
2024-061	148	Mission500		090 090	090 090		090 - NEGATIVE	113	113	113	100	
2024-061	151	Clari. Uro		090 090	090 090		090 - NEGATIVE	20	20	20	100	
2024-062	011	AMES NM10S		090 090	090 090		090 - NEGATIVE	40	40	40	100	
2024-062	013	BAYER CLI		090 090	090 090		090 - NEGATIVE	24	24	24	100	
2024-062	067	URISCAN		090 090	090 090		090 - NEGATIVE	56	56	56	100	
2024-062	072	URS-9-TECO		090 090	090 090		090 - NEGATIVE	59	59	59	100	
2024-062	080	ROCHE (CHE		090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-062	089	AIMSTRIP		090 090	090 090		090 - NEGATIVE	144	144	144	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-062	094 CLINITEK			090 090	090 090		090 - NEGATIVE	104	104	104	100	
2024-062	102 ACON LAB			090 090	090 090		090 - NEGATIVE	128	128	128	100	
2024-062	131 iCHEM VELO			090 090	090 090		090 - NEGATIVE	30	30	30	100	
2024-062	138 URS-10T			090 090	090 090		090 - NEGATIVE	13	13	13	100	
2024-062	140 MISSION A			090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-062	145 CLINITEK			090 090	090 090		090 - NEGATIVE	36	36	36	100	
2024-062	147 Mission120			090 090	090 090		090 - NEGATIVE	42	42	42	100	
2024-062	148 Mission500			090 090	090 090		094 - LARGE-3-4+	113	1	112	0	
2024-062	148 Mission500			090 090	090 090		090 - NEGATIVE	113	112	112	100	
2024-062	151 Clari. Uro			090 090	090 090		090 - NEGATIVE	20	20	20	100	
060 URINALYSIS-KETONES												
2024-063	011 AMES NM10S			093 094	093 094		093 - MOD. (2+)	40	5	40	100	
2024-063	011 AMES NM10S			093 094	093 094		094 - LARGE-3-4+	40	35	40	100	
2024-063	013 BAYER CLI			093 094	093 094		094 - LARGE-3-4+	24	20	24	100	
2024-063	013 BAYER CLI			093 094	093 094		093 - MOD. (2+)	24	4	24	100	
2024-063	067 URISCAN			093 094	093 094		093 - MOD. (2+)	56	23	55	100	
2024-063	067 URISCAN			093 094	093 094		094 - LARGE-3-4+	56	32	55	100	
2024-063	067 URISCAN			093 094	093 094		090 - NEGATIVE	56	1	55	0	
2024-063	072 URS-9-TECO			093 094	093 094		094 - LARGE-3-4+	59	53	59	100	
2024-063	072 URS-9-TECO			093 094	093 094		093 - MOD. (2+)	59	6	59	100	
2024-063	080 ROCHE (CHE			093 094	093 094		093 - MOD. (2+)	37	3	35	100	
2024-063	080 ROCHE (CHE			093 094	093 094		092 - SMALL (1+)	37	2	35	0	
2024-063	080 ROCHE (CHE			093 094	093 094		094 - LARGE-3-4+	37	32	35	100	
2024-063	089 AIMSTRIP			093 094	093 094		094 - LARGE-3-4+	144	134	144	100	
2024-063	089 AIMSTRIP			093 094	093 094		093 - MOD. (2+)	144	10	144	100	
2024-063	094 CLINITEK			093 094	093 094		094 - LARGE-3-4+	104	92	104	100	
2024-063	094 CLINITEK			093 094	093 094		093 - MOD. (2+)	104	12	104	100	
2024-063	102 ACON LAB			093 094	093 094		094 - LARGE-3-4+	128	122	127	100	
2024-063	102 ACON LAB			093 094	093 094		092 - SMALL (1+)	128	1	127	0	
2024-063	102 ACON LAB			093 094	093 094		093 - MOD. (2+)	128	5	127	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	131	iCHEM VELO		092 094	093 094		094 - LARGE-3-4+	30	13	30	100	
2024-063	131	iCHEM VELO		092 094	093 094		093 - MOD. (2+)	30	17	30	100	
2024-063	138	URS-10T		093 094	093 094		093 - MOD. (2+)	13	2	13	100	
2024-063	138	URS-10T		093 094	093 094		094 - LARGE-3-4+	13	11	13	100	
2024-063	140	MISSION A		093 094	093 094		093 - MOD. (2+)	43	1	43	100	
2024-063	140	MISSION A		093 094	093 094		094 - LARGE-3-4+	43	42	43	100	
2024-063	145	CLINITEK		093 094	093 094		094 - LARGE-3-4+	36	35	36	100	
2024-063	145	CLINITEK		093 094	093 094		093 - MOD. (2+)	36	1	36	100	
2024-063	147	Mission120		093 094	093 094		094 - LARGE-3-4+	42	42	42	100	
2024-063	148	Mission500		093 094	093 094		093 - MOD. (2+)	113	2	112	100	
2024-063	148	Mission500		093 094	093 094		090 - NEGATIVE	113	1	112	0	
2024-063	148	Mission500		093 094	093 094		094 - LARGE-3-4+	113	110	112	100	
2024-063	151	Clari. Uro		093 094	093 094		094 - LARGE-3-4+	20	20	20	100	
060 URINALYSIS-KETONES												
2024-064	011	AMES NM10S		092 094	092 094		092 - SMALL (1+)	40	10	40	100	
2024-064	011	AMES NM10S		092 094	092 094		093 - MOD. (2+)	40	29	40	100	
2024-064	011	AMES NM10S		092 094	092 094		094 - LARGE-3-4+	40	1	40	100	
2024-064	013	BAYER CLI		092 094	092 094		093 - MOD. (2+)	24	12	24	100	
2024-064	013	BAYER CLI		092 094	092 094		092 - SMALL (1+)	24	12	24	100	
2024-064	067	URISCAN		092 094	092 094		092 - SMALL (1+)	56	14	56	100	
2024-064	067	URISCAN		092 094	092 094		094 - LARGE-3-4+	56	5	56	100	
2024-064	067	URISCAN		092 094	092 094		093 - MOD. (2+)	56	37	56	100	
2024-064	072	URS-9-TECO		092 094	092 094		094 - LARGE-3-4+	59	12	59	100	
2024-064	072	URS-9-TECO		092 094	092 094		092 - SMALL (1+)	59	12	59	100	
2024-064	072	URS-9-TECO		092 094	092 094		093 - MOD. (2+)	59	35	59	100	
2024-064	080	ROCHE (CHE		092 094	092 094		094 - LARGE-3-4+	37	4	36	100	
2024-064	080	ROCHE (CHE		092 094	092 094		091 - TRACE	37	1	36	0	
2024-064	080	ROCHE (CHE		092 094	092 094		093 - MOD. (2+)	37	25	36	100	
2024-064	080	ROCHE (CHE		092 094	092 094		092 - SMALL (1+)	37	7	36	100	
2024-064	089	AIMSTRIP		092 094	092 094		093 - MOD. (2+)	144	100	144	100	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	089	AIMSTRIP		092 094	092 094		092 - SMALL (1+)	144	28	144	100	
2024-064	089	AIMSTRIP		092 094	092 094		094 - LARGE-3-4+	144	16	144	100	
2024-064	094	CLINITEK		092 094	092 094		091 - TRACE	104	1	103	0	
2024-064	094	CLINITEK		092 094	092 094		093 - MOD. (2+)	104	69	103	100	
2024-064	094	CLINITEK		092 094	092 094		092 - SMALL (1+)	104	34	103	100	
2024-064	102	ACON LAB		092 094	092 094		092 - SMALL (1+)	128	13	124	100	
2024-064	102	ACON LAB		092 094	092 094		093 - MOD. (2+)	128	97	124	100	
2024-064	102	ACON LAB		092 094	092 094		094 - LARGE-3-4+	128	14	124	100	
2024-064	102	ACON LAB		092 094	092 094		091 - TRACE	128	3	124	0	
2024-064	102	ACON LAB		092 094	092 094		090 - NEGATIVE	128	1	124	0	
2024-064	131	iCHEM VELO		091 093	092 094		092 - SMALL (1+)	30	20	30	100	
2024-064	131	iCHEM VELO		091 093	092 094		093 - MOD. (2+)	30	7	30	100	
2024-064	131	iCHEM VELO		091 093	092 094		094 - LARGE-3-4+	30	3	30	100	
2024-064	138	URS-10T		092 094	092 094		092 - SMALL (1+)	13	3	13	100	
2024-064	138	URS-10T		092 094	092 094		093 - MOD. (2+)	13	8	13	100	
2024-064	138	URS-10T		092 094	092 094		094 - LARGE-3-4+	13	2	13	100	
2024-064	140	MISSION A		092 094	092 094		092 - SMALL (1+)	43	1	43	100	
2024-064	140	MISSION A		092 094	092 094		094 - LARGE-3-4+	43	14	43	100	
2024-064	140	MISSION A		092 094	092 094		093 - MOD. (2+)	43	28	43	100	
2024-064	145	CLINITEK		092 094	092 094		093 - MOD. (2+)	36	29	36	100	
2024-064	145	CLINITEK		092 094	092 094		092 - SMALL (1+)	36	7	36	100	
2024-064	147	Mission120		093 094	092 094		093 - MOD. (2+)	42	18	42	100	
2024-064	147	Mission120		093 094	092 094		094 - LARGE-3-4+	42	24	42	100	
2024-064	148	Mission500		092 094	092 094		094 - LARGE-3-4+	113	11	112	100	
2024-064	148	Mission500		092 094	092 094		090 - NEGATIVE	113	1	112	0	
2024-064	148	Mission500		092 094	092 094		093 - MOD. (2+)	113	98	112	100	
2024-064	148	Mission500		092 094	092 094		092 - SMALL (1+)	113	3	112	100	
2024-064	151	Clari. Uro		092 094	092 094		093 - MOD. (2+)	20	14	20	100	
2024-064	151	Clari. Uro		092 094	092 094		094 - LARGE-3-4+	20	6	20	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
060 URINALYSIS-KETONES												
2024-065	011 AMES NM10S			090 090	090 090		091 - TRACE	40	1	39	0	
2024-065	011 AMES NM10S			090 090	090 090		090 - NEGATIVE	40	39	39	100	
2024-065	013 BAYER CLI			090 090	090 090		090 - NEGATIVE	24	24	24	100	
2024-065	067 URISCAN			090 090	090 090		090 - NEGATIVE	56	55	55	100	
2024-065	067 URISCAN			090 090	090 090		093 - MOD. (2+)	56	1	55	0	
2024-065	072 URS-9-TECO			090 090	090 090		090 - NEGATIVE	59	59	59	100	
2024-065	080 ROCHE (CHE			090 090	090 090		090 - NEGATIVE	37	37	37	100	
2024-065	089 AIMSTRIP			090 090	090 090		090 - NEGATIVE	144	144	144	100	
2024-065	094 CLINITEK			090 090	090 090		090 - NEGATIVE	104	104	104	100	
2024-065	102 ACON LAB			090 090	090 090		090 - NEGATIVE	128	128	128	100	
2024-065	131 iCHEM VELO			090 090	090 090		090 - NEGATIVE	30	30	30	100	
2024-065	138 URS-10T			090 090	090 090		090 - NEGATIVE	13	13	13	100	
2024-065	140 MISSION A			090 090	090 090		090 - NEGATIVE	43	43	43	100	
2024-065	145 CLINITEK			090 090	090 090		090 - NEGATIVE	36	36	36	100	
2024-065	147 Mission120			090 090	090 090		090 - NEGATIVE	42	42	42	100	
2024-065	148 Mission500			090 090	090 090		090 - NEGATIVE	113	112	112	100	
2024-065	148 Mission500			090 090	090 090		093 - MOD. (2+)	113	1	112	0	
2024-065	151 Clari. Uro			090 090	090 090		090 - NEGATIVE	20	20	20	100	
061 URINALYSIS-NITRATE												
2024-061	011 AMES NM10S			070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-061	013 BAYER CLI			070 070	070 070		070 - NEGATIVE	24	24	24	100	
2024-061	067 URISCAN			070 070	070 070		070 - NEGATIVE	56	56	56	100	
2024-061	072 URS-9-TECO			070 070	070 070		070 - NEGATIVE	59	59	59	100	
2024-061	080 ROCHE (CHE			070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-061	089 AIMSTRIP			070 070	070 070		070 - NEGATIVE	144	144	144	100	
2024-061	094 CLINITEK			070 070	070 070		070 - NEGATIVE	104	104	104	100	
2024-061	102 ACON LAB			070 070	070 070		070 - NEGATIVE	128	128	128	100	
2024-061	131 iCHEM VELO			070 070	070 070		070 - NEGATIVE	30	30	30	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	138	URS-10T		070 070	070 070		070 - NEGATIVE	13	13	13	100	
2024-061	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2024-061	145	CLINITEK		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2024-061	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100	
2024-061	148	Mission500		070 070	070 070		070 - NEGATIVE	113	113	113	100	
2024-061	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100	
061 URINALYSIS-NITRATE												
2024-062	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-062	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	24	24	24	100	
2024-062	067	URISCAN		070 070	070 070		070 - NEGATIVE	56	56	56	100	
2024-062	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	59	59	59	100	
2024-062	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-062	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	144	144	144	100	
2024-062	094	CLINITEK		070 070	070 070		070 - NEGATIVE	104	104	104	100	
2024-062	102	ACON LAB		070 070	070 070		070 - NEGATIVE	128	128	128	100	
2024-062	131	iCHEM VELO		070 070	070 070		070 - NEGATIVE	30	30	30	100	
2024-062	138	URS-10T		070 070	070 070		070 - NEGATIVE	13	13	13	100	
2024-062	140	MISSION A		070 070	070 070		070 - NEGATIVE	42	42	42	100	
2024-062	145	CLINITEK		070 070	070 070		070 - NEGATIVE	36	36	36	100	
2024-062	147	Mission120		070 070	070 070		070 - NEGATIVE	43	43	43	100	
2024-062	148	Mission500		070 070	070 070		070 - NEGATIVE	113	113	113	100	
2024-062	151	Clari. Uro		070 070	070 070		070 - NEGATIVE	20	20	20	100	
2024-063	011	AMES NM10S		070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-063	013	BAYER CLI		070 070	070 070		070 - NEGATIVE	24	24	24	100	
2024-063	067	URISCAN		070 070	070 070		070 - NEGATIVE	56	56	56	100	
2024-063	072	URS-9-TECO		070 070	070 070		070 - NEGATIVE	59	59	59	100	
2024-063	080	ROCHE (CHE		070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-063	089	AIMSTRIP		070 070	070 070		070 - NEGATIVE	144	143	143	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	089 AIMSTRIP			070 070	070 070		072 - POSITIVE	144	1	143	0	
2024-063	094 CLINITEK			070 070	070 070		070 - NEGATIVE	104	104	104	100	
2024-063	102 ACON LAB			070 070	070 070		070 - NEGATIVE	128	128	128	100	
2024-063	131 iCHEM VELO			070 070	070 070		070 - NEGATIVE	30	30	30	100	
2024-063	138 URS-10T			070 070	070 070		070 - NEGATIVE	13	13	13	100	
2024-063	140 MISSION A			070 070	070 070		070 - NEGATIVE	42	42	42	100	
2024-063	145 CLINITEK			070 070	070 070		070 - NEGATIVE	36	36	36	100	
2024-063	147 Mission120			070 070	070 070		070 - NEGATIVE	43	43	43	100	
2024-063	148 Mission500			070 070	070 070		070 - NEGATIVE	113	113	113	100	
2024-063	151 Clari. Uro			070 070	070 070		070 - NEGATIVE	20	20	20	100	
061 URINALYSIS-NITRATE												
2024-064	011 AMES NM10S			071 072	071 072		072 - POSITIVE	40	40	40	100	
2024-064	013 BAYER CLI			071 072	071 072		072 - POSITIVE	24	24	24	100	
2024-064	067 URISCAN			071 072	071 072		072 - POSITIVE	56	56	56	100	
2024-064	072 URS-9-TECO			071 072	071 072		072 - POSITIVE	59	59	59	100	
2024-064	080 ROCHE (CHE			071 072	071 072		072 - POSITIVE	37	37	37	100	
2024-064	089 AIMSTRIP			071 072	071 072		072 - POSITIVE	144	143	144	100	
2024-064	089 AIMSTRIP			071 072	071 072		071 - WEAK POS.	144	1	144	100	
2024-064	094 CLINITEK			071 072	071 072		072 - POSITIVE	104	104	104	100	
2024-064	102 ACON LAB			071 072	071 072		072 - POSITIVE	128	128	128	100	
2024-064	131 iCHEM VELO			071 072	071 072		072 - POSITIVE	30	30	30	100	
2024-064	138 URS-10T			071 072	071 072		072 - POSITIVE	13	13	13	100	
2024-064	140 MISSION A			071 072	071 072		072 - POSITIVE	42	42	42	100	
2024-064	145 CLINITEK			071 072	071 072		072 - POSITIVE	36	36	36	100	
2024-064	147 Mission120			071 072	071 072		072 - POSITIVE	43	43	43	100	
2024-064	148 Mission500			071 072	071 072		070 - NEGATIVE	113	1	112	0	
2024-064	148 Mission500			071 072	071 072		072 - POSITIVE	113	112	112	100	
2024-064	151 Clari. Uro			071 072	071 072		072 - POSITIVE	20	20	20	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
061 URINALYSIS-NITRATE												
2024-065	011 AMES NM10S			070 070	070 070		070 - NEGATIVE	40	40	40	100	
2024-065	013 BAYER CLI			070 070	070 070		070 - NEGATIVE	24	24	24	100	
2024-065	067 URISCAN			070 070	070 070		070 - NEGATIVE	56	56	56	100	
2024-065	072 URS-9-TECO			070 070	070 070		072 - POSITIVE	59	1	58	0	
2024-065	072 URS-9-TECO			070 070	070 070		070 - NEGATIVE	59	58	58	100	
2024-065	080 ROCHE (CHE			070 070	070 070		070 - NEGATIVE	37	37	37	100	
2024-065	089 AIMSTRIP			070 070	070 070		070 - NEGATIVE	144	144	144	100	
2024-065	094 CLINITEK			070 070	070 070		070 - NEGATIVE	104	104	104	100	
2024-065	102 ACON LAB			070 070	070 070		070 - NEGATIVE	128	128	128	100	
2024-065	131 iCHEM VELO			070 070	070 070		070 - NEGATIVE	30	30	30	100	
2024-065	138 URS-10T			070 070	070 070		070 - NEGATIVE	13	13	13	100	
2024-065	140 MISSION A			070 070	070 070		070 - NEGATIVE	42	42	42	100	
2024-065	145 CLINITEK			070 070	070 070		070 - NEGATIVE	36	36	36	100	
2024-065	147 Mission120			070 070	070 070		070 - NEGATIVE	43	43	43	100	
2024-065	148 Mission500			070 070	070 070		070 - NEGATIVE	113	112	112	100	
2024-065	148 Mission500			070 070	070 070		072 - POSITIVE	113	1	112	0	
2024-065	151 Clari. Uro			070 070	070 070		070 - NEGATIVE	20	20	20	100	
062 URINALYSIS-pH												
2024-061	011 AMES NM10S			084 088	084 088		086 - 7.0	40	40	40	100	
2024-061	013 BAYER CLI			084 088	084 088		086 - 7.0	24	24	24	100	
2024-061	067 URISCAN			083 087	084 088		085 - 6.5	56	40	56	100	
2024-061	067 URISCAN			083 087	084 088		087 - 7.5	56	1	56	100	
2024-061	067 URISCAN			083 087	084 088		086 - 7.0	56	15	56	100	
2024-061	072 URS-9-TECO			084 088	084 088		086 - 7.0	59	50	59	100	
2024-061	072 URS-9-TECO			084 088	084 088		085 - 6.5	59	9	59	100	
2024-061	080 ROCHE (CHE			084 088	084 088		086 - 7.0	37	37	37	100	
2024-061	089 AIMSTRIP			084 088	084 088		084 - 6.0	144	1	144	100	
2024-061	089 AIMSTRIP			084 088	084 088		087 - 7.5	144	1	144	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	089	AIMSTRIP		084 088	084 088		086 - 7.0	144	120	144	100	
2024-061	089	AIMSTRIP		084 088	084 088		085 - 6.5	144	22	144	100	
2024-061	094	CLINITEK		084 088	084 088		086 - 7.0	104	103	104	100	
2024-061	094	CLINITEK		084 088	084 088		085 - 6.5	104	1	104	100	
2024-061	102	ACON LAB		084 088	084 088		086 - 7.0	128	93	128	100	
2024-061	102	ACON LAB		084 088	084 088		085 - 6.5	128	34	128	100	
2024-061	102	ACON LAB		084 088	084 088		087 - 7.5	128	1	128	100	
2024-061	131	iCHEM VELO		084 088	084 088		086 - 7.0	30	30	30	100	
2024-061	138	URS-10T		084 088	084 088		086 - 7.0	13	13	13	100	
2024-061	140	MISSION A		083 087	084 088		086 - 7.0	42	16	42	100	
2024-061	140	MISSION A		083 087	084 088		085 - 6.5	42	26	42	100	
2024-061	145	CLINITEK		084 088	084 088		086 - 7.0	36	36	36	100	
2024-061	147	Mission120		083 087	084 088		085 - 6.5	42	40	42	100	
2024-061	147	Mission120		083 087	084 088		084 - 6.0	42	1	42	100	
2024-061	147	Mission120		083 087	084 088		086 - 7.0	42	1	42	100	
2024-061	148	Mission500		084 088	084 088		085 - 6.5	114	13	114	100	
2024-061	148	Mission500		084 088	084 088		086 - 7.0	114	101	114	100	
2024-061	151	Clari. Uro		083 087	084 088		086 - 7.0	20	8	20	100	
2024-061	151	Clari. Uro		083 087	084 088		085 - 6.5	20	12	20	100	
062 URINALYSIS-pH												
2024-062	011	AMES NM10S		082 086	082 086		085 - 6.5	40	1	40	100	
2024-062	011	AMES NM10S		082 086	082 086		083 - 5.5	40	1	40	100	
2024-062	011	AMES NM10S		082 086	082 086		084 - 6.0	40	38	40	100	
2024-062	013	BAYER CLI		082 086	082 086		084 - 6.0	24	22	24	100	
2024-062	013	BAYER CLI		082 086	082 086		085 - 6.5	24	2	24	100	
2024-062	067	URISCAN		081 085	082 086		084 - 6.0	56	27	56	100	
2024-062	067	URISCAN		081 085	082 086		083 - 5.5	56	27	56	100	
2024-062	067	URISCAN		081 085	082 086		082 - 5.0	56	1	56	100	
2024-062	067	URISCAN		081 085	082 086		085 - 6.5	56	1	56	100	
2024-062	072	URS-9-TECO		082 086	082 086		083 - 5.5	59	1	59	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-062	072	URS-9-TECO		082 086	082 086		084 - 6.0	59	35	59	100	
2024-062	072	URS-9-TECO		082 086	082 086		086 - 7.0	59	1	59	100	
2024-062	072	URS-9-TECO		082 086	082 086		085 - 6.5	59	22	59	100	
2024-062	080	ROCHE (CHE		082 086	082 086		085 - 6.5	37	1	37	100	
2024-062	080	ROCHE (CHE		082 086	082 086		084 - 6.0	37	36	37	100	
2024-062	089	AIMSTRIP		082 086	082 086		082 - 5.0	144	1	144	100	
2024-062	089	AIMSTRIP		082 086	082 086		085 - 6.5	144	9	144	100	
2024-062	089	AIMSTRIP		082 086	082 086		083 - 5.5	144	1	144	100	
2024-062	089	AIMSTRIP		082 086	082 086		084 - 6.0	144	132	144	100	
2024-062	089	AIMSTRIP		082 086	082 086		086 - 7.0	144	1	144	100	
2024-062	094	CLINITEK		082 086	082 086		084 - 6.0	104	95	104	100	
2024-062	094	CLINITEK		082 086	082 086		085 - 6.5	104	9	104	100	
2024-062	102	ACON LAB		082 086	082 086		085 - 6.5	128	2	128	100	
2024-062	102	ACON LAB		082 086	082 086		084 - 6.0	128	125	128	100	
2024-062	102	ACON LAB		082 086	082 086		086 - 7.0	128	1	128	100	
2024-062	131	iCHEM VELO		082 086	082 086		084 - 6.0	30	30	30	100	
2024-062	138	URS-10T		082 086	082 086		085 - 6.5	13	4	13	100	
2024-062	138	URS-10T		082 086	082 086		084 - 6.0	13	8	13	100	
2024-062	138	URS-10T		082 086	082 086		083 - 5.5	13	1	13	100	
2024-062	140	MISSION A		082 086	082 086		084 - 6.0	42	40	42	100	
2024-062	140	MISSION A		082 086	082 086		083 - 5.5	42	1	42	100	
2024-062	140	MISSION A		082 086	082 086		085 - 6.5	42	1	42	100	
2024-062	145	CLINITEK		082 086	082 086		084 - 6.0	36	36	36	100	
2024-062	147	Mission120		082 086	082 086		084 - 6.0	42	41	42	100	
2024-062	147	Mission120		082 086	082 086		083 - 5.5	42	1	42	100	
2024-062	148	Mission500		082 086	082 086		086 - 7.0	114	1	114	100	
2024-062	148	Mission500		082 086	082 086		084 - 6.0	114	112	114	100	
2024-062	148	Mission500		082 086	082 086		083 - 5.5	114	1	114	100	
2024-062	151	Clari. Uro		082 086	082 086		084 - 6.0	20	20	20	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
062 URINALYSIS-pH													
2024-063	011 AMES NM10S			085 088	084 088		088 - 8.00R MORE	40	1	40	100		
2024-063	011 AMES NM10S			085 088	084 088		086 - 7.0	40	9	40	100		
2024-063	011 AMES NM10S			085 088	084 088		087 - 7.5	40	30	40	100		
2024-063	013 BAYER CLI			085 088	084 088		087 - 7.5	24	18	24	100		
2024-063	013 BAYER CLI			085 088	084 088		086 - 7.0	24	6	24	100		
2024-063	067 URISCAN			084 088	084 088		087 - 7.5	56	14	56	100		
2024-063	067 URISCAN			084 088	084 088		086 - 7.0	56	40	56	100		
2024-063	067 URISCAN			084 088	084 088		085 - 6.5	56	2	56	100		
2024-063	072 URS-9-TECO			084 088	084 088		085 - 6.5	59	1	59	100		
2024-063	072 URS-9-TECO			084 088	084 088		087 - 7.5	59	17	59	100		
2024-063	072 URS-9-TECO			084 088	084 088		086 - 7.0	59	41	59	100		
2024-063	080 ROCHE (CHE			084 088	084 088		086 - 7.0	37	37	37	100		
2024-063	089 AIMSTRIP			084 088	084 088		086 - 7.0	144	89	144	100		
2024-063	089 AIMSTRIP			084 088	084 088		087 - 7.5	144	55	144	100		
2024-063	094 CLINITEK			085 088	084 088		087 - 7.5	104	87	104	100		
2024-063	094 CLINITEK			085 088	084 088		086 - 7.0	104	17	104	100		
2024-063	102 ACON LAB			084 088	084 088		086 - 7.0	128	100	128	100		
2024-063	102 ACON LAB			084 088	084 088		087 - 7.5	128	28	128	100		
2024-063	131 iCHEM VELO			084 088	084 088		086 - 7.0	30	30	30	100		
2024-063	138 URS-10T			085 088	084 088		085 - 6.5	13	1	13	100		
2024-063	138 URS-10T			085 088	084 088		087 - 7.5	13	9	13	100		
2024-063	138 URS-10T			085 088	084 088		086 - 7.0	13	3	13	100		
2024-063	140 MISSION A			084 088	084 088		086 - 7.0	42	33	42	100		
2024-063	140 MISSION A			084 088	084 088		087 - 7.5	42	9	42	100		
2024-063	145 CLINITEK			085 088	084 088		086 - 7.0	36	6	36	100		
2024-063	145 CLINITEK			085 088	084 088		087 - 7.5	36	30	36	100		
2024-063	147 Mission120			084 088	084 088		087 - 7.5	42	2	42	100		
2024-063	147 Mission120			084 088	084 088		086 - 7.0	42	40	42	100		
2024-063	148 Mission500			084 088	084 088		086 - 7.0	114	111	114	100		



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	148	Mission500		084 088	084 088		084 - 6.0	114	2	114	100	
2024-063	148	Mission500		084 088	084 088		087 - 7.5	114	1	114	100	
2024-063	151	Clari. Uro		084 088	084 088		087 - 7.5	20	5	20	100	
2024-063	151	Clari. Uro		084 088	084 088		086 - 7.0	20	15	20	100	
062 URINALYSIS-pH												
2024-064	011	AMES NM10S		081 085	081 085		082 - 5.0	40	11	40	100	
2024-064	011	AMES NM10S		081 085	081 085		084 - 6.0	40	11	40	100	
2024-064	011	AMES NM10S		081 085	081 085		083 - 5.5	40	18	40	100	
2024-064	013	BAYER CLI		080 084	081 085		083 - 5.5	24	9	24	100	
2024-064	013	BAYER CLI		080 084	081 085		082 - 5.0	24	11	24	100	
2024-064	013	BAYER CLI		080 084	081 085		084 - 6.0	24	4	24	100	
2024-064	067	URISCAN		080 084	081 085		082 - 5.0	56	45	56	100	
2024-064	067	URISCAN		080 084	081 085		083 - 5.5	56	10	56	100	
2024-064	067	URISCAN		080 084	081 085		084 - 6.0	56	1	56	100	
2024-064	072	URS-9-TECO		082 086	081 085		085 - 6.5	59	3	59	100	
2024-064	072	URS-9-TECO		082 086	081 085		082 - 5.0	59	13	59	100	
2024-064	072	URS-9-TECO		082 086	081 085		083 - 5.5	59	7	59	100	
2024-064	072	URS-9-TECO		082 086	081 085		084 - 6.0	59	36	59	100	
2024-064	080	ROCHE (CHE		080 084	081 085		082 - 5.0	37	37	37	100	
2024-064	089	AIMSTRIP		082 086	081 085		082 - 5.0	144	43	144	100	
2024-064	089	AIMSTRIP		082 086	081 085		083 - 5.5	144	39	144	100	
2024-064	089	AIMSTRIP		082 086	081 085		084 - 6.0	144	62	144	100	
2024-064	094	CLINITEK		081 085	081 085		082 - 5.0	104	10	104	100	
2024-064	094	CLINITEK		081 085	081 085		084 - 6.0	104	42	104	100	
2024-064	094	CLINITEK		081 085	081 085		083 - 5.5	104	52	104	100	
2024-064	102	ACON LAB		082 086	081 085		082 - 5.0	128	34	128	100	
2024-064	102	ACON LAB		082 086	081 085		084 - 6.0	128	75	128	100	
2024-064	102	ACON LAB		082 086	081 085		083 - 5.5	128	19	128	100	
2024-064	131	iCHEM VELO		080 084	081 085		082 - 5.0	30	29	30	100	
2024-064	131	iCHEM VELO		080 084	081 085		084 - 6.0	30	1	30	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	138	URS-10T		082 086	081 085		084 - 6.0	13	6	13	100	
2024-064	138	URS-10T		082 086	081 085		083 - 5.5	13	2	13	100	
2024-064	138	URS-10T		082 086	081 085		082 - 5.0	13	5	13	100	
2024-064	140	MISSION A		082 086	081 085		082 - 5.0	42	10	42	100	
2024-064	140	MISSION A		082 086	081 085		084 - 6.0	42	19	42	100	
2024-064	140	MISSION A		082 086	081 085		083 - 5.5	42	13	42	100	
2024-064	145	CLINITEK		081 085	081 085		083 - 5.5	36	27	36	100	
2024-064	145	CLINITEK		081 085	081 085		082 - 5.0	36	9	36	100	
2024-064	147	Mission120		081 085	081 085		083 - 5.5	42	30	42	100	
2024-064	147	Mission120		081 085	081 085		084 - 6.0	42	3	42	100	
2024-064	147	Mission120		081 085	081 085		082 - 5.0	42	9	42	100	
2024-064	148	Mission500		082 086	081 085		083 - 5.5	114	2	114	100	
2024-064	148	Mission500		082 086	081 085		084 - 6.0	114	108	114	100	
2024-064	148	Mission500		082 086	081 085		086 - 7.0	114	1	114	100	
2024-064	148	Mission500		082 086	081 085		082 - 5.0	114	3	114	100	
2024-064	151	Clari. Uro		081 085	081 085		083 - 5.5	20	8	20	100	
2024-064	151	Clari. Uro		081 085	081 085		084 - 6.0	20	8	20	100	
2024-064	151	Clari. Uro		081 085	081 085		082 - 5.0	20	4	20	100	
062 URINALYSIS-pH												
2024-065	011	AMES NM10S		084 088	084 088		086 - 7.0	40	24	40	100	
2024-065	011	AMES NM10S		084 088	084 088		087 - 7.5	40	16	40	100	
2024-065	013	BAYER CLI		084 088	084 088		086 - 7.0	24	18	24	100	
2024-065	013	BAYER CLI		084 088	084 088		087 - 7.5	24	6	24	100	
2024-065	067	URISCAN		084 088	084 088		086 - 7.0	56	47	56	100	
2024-065	067	URISCAN		084 088	084 088		085 - 6.5	56	4	56	100	
2024-065	067	URISCAN		084 088	084 088		087 - 7.5	56	4	56	100	
2024-065	067	URISCAN		084 088	084 088		084 - 6.0	56	1	56	100	
2024-065	072	URS-9-TECO		084 088	084 088		086 - 7.0	59	50	59	100	
2024-065	072	URS-9-TECO		084 088	084 088		087 - 7.5	59	1	59	100	
2024-065	072	URS-9-TECO		084 088	084 088		084 - 6.0	59	2	59	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-065	072	URS-9-TECO		084 088	084 088		085 - 6.5	59	6	59	100	
2024-065	080	ROCHE (CHE		084 088	084 088		086 - 7.0	37	37	37	100	
2024-065	089	AIMSTRIP		084 088	084 088		087 - 7.5	144	23	144	100	
2024-065	089	AIMSTRIP		084 088	084 088		084 - 6.0	144	1	144	100	
2024-065	089	AIMSTRIP		084 088	084 088		086 - 7.0	144	120	144	100	
2024-065	094	CLINITEK		084 088	084 088		087 - 7.5	104	38	104	100	
2024-065	094	CLINITEK		084 088	084 088		086 - 7.0	104	65	104	100	
2024-065	094	CLINITEK		084 088	084 088		085 - 6.5	104	1	104	100	
2024-065	102	ACON LAB		084 088	084 088		085 - 6.5	128	9	128	100	
2024-065	102	ACON LAB		084 088	084 088		087 - 7.5	128	9	128	100	
2024-065	102	ACON LAB		084 088	084 088		084 - 6.0	128	2	128	100	
2024-065	102	ACON LAB		084 088	084 088		086 - 7.0	128	108	128	100	
2024-065	131	iCHEM VELO		084 088	084 088		086 - 7.0	30	30	30	100	
2024-065	138	URS-10T		084 088	084 088		085 - 6.5	13	2	13	100	
2024-065	138	URS-10T		084 088	084 088		087 - 7.5	13	1	13	100	
2024-065	138	URS-10T		084 088	084 088		086 - 7.0	13	10	13	100	
2024-065	140	MISSION A		084 088	084 088		086 - 7.0	42	34	42	100	
2024-065	140	MISSION A		084 088	084 088		085 - 6.5	42	8	42	100	
2024-065	145	CLINITEK		084 088	084 088		086 - 7.0	36	36	36	100	
2024-065	147	Mission120		084 088	084 088		086 - 7.0	42	23	42	100	
2024-065	147	Mission120		084 088	084 088		085 - 6.5	42	19	42	100	
2024-065	148	Mission500		084 088	084 088		084 - 6.0	114	1	114	100	
2024-065	148	Mission500		084 088	084 088		086 - 7.0	114	112	114	100	
2024-065	148	Mission500		084 088	084 088		085 - 6.5	114	1	114	100	
2024-065	151	Clari. Uro		084 088	084 088		087 - 7.5	20	1	20	100	
2024-065	151	Clari. Uro		084 088	084 088		086 - 7.0	20	18	20	100	
2024-065	151	Clari. Uro		084 088	084 088		085 - 6.5	20	1	20	100	
064 URIN-PROTEIN QUALI.												
2024-061	011	AMES NM10S		053 055	053 055		055 - 3+	40	14	40	100	
2024-061	011	AMES NM10S		053 055	053 055		053 - 1+	40	2	40	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	011	AMES NM10S		053 055	053 055		054 - 2+	40	24	40	100	
2024-061	013	BAYER CLI		053 055	053 055		055 - 3+	24	10	24	100	
2024-061	013	BAYER CLI		053 055	053 055		053 - 1+	24	1	24	100	
2024-061	013	BAYER CLI		053 055	053 055		054 - 2+	24	13	24	100	
2024-061	067	URISCAN		053 055	053 055		053 - 1+	56	12	56	100	
2024-061	067	URISCAN		053 055	053 055		054 - 2+	56	41	56	100	
2024-061	067	URISCAN		053 055	053 055		055 - 3+	56	3	56	100	
2024-061	072	URS-9-TECO		053 055	053 055		055 - 3+	59	24	59	100	
2024-061	072	URS-9-TECO		053 055	053 055		054 - 2+	59	35	59	100	
2024-061	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100	
2024-061	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	25	37	100	
2024-061	089	AIMSTRIP		053 055	053 055		053 - 1+	143	1	141	100	
2024-061	089	AIMSTRIP		053 055	053 055		054 - 2+	143	99	141	100	
2024-061	089	AIMSTRIP		053 055	053 055		056 - 4+	143	2	141	0	
2024-061	089	AIMSTRIP		053 055	053 055		055 - 3+	143	41	141	100	
2024-061	094	CLINITEK		053 055	053 055		055 - 3+	104	11	102	100	
2024-061	094	CLINITEK		053 055	053 055		054 - 2+	104	91	102	100	
2024-061	094	CLINITEK		053 055	053 055		056 - 4+	104	2	102	0	
2024-061	102	ACON LAB		053 055	053 055		056 - 4+	129	3	126	0	
2024-061	102	ACON LAB		053 055	053 055		055 - 3+	129	36	126	100	
2024-061	102	ACON LAB		053 055	053 055		053 - 1+	129	3	126	100	
2024-061	102	ACON LAB		053 055	053 055		054 - 2+	129	87	126	100	
2024-061	131	iCHEM VELO		053 055	053 055		055 - 3+	30	13	29	100	
2024-061	131	iCHEM VELO		053 055	053 055		054 - 2+	30	16	29	100	
2024-061	131	iCHEM VELO		053 055	053 055		056 - 4+	30	1	29	0	
2024-061	138	URS-10T		054 056	053 055		055 - 3+	13	6	13	100	
2024-061	138	URS-10T		054 056	053 055		054 - 2+	13	6	13	100	
2024-061	138	URS-10T		054 056	053 055		056 - 4+	13	1	13	100	
2024-061	140	MISSION A		053 055	053 055		055 - 3+	41	7	41	100	
2024-061	140	MISSION A		053 055	053 055		053 - 1+	41	1	41	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	140	MISSION A		053 055	053 055		054 - 2+	41	33	41	100	
2024-061	145	CLINITEK		053 055	053 055		056 - 4+	36	1	35	0	
2024-061	145	CLINITEK		053 055	053 055		054 - 2+	36	34	35	100	
2024-061	145	CLINITEK		053 055	053 055		055 - 3+	36	1	35	100	
2024-061	147	Mission120		053 055	053 055		053 - 1+	43	5	43	100	
2024-061	147	Mission120		053 055	053 055		054 - 2+	43	38	43	100	
2024-061	148	Mission500		053 055	053 055		055 - 3+	114	43	114	100	
2024-061	148	Mission500		053 055	053 055		054 - 2+	114	66	114	100	
2024-061	148	Mission500		053 055	053 055		053 - 1+	114	5	114	100	
2024-061	151	Clari. Uro		053 055	053 055		054 - 2+	20	17	20	100	
2024-061	151	Clari. Uro		053 055	053 055		055 - 3+	20	3	20	100	
064 URIN-PROTEIN QUALI.												
2024-062	011	AMES NM10S		053 055	053 055		055 - 3+	40	7	40	100	
2024-062	011	AMES NM10S		053 055	053 055		053 - 1+	40	5	40	100	
2024-062	011	AMES NM10S		053 055	053 055		054 - 2+	40	28	40	100	
2024-062	013	BAYER CLI		053 055	053 055		053 - 1+	24	1	24	100	
2024-062	013	BAYER CLI		053 055	053 055		054 - 2+	24	17	24	100	
2024-062	013	BAYER CLI		053 055	053 055		055 - 3+	24	6	24	100	
2024-062	067	URISCAN		053 055	053 055		053 - 1+	56	18	56	100	
2024-062	067	URISCAN		053 055	053 055		054 - 2+	56	37	56	100	
2024-062	067	URISCAN		053 055	053 055		055 - 3+	56	1	56	100	
2024-062	072	URS-9-TECO		053 055	053 055		055 - 3+	59	12	59	100	
2024-062	072	URS-9-TECO		053 055	053 055		053 - 1+	59	5	59	100	
2024-062	072	URS-9-TECO		053 055	053 055		054 - 2+	59	42	59	100	
2024-062	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	1	37	100	
2024-062	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100	
2024-062	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	24	37	100	
2024-062	089	AIMSTRIP		053 055	053 055		055 - 3+	143	17	142	100	
2024-062	089	AIMSTRIP		053 055	053 055		056 - 4+	143	1	142	0	
2024-062	089	AIMSTRIP		053 055	053 055		054 - 2+	143	122	142	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-062	089	AIMSTRIP		053 055	053 055		053 - 1+	143	3	142	100	
2024-062	094	CLINITEK		053 055	053 055		054 - 2+	104	96	104	100	
2024-062	094	CLINITEK		053 055	053 055		053 - 1+	104	2	104	100	
2024-062	094	CLINITEK		053 055	053 055		055 - 3+	104	6	104	100	
2024-062	102	ACON LAB		053 055	053 055		055 - 3+	129	21	127	100	
2024-062	102	ACON LAB		053 055	053 055		053 - 1+	129	6	127	100	
2024-062	102	ACON LAB		053 055	053 055		056 - 4+	129	2	127	0	
2024-062	102	ACON LAB		053 055	053 055		054 - 2+	129	100	127	100	
2024-062	131	iCHEM VELO		053 055	053 055		054 - 2+	30	28	30	100	
2024-062	131	iCHEM VELO		053 055	053 055		053 - 1+	30	1	30	100	
2024-062	131	iCHEM VELO		053 055	053 055		055 - 3+	30	1	30	100	
2024-062	138	URS-10T		053 055	053 055		054 - 2+	13	10	12	100	
2024-062	138	URS-10T		053 055	053 055		056 - 4+	13	1	12	0	
2024-062	138	URS-10T		053 055	053 055		055 - 3+	13	2	12	100	
2024-062	140	MISSION A		053 055	053 055		055 - 3+	41	2	41	100	
2024-062	140	MISSION A		053 055	053 055		053 - 1+	41	2	41	100	
2024-062	140	MISSION A		053 055	053 055		054 - 2+	41	37	41	100	
2024-062	145	CLINITEK		053 055	053 055		054 - 2+	36	36	36	100	
2024-062	147	Mission120		053 055	053 055		053 - 1+	43	8	43	100	
2024-062	147	Mission120		053 055	053 055		054 - 2+	43	35	43	100	
2024-062	148	Mission500		053 055	053 055		054 - 2+	114	97	114	100	
2024-062	148	Mission500		053 055	053 055		053 - 1+	114	10	114	100	
2024-062	148	Mission500		053 055	053 055		055 - 3+	114	7	114	100	
2024-062	151	Clari. Uro		053 055	053 055		054 - 2+	20	16	20	100	
2024-062	151	Clari. Uro		053 055	053 055		053 - 1+	20	2	20	100	
2024-062	151	Clari. Uro		053 055	053 055		055 - 3+	20	2	20	100	
064 URIN-PROTEIN QUALI.												
2024-063	011	AMES NM10S		053 055	053 055		054 - 2+	40	24	40	100	
2024-063	011	AMES NM10S		053 055	053 055		053 - 1+	40	2	40	100	
2024-063	011	AMES NM10S		053 055	053 055		055 - 3+	40	14	40	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
2024-063	013	BAYER CLI		053 055	053 055		055 - 3+	24	8	24	100		
2024-063	013	BAYER CLI		053 055	053 055		053 - 1+	24	1	24	100		
2024-063	013	BAYER CLI		053 055	053 055		054 - 2+	24	15	24	100		
2024-063	067	URISCAN		053 055	053 055		053 - 1+	56	7	56	100		
2024-063	067	URISCAN		053 055	053 055		054 - 2+	56	42	56	100		
2024-063	067	URISCAN		053 055	053 055		055 - 3+	56	7	56	100		
2024-063	072	URS-9-TECO		053 055	053 055		055 - 3+	59	28	59	100		
2024-063	072	URS-9-TECO		053 055	053 055		054 - 2+	59	31	59	100		
2024-063	080	ROCHE (CHE		053 055	053 055		055 - 3+	37	12	37	100		
2024-063	080	ROCHE (CHE		053 055	053 055		053 - 1+	37	1	37	100		
2024-063	080	ROCHE (CHE		053 055	053 055		054 - 2+	37	24	37	100		
2024-063	089	AIMSTRIP		053 055	053 055		056 - 4+	143	2	141	0		
2024-063	089	AIMSTRIP		053 055	053 055		055 - 3+	143	46	141	100		
2024-063	089	AIMSTRIP		053 055	053 055		053 - 1+	143	1	141	100		
2024-063	089	AIMSTRIP		053 055	053 055		054 - 2+	143	94	141	100		
2024-063	094	CLINITEK		053 055	053 055		055 - 3+	104	10	103	100		
2024-063	094	CLINITEK		053 055	053 055		053 - 1+	104	1	103	100		
2024-063	094	CLINITEK		053 055	053 055		054 - 2+	104	92	103	100		
2024-063	094	CLINITEK		053 055	053 055		056 - 4+	104	1	103	0		
2024-063	102	ACON LAB		053 055	053 055		054 - 2+	129	79	127	100		
2024-063	102	ACON LAB		053 055	053 055		053 - 1+	129	2	127	100		
2024-063	102	ACON LAB		053 055	053 055		056 - 4+	129	2	127	0		
2024-063	102	ACON LAB		053 055	053 055		055 - 3+	129	46	127	100		
2024-063	131	iCHEM VELO		054 056	053 055		056 - 4+	30	1	30	100		
2024-063	131	iCHEM VELO		054 056	053 055		054 - 2+	30	14	30	100		
2024-063	131	iCHEM VELO		054 056	053 055		055 - 3+	30	15	30	100		
2024-063	138	URS-10T		053 055	053 055		055 - 3+	13	5	12	100		
2024-063	138	URS-10T		053 055	053 055		054 - 2+	13	7	12	100		
2024-063	138	URS-10T		053 055	053 055		056 - 4+	13	1	12	0		
2024-063	140	MISSION A		053 055	053 055		054 - 2+	41	31	41	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	140	MISSION A		053 055	053 055		053 - 1+	41	2	41	100	
2024-063	140	MISSION A		053 055	053 055		055 - 3+	41	8	41	100	
2024-063	145	CLINITEK		053 055	053 055		054 - 2+	36	33	35	100	
2024-063	145	CLINITEK		053 055	053 055		056 - 4+	36	1	35	0	
2024-063	145	CLINITEK		053 055	053 055		055 - 3+	36	2	35	100	
2024-063	147	Mission120		053 055	053 055		054 - 2+	43	38	43	100	
2024-063	147	Mission120		053 055	053 055		053 - 1+	43	5	43	100	
2024-063	148	Mission500		053 055	053 055		054 - 2+	114	68	114	100	
2024-063	148	Mission500		053 055	053 055		053 - 1+	114	6	114	100	
2024-063	148	Mission500		053 055	053 055		055 - 3+	114	40	114	100	
2024-063	151	Clari. Uro		053 055	053 055		054 - 2+	20	17	20	100	
2024-063	151	Clari. Uro		053 055	053 055		055 - 3+	20	3	20	100	
064 URIN-PROTEIN QUALI.												
2024-064	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	40	40	40	100	
2024-064	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	24	24	24	100	
2024-064	067	URISCAN		051 051	051 051		051 - NEGATIVE	56	56	56	100	
2024-064	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	59	59	59	100	
2024-064	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	36	36	100	
2024-064	080	ROCHE (CHE		051 051	051 051		053 - 1+	37	1	36	0	
2024-064	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	143	143	143	100	
2024-064	094	CLINITEK		051 051	051 051		051 - NEGATIVE	104	104	104	100	
2024-064	102	ACON LAB		051 051	051 051		051 - NEGATIVE	129	129	129	100	
2024-064	131	iCHEM VELO		051 051	051 051		051 - NEGATIVE	30	30	30	100	
2024-064	138	URS-10T		051 051	051 051		051 - NEGATIVE	13	13	13	100	
2024-064	140	MISSION A		051 051	051 051		051 - NEGATIVE	41	39	39	100	
2024-064	140	MISSION A		051 051	051 051		052 - TRACES	41	2	39	0	
2024-064	145	CLINITEK		051 051	051 051		051 - NEGATIVE	36	36	36	100	
2024-064	147	Mission120		051 051	051 051		051 - NEGATIVE	43	43	43	100	
2024-064	148	Mission500		051 051	051 051		051 - NEGATIVE	114	114	114	100	
2024-064	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	20	20	20	100	



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
064 URIN-PROTEIN QUALI.													
2024-065	011	AMES NM10S		051 051	051 051		051 - NEGATIVE	40	40	40	100		
2024-065	013	BAYER CLI		051 051	051 051		052 - TRACES	24	1	23	0		
2024-065	013	BAYER CLI		051 051	051 051		051 - NEGATIVE	24	23	23	100		
2024-065	067	URISCAN		051 051	051 051		052 - TRACES	56	1	55	0		
2024-065	067	URISCAN		051 051	051 051		051 - NEGATIVE	56	55	55	100		
2024-065	072	URS-9-TECO		051 051	051 051		051 - NEGATIVE	59	59	59	100		
2024-065	080	ROCHE (CHE		051 051	051 051		051 - NEGATIVE	37	36	36	100		
2024-065	080	ROCHE (CHE		051 051	051 051		052 - TRACES	37	1	36	0		
2024-065	089	AIMSTRIP		051 051	051 051		052 - TRACES	143	1	142	0		
2024-065	089	AIMSTRIP		051 051	051 051		051 - NEGATIVE	143	142	142	100		
2024-065	094	CLINITEK		051 051	051 051		051 - NEGATIVE	104	104	104	100		
2024-065	102	ACON LAB		051 051	051 051		051 - NEGATIVE	129	127	127	100		
2024-065	102	ACON LAB		051 051	051 051		052 - TRACES	129	2	127	0		
2024-065	131	ICHEM VELO		051 051	051 051		051 - NEGATIVE	30	30	30	100		
2024-065	138	URS-10T		051 051	051 051		051 - NEGATIVE	13	13	13	100		
2024-065	140	MISSION A		051 051	051 051		052 - TRACES	41	2	39	0		
2024-065	140	MISSION A		051 051	051 051		051 - NEGATIVE	41	39	39	100		
2024-065	145	CLINITEK		051 051	051 051		051 - NEGATIVE	36	36	36	100		
2024-065	147	Mission120		051 051	051 051		051 - NEGATIVE	43	43	43	100		
2024-065	148	Mission500		051 051	051 051		053 - 1+	114	1	113	0		
2024-065	148	Mission500		051 051	051 051		051 - NEGATIVE	114	113	113	100		
2024-065	151	Clari. Uro		051 051	051 051		051 - NEGATIVE	20	20	20	100		
066 URINAL.-UROBILINOGEN													
2024-061	011	AMES NM10S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-061	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	24	24	24	100		
2024-061	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100		
2024-061	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	59	59	59	100		
2024-061	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	089 AIMSTRIP			061 061	061 061		061 - NORMAL,NEG	144	144	144	100	
2024-061	094 CLINITEK			061 061	061 061		061 - NORMAL,NEG	104	104	104	100	
2024-061	102 ACON LAB			061 061	061 061		061 - NORMAL,NEG	126	126	126	100	
2024-061	131 iCHEM VELO			061 061	061 061		061 - NORMAL,NEG	30	30	30	100	
2024-061	138 URS-10T			061 061	061 061		061 - NORMAL,NEG	13	13	13	100	
2024-061	140 MISSION A			061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-061	145 CLINITEK			061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2024-061	147 Mission120			061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-061	148 Mission500			061 061	061 061		061 - NORMAL,NEG	112	112	112	100	
2024-061	151 Clari. Uro			061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
066 URINAL.-UROBILINOGEN												
2024-062	011 AMES NM10S			061 061	061 061		061 - NORMAL,NEG	40	40	40	100	
2024-062	013 BAYER CLI			061 061	061 061		061 - NORMAL,NEG	24	24	24	100	
2024-062	067 URISCAN			061 061	061 061		061 - NORMAL,NEG	56	56	56	100	
2024-062	072 URS-9-TECO			061 061	061 061		061 - NORMAL,NEG	59	59	59	100	
2024-062	080 ROCHE (CHE			061 061	061 061		061 - NORMAL,NEG	37	37	37	100	
2024-062	089 AIMSTRIP			061 061	061 061		061 - NORMAL,NEG	144	144	144	100	
2024-062	094 CLINITEK			061 061	061 061		061 - NORMAL,NEG	104	104	104	100	
2024-062	102 ACON LAB			061 061	061 061		061 - NORMAL,NEG	126	126	126	100	
2024-062	131 iCHEM VELO			061 061	061 061		061 - NORMAL,NEG	30	30	30	100	
2024-062	138 URS-10T			061 061	061 061		061 - NORMAL,NEG	13	13	13	100	
2024-062	140 MISSION A			061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-062	145 CLINITEK			061 061	061 061		061 - NORMAL,NEG	36	36	36	100	
2024-062	147 Mission120			061 061	061 061		061 - NORMAL,NEG	43	43	43	100	
2024-062	148 Mission500			061 061	061 061		061 - NORMAL,NEG	112	112	112	100	
2024-062	151 Clari. Uro			061 061	061 061		061 - NORMAL,NEG	20	20	20	100	
2024-063	011 AMES NM10S			061 063	061 063		063 - 4	40	17	40	100	
2024-063	011 AMES NM10S			061 063	061 063		062 - 2	40	19	40	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	011	AMES NM10S		061 063	061 063		061 - NORMAL,NEG	40	4	40	100	
2024-063	013	BAYER CLI		061 063	061 063		062 - 2	24	14	24	100	
2024-063	013	BAYER CLI		061 063	061 063		063 - 4	24	2	24	100	
2024-063	013	BAYER CLI		061 063	061 063		061 - NORMAL,NEG	24	8	24	100	
2024-063	067	URISCAN			061 063		062 - 2	56	9	56	100	
2024-063	067	URISCAN			061 063		061 - NORMAL,NEG	56	21	56	100	
2024-063	067	URISCAN			061 063		063 - 4	56	26	56	100	
2024-063	072	URS-9-TECO		061 063	061 063		061 - NORMAL,NEG	59	9	58	100	
2024-063	072	URS-9-TECO		061 063	061 063		064 - 8	59	1	58	0	
2024-063	072	URS-9-TECO		061 063	061 063		062 - 2	59	40	58	100	
2024-063	072	URS-9-TECO		061 063	061 063		063 - 4	59	9	58	100	
2024-063	080	ROCHE (CHE		061 061	061 063		061 - NORMAL,NEG	37	30	37	100	
2024-063	080	ROCHE (CHE		061 061	061 063		062 - 2	37	5	37	100	
2024-063	080	ROCHE (CHE		061 061	061 063		063 - 4	37	2	37	100	
2024-063	089	AIMSTRIP			061 063		063 - 4	144	2	144	100	
2024-063	089	AIMSTRIP			061 063		061 - NORMAL,NEG	144	111	144	100	
2024-063	089	AIMSTRIP			061 063		062 - 2	144	31	144	100	
2024-063	094	CLINITEK		062 064	061 063		061 - NORMAL,NEG	104	11	104	100	
2024-063	094	CLINITEK		062 064	061 063		064 - 8	104	1	104	100	
2024-063	094	CLINITEK		062 064	061 063		063 - 4	104	54	104	100	
2024-063	094	CLINITEK		062 064	061 063		062 - 2	104	38	104	100	
2024-063	102	ACON LAB			061 063		061 - NORMAL,NEG	126	97	126	100	
2024-063	102	ACON LAB			061 063		063 - 4	126	3	126	100	
2024-063	102	ACON LAB			061 063		062 - 2	126	26	126	100	
2024-063	131	iCHEM VELO		062 064	061 063		063 - 4	30	29	30	100	
2024-063	131	iCHEM VELO		062 064	061 063		061 - NORMAL,NEG	30	1	30	100	
2024-063	138	URS-10T		061 063	061 063		063 - 4	13	3	13	100	
2024-063	138	URS-10T		061 063	061 063		062 - 2	13	7	13	100	
2024-063	138	URS-10T		061 063	061 063		061 - NORMAL,NEG	13	3	13	100	
2024-063	140	MISSION A			061 063		061 - NORMAL,NEG	43	33	43	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS				
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-063	140 MISSION A				061 063		062 - 2	43	7	43	100
2024-063	140 MISSION A				061 063		063 - 4	43	3	43	100
2024-063	145 CLINITEK			061 063	061 063		062 - 2	36	34	36	100
2024-063	145 CLINITEK			061 063	061 063		061 - NORMAL,NEG	36	2	36	100
2024-063	147 Mission120			061 061	061 063		061 - NORMAL,NEG	43	40	43	100
2024-063	147 Mission120			061 061	061 063		062 - 2	43	3	43	100
2024-063	148 Mission500			061 061	061 063		061 - NORMAL,NEG	112	109	112	100
2024-063	148 Mission500			061 061	061 063		062 - 2	112	2	112	100
2024-063	148 Mission500			061 061	061 063		063 - 4	112	1	112	100
2024-063	151 Clari. Uro				061 063		061 - NORMAL,NEG	20	13	20	100
2024-063	151 Clari. Uro				061 063		063 - 4	20	1	20	100
2024-063	151 Clari. Uro				061 063		062 - 2	20	6	20	100
066 URINAL.-UROBILINOGEN											
2024-064	011 AMES NM10S			061 061	061 061		061 - NORMAL,NEG	40	40	40	100
2024-064	013 BAYER CLI			061 061	061 061		061 - NORMAL,NEG	24	24	24	100
2024-064	067 URISCAN			061 061	061 061		061 - NORMAL,NEG	56	56	56	100
2024-064	072 URS-9-TECO			061 061	061 061		061 - NORMAL,NEG	59	59	59	100
2024-064	080 ROCHE (CHE			061 061	061 061		061 - NORMAL,NEG	37	37	37	100
2024-064	089 AIMSTRIP			061 061	061 061		061 - NORMAL,NEG	144	143	143	100
2024-064	089 AIMSTRIP			061 061	061 061		062 - 2	144	1	143	0
2024-064	094 CLINITEK			061 061	061 061		061 - NORMAL,NEG	104	104	104	100
2024-064	102 ACON LAB			061 061	061 061		061 - NORMAL,NEG	126	126	126	100
2024-064	131 iCHEM VELO			061 061	061 061		061 - NORMAL,NEG	30	30	30	100
2024-064	138 URS-10T			061 061	061 061		061 - NORMAL,NEG	13	13	13	100
2024-064	140 MISSION A			061 061	061 061		061 - NORMAL,NEG	43	42	42	100
2024-064	140 MISSION A			061 061	061 061		063 - 4	43	1	42	0
2024-064	145 CLINITEK			061 061	061 061		061 - NORMAL,NEG	36	36	36	100
2024-064	147 Mission120			061 061	061 061		061 - NORMAL,NEG	43	43	43	100
2024-064	148 Mission500			061 061	061 061		061 - NORMAL,NEG	112	112	112	100
2024-064	151 Clari. Uro			061 061	061 061		061 - NORMAL,NEG	20	20	20	100

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
066 URINAL.-UROBILINOGEN													
2024-065	011	AMES NMI0S		061 061	061 061		061 - NORMAL,NEG	40	40	40	100		
2024-065	013	BAYER CLI		061 061	061 061		061 - NORMAL,NEG	24	24	24	100		
2024-065	067	URISCAN		061 061	061 061		061 - NORMAL,NEG	56	56	56	100		
2024-065	072	URS-9-TECO		061 061	061 061		061 - NORMAL,NEG	59	59	59	100		
2024-065	080	ROCHE (CHE		061 061	061 061		061 - NORMAL,NEG	37	37	37	100		
2024-065	089	AIMSTRIP		061 061	061 061		061 - NORMAL,NEG	144	144	144	100		
2024-065	094	CLINITEK		061 061	061 061		061 - NORMAL,NEG	104	104	104	100		
2024-065	102	ACON LAB		061 061	061 061		061 - NORMAL,NEG	126	126	126	100		
2024-065	131	iCHEM VELO		061 061	061 061		061 - NORMAL,NEG	30	30	30	100		
2024-065	138	URS-10T		061 061	061 061		061 - NORMAL,NEG	13	13	13	100		
2024-065	140	MISSION A		061 061	061 061		061 - NORMAL,NEG	43	43	43	100		
2024-065	145	CLINITEK		061 061	061 061		061 - NORMAL,NEG	36	36	36	100		
2024-065	147	Mission120		061 061	061 061		061 - NORMAL,NEG	43	43	43	100		
2024-065	148	Mission500		061 061	061 061		061 - NORMAL,NEG	112	112	112	100		
2024-065	151	Clari. Uro		061 061	061 061		061 - NORMAL,NEG	20	20	20	100		
184 URINALYSIS LEUKOCYTE													
2024-061	011	AMES NMI0S		001 001	001 001		001 - Negative	40	40	40	100		
2024-061	013	BAYER CLI		001 001	001 001		001 - Negative	24	24	24	100		
2024-061	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100		
2024-061	072	URS-9-TECO		001 001	001 001		001 - Negative	57	57	57	100		
2024-061	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100		
2024-061	089	AIMSTRIP		001 001	001 001		001 - Negative	143	143	143	100		
2024-061	094	CLINITEK		001 001	001 001		001 - Negative	103	103	103	100		
2024-061	102	ACON LAB		001 001	001 001		001 - Negative	119	119	119	100		
2024-061	131	iCHEM VELO		001 001	001 001		001 - Negative	30	30	30	100		
2024-061	138	URS-10T		001 001	001 001		001 - Negative	12	12	12	100		
2024-061	140	MISSION A		001 001	001 001		001 - Negative	45	45	45	100		
2024-061	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY			SUB: 50 URINALYSIS				GRP: 70 URINALYSIS					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-061	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-061	148	Mission500		001 001	001 001		001 - Negative	115	115	115	100	
2024-061	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
184 URINALYSIS LEUKOCYTE												
2024-062	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-062	013	BAYER CLI		001 001	001 001		001 - Negative	24	24	24	100	
2024-062	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2024-062	072	URS-9-TECO		001 001	001 001		001 - Negative	57	57	57	100	
2024-062	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-062	089	AIMSTRIP		001 001	001 001		001 - Negative	143	143	143	100	
2024-062	094	CLINITEK		001 001	001 001		001 - Negative	103	103	103	100	
2024-062	102	ACON LAB		001 001	001 001		001 - Negative	119	119	119	100	
2024-062	131	iCHEM VELO		001 001	001 001		001 - Negative	30	30	30	100	
2024-062	138	URS-10T		001 001	001 001		001 - Negative	12	12	12	100	
2024-062	140	MISSION A		001 001	001 001		001 - Negative	45	45	45	100	
2024-062	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-062	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-062	148	Mission500		001 001	001 001		001 - Negative	115	115	115	100	
2024-062	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
2024-063	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	
2024-063	013	BAYER CLI		001 001	001 001		001 - Negative	24	24	24	100	
2024-063	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2024-063	072	URS-9-TECO		001 001	001 001		001 - Negative	57	57	57	100	
2024-063	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	33	33	100	
2024-063	080	ROCHE (CHE		001 001	001 001		002 - Traces	34	1	33	0	
2024-063	089	AIMSTRIP		001 001	001 001		001 - Negative	143	143	143	100	
2024-063	094	CLINITEK		001 001	001 001		001 - Negative	103	103	103	100	
2024-063	102	ACON LAB		001 001	001 001		003 - Small	119	1	118	0	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-063	102	ACON LAB		001 001	001 001		001 - Negative	119	118	118	100	
2024-063	131	iCHEM VELO		001 001	001 001		002 - Traces	30	1	29	0	
2024-063	131	iCHEM VELO		001 001	001 001		001 - Negative	30	29	29	100	
2024-063	138	URS-10T		001 001	001 001		001 - Negative	12	12	12	100	
2024-063	140	MISSION A		001 001	001 001		001 - Negative	45	45	45	100	
2024-063	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-063	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-063	148	Mission500		001 001	001 001		001 - Negative	115	115	115	100	
2024-063	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	
184 URINALYSIS LEUKOCYTE												
2024-064	011	AMES NM10S		002 004	003 005		004 - Moderate	40	6	40	100	
2024-064	011	AMES NM10S		002 004	003 005		002 - Traces	40	2	40	100	
2024-064	011	AMES NM10S		002 004	003 005		003 - Small	40	32	40	100	
2024-064	013	BAYER CLI		002 004	003 005		004 - Moderate	24	2	24	100	
2024-064	013	BAYER CLI		002 004	003 005		003 - Small	24	22	24	100	
2024-064	067	URISCAN		004 005	003 005		004 - Moderate	56	22	56	100	
2024-064	067	URISCAN		004 005	003 005		003 - Small	56	8	56	100	
2024-064	067	URISCAN		004 005	003 005		005 - Large	56	26	56	100	
2024-064	072	URS-9-TECO		003 005	003 005		004 - Moderate	57	37	56	100	
2024-064	072	URS-9-TECO		003 005	003 005		005 - Large	57	3	56	100	
2024-064	072	URS-9-TECO		003 005	003 005		002 - Traces	57	1	56	0	
2024-064	072	URS-9-TECO		003 005	003 005		003 - Small	57	16	56	100	
2024-064	080	ROCHE (CHE		004 005	003 005		004 - Moderate	34	4	34	100	
2024-064	080	ROCHE (CHE		004 005	003 005		003 - Small	34	1	34	100	
2024-064	080	ROCHE (CHE		004 005	003 005		005 - Large	34	29	34	100	
2024-064	089	AIMSTRIP		002 004	003 005		005 - Large	143	1	143	100	
2024-064	089	AIMSTRIP		002 004	003 005		002 - Traces	143	31	143	100	
2024-064	089	AIMSTRIP		002 004	003 005		004 - Moderate	143	15	143	100	
2024-064	089	AIMSTRIP		002 004	003 005		003 - Small	143	96	143	100	
2024-064	094	CLINITEK		002 004	003 005		002 - Traces	103	2	103	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-064	094	CLINITEK		002 004	003 005		004 - Moderate	103	2	103	100	
2024-064	094	CLINITEK		002 004	003 005		003 - Small	103	99	103	100	
2024-064	102	ACON LAB		002 004	003 005		004 - Moderate	119	26	118	100	
2024-064	102	ACON LAB		002 004	003 005		001 - Negative	119	1	118	0	
2024-064	102	ACON LAB		002 004	003 005		003 - Small	119	72	118	100	
2024-064	102	ACON LAB		002 004	003 005		002 - Traces	119	20	118	100	
2024-064	131	iCHEM VELO		004 005	003 005		005 - Large	30	28	30	100	
2024-064	131	iCHEM VELO		004 005	003 005		004 - Moderate	30	2	30	100	
2024-064	138	URS-10T		003 005	003 005		003 - Small	12	6	12	100	
2024-064	138	URS-10T		003 005	003 005		004 - Moderate	12	6	12	100	
2024-064	140	MISSION A		002 004	003 005		003 - Small	45	26	44	100	
2024-064	140	MISSION A		002 004	003 005		002 - Traces	45	10	44	100	
2024-064	140	MISSION A		002 004	003 005		001 - Negative	45	1	44	0	
2024-064	140	MISSION A		002 004	003 005		004 - Moderate	45	8	44	100	
2024-064	145	CLINITEK		003 005	003 005		003 - Small	36	2	36	100	
2024-064	145	CLINITEK		003 005	003 005		004 - Moderate	36	34	36	100	
2024-064	147	Mission120		002 004	003 005		002 - Traces	42	20	42	100	
2024-064	147	Mission120		002 004	003 005		004 - Moderate	42	2	42	100	
2024-064	147	Mission120		002 004	003 005		003 - Small	42	20	42	100	
2024-064	148	Mission500		002 004	003 005		002 - Traces	115	32	112	100	
2024-064	148	Mission500		002 004	003 005		005 - Large	115	1	112	100	
2024-064	148	Mission500		002 004	003 005		004 - Moderate	115	19	112	100	
2024-064	148	Mission500		002 004	003 005		001 - Negative	115	3	112	0	
2024-064	148	Mission500		002 004	003 005		003 - Small	115	60	112	100	
2024-064	151	Clari. Uro		002 004	003 005		004 - Moderate	20	3	20	100	
2024-064	151	Clari. Uro		002 004	003 005		003 - Small	20	13	20	100	
2024-064	151	Clari. Uro		002 004	003 005		005 - Large	20	1	20	100	
2024-064	151	Clari. Uro		002 004	003 005		002 - Traces	20	3	20	100	
184 URINALYSIS LEUKOCYTE												
2024-065	011	AMES NM10S		001 001	001 001		001 - Negative	40	40	40	100	



**Participant Summary**  
**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 70 URINALYSIS						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
2024-065	013	BAYER CLI		001 001	001 001		001 - Negative	24	24	24	100	
2024-065	067	URISCAN		001 001	001 001		001 - Negative	56	56	56	100	
2024-065	072	URS-9-TECO		001 001	001 001		001 - Negative	57	57	57	100	
2024-065	080	ROCHE (CHE		001 001	001 001		001 - Negative	34	34	34	100	
2024-065	089	AIMSTRIP		001 001	001 001		001 - Negative	143	143	143	100	
2024-065	094	CLINITEK		001 001	001 001		001 - Negative	103	103	103	100	
2024-065	102	ACON LAB		001 001	001 001		001 - Negative	119	119	119	100	
2024-065	131	iCHEM VELO		001 001	001 001		001 - Negative	30	30	30	100	
2024-065	138	URS-10T		001 001	001 001		001 - Negative	12	12	12	100	
2024-065	140	MISSION A		001 001	001 001		001 - Negative	45	44	44	100	
2024-065	140	MISSION A		001 001	001 001		004 - Moderate	45	1	44	0	
2024-065	145	CLINITEK		001 001	001 001		001 - Negative	36	36	36	100	
2024-065	147	Mission120		001 001	001 001		001 - Negative	42	42	42	100	
2024-065	148	Mission500		001 001	001 001		004 - Moderate	115	1	114	0	
2024-065	148	Mission500		001 001	001 001		001 - Negative	115	114	114	100	
2024-065	151	Clari. Uro		001 001	001 001		001 - Negative	20	20	20	100	

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 80 PREGNANCY TEST						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score	
063 URI-PREGNANCY TEST												
2024-061	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100
2024-061	101	HCG Alere		002	002	002	002	002 - POSITIVE	22	22	22	100
2024-062	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2024-062	101	HCG Alere		001	001	001	001	001 - NEGATIVE	22	22	22	100
2024-063	091	AIM STEP		002	002	002	002	002 - POSITIVE	32	32	32	100
2024-063	101	HCG Alere		002	002	002	002	002 - POSITIVE	22	22	22	100
2024-064	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2024-064	101	HCG Alere		001	001	001	001	001 - NEGATIVE	22	22	22	100
2024-065	091	AIM STEP		001	001	001	001	001 - NEGATIVE	32	32	32	100
2024-065	101	HCG Alere		001	001	001	001	001 - NEGATIVE	22	22	22	100

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS				GRP: 75 URINALYSIS SEDIMENT					
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
150 URINAL.- SEDIMENT											
2024-071					012	012	010 - RENAL TUB.	907	95	809	0
2024-071					012	012	012 - TRANSITIO.	907	809	809	100
2024-071					012	012	009 - LEUKOCYTE	907	1	809	0
2024-071					012	012	033 - OVAL FAT B	907	2	809	0
2024-072					008	008	038 - YEAST/FUN.	907	4	896	0

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 50 URINALYSIS			GRP: 75 URINALYSIS SEDIMENT						
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score
2024-072					008	008	005 - RED CELL C	907	3	896	0
2024-072					008	008	008 - ERYTHROCYT	907	896	896	100
2024-072					008	008	034 - OIL DROPL.	907	4	896	0
150 URINAL.- SEDIMENT											
2024-073					033	033	009 - LEUKOCYTE	907	7	890	0
2024-073					033	033	034 - OIL DROPL.	907	2	890	0
2024-073					033	033	033 - OVAL FAT B	907	890	890	100
2024-073					033	033	012 - TRANSITIO.	907	2	890	0
2024-073					033	033	027 - CA. PHOSP.	907	2	890	0
2024-073					033	033	010 - RENAL TUB.	907	3	890	0
2024-073					033	033	011 - SQUAMOUS E	907	1	890	0
2024-074					005	005	005 - RED CELL C	907	891	891	100
2024-074					005	005	008 - ERYTHROCYT	907	2	891	0
2024-074					005	005	002 - FATTY CAST	907	5	891	0
2024-074					005	005	033 - OVAL FAT B	907	1	891	0
2024-074					005	005	007 - WHITE CELL	907	8	891	0
2024-075					027	027	014 - CA. OXALAT	907	2	894	0
2024-075					027	027	021 - SULFANAM.	907	1	894	0
2024-075					027	027	022 - TYROSINE	907	1	894	0
2024-075					027	027	020 - SODIUM UR.	907	2	894	0
2024-075					027	027	028 - TRIPLE PH.	907	1	894	0
2024-075					027	027	005 - RED CELL C	907	1	894	0
2024-075					027	027	015 - CA. SULFAT	907	4	894	0
2024-075					027	027	027 - CA. PHOSP.	907	894	894	100
2024-075					027	027	023 - URIC ACID	907	1	894	0

4/1/2024

PROFICIENCY TESTING SERVICE  
LABORATORY SERVICES PROGRAM  
DEPARTMENT OF HEALTH OF PUERTO RICO

PAGE : 116 (124)  
DATE : 4/1/2024  
TIME : 14:02:07

## **Participant Summary**

**MONTH 2 OF YEAR 2024**

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPE: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 98 OCCULT BLOOD							
TEST SAMPLE	LEVEL 1 RESULT CODE	LEVEL 2 RESULT CODE	LEVEL 3 RESULT CODE	PART LOW/HIGH	REFEREE LOW/HIGH	COMMER LOW/HIGH	REPORTED VALUE	PART LABS	# LABS ANSW	# "SF" LABS	Score		
154 FECAL OCCULT BLOOD													
2024-081	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	389	1	388	0	
2024-081	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	389	388	388	100	
2024-081	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	734	734	734	100	
2024-082	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	389	388	388	100	
2024-082	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	389	1	388	0	
2024-082	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	734	734	734	100	
2024-083	001	PEROXIDASE		002	002	002	002	001 - NEGATIVE	389	1	388	0	
2024-083	001	PEROXIDASE		002	002	002	002	002 - POSITIVE	389	388	388	100	
2024-083	002	INMMUASSAY		002	002	002	002	001 - NEGATIVE	734	1	733	0	
2024-083	002	INMMUASSAY		002	002	002	002	002 - POSITIVE	734	733	733	100	
2024-084	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	389	386	386	100	
2024-084	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	389	3	386	0	
2024-084	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	734	1	733	0	
2024-084	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	734	733	733	100	
2024-085	001	PEROXIDASE		001	001	001	001	001 - NEGATIVE	389	388	388	100	
2024-085	001	PEROXIDASE		001	001	001	001	002 - POSITIVE	389	1	388	0	
2024-085	002	INMMUASSAY		001	001	001	001	002 - POSITIVE	734	3	731	0	
2024-085	002	INMMUASSAY		001	001	001	001	001 - NEGATIVE	734	731	731	100	
SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS				GRP: 90 SPECIAL TEST							

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST					
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
068	CARCINOE. ANTIG. CEA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}			
2024-031	29 VITROS			12	43.100	1.437	3.33	38.800	47.400
2024-031	38 ROCHE E			17	34.829	1.726	4.96	29.700	40.000
2024-031	44 BECK.COUL.			21	31.245	1.731	5.54	26.100	36.400
2024-031	50 ARC			10	44.900	2.149	4.79	38.500	51.300
2024-032	29 VITROS			12	0.450	0.050	11.11	0.300	0.600
2024-032	38 ROCHE E			17	0.712	0.128	17.96	0.500	0.900
2024-032	44 BECK.COUL.			21	0.605	0.059	9.74	0.500	0.800
2024-032	50 ARC			10	1.150	0.450	39.13	0.900	1.400
2024-033	29 VITROS			12	14.233	0.205	1.44	13.600	14.800
2024-033	38 ROCHE E			17	12.700	0.502	3.95	11.200	14.200
2024-033	44 BECK.COUL.			21	10.414	0.579	5.56	8.700	12.200
2024-033	50 ARC			10	15.950	0.836	5.24	13.400	18.500
2024-034	29 VITROS			12	28.708	0.860	2.99	26.100	31.300
2024-034	38 ROCHE E			17	24.135	1.138	4.72	20.700	27.500
2024-034	44 BECK.COUL.			21	20.338	1.001	4.92	17.300	23.300
2024-034	50 ARC			10	30.420	2.008	6.60	24.400	36.400
2024-035	29 VITROS			12	12.050	0.318	2.64	11.100	13.000
2024-035	38 ROCHE E			17	10.747	0.470	4.38	9.300	12.200
2024-035	44 BECK.COUL.			21	8.710	0.534	6.13	7.100	10.300
2024-035	50 ARC			10	13.510	0.723	5.35	11.300	15.700
069	PROS. SPEC-ANTIG-PSA								
2024-031	29 VITROS			47	11.557	0.436	3.77	10.300	12.900
2024-031	36 TOSOH AIA			10	14.540	1.159	7.97	11.100	18.000
2024-031	38 ROCHE E			51	22.639	1.377	6.08	18.500	26.800
2024-031	44 BECK.COUL.			53	23.126	1.540	6.66	18.500	27.700

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 90 SPECIAL TEST				
ANALYTE					NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-031	50	ARC		22	18.682	0.642	3.44	16.800	20.600	
2024-031	57	S. EXL 200		64	22.548	0.990	4.39	19.600	25.500	
2024-031	58	APELLICA		11	19.236	0.855	4.45	16.700	21.800	
069	PROS. SPEC-ANTIG-PSA	CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE	3	SD OR 25 %	{LOWER}				
2024-032	29	VITROS		47	0.200	0.000	0.00	0.200	0.200	
2024-032	36	TOSOH AIA		10	0.160	0.049	30.62	0.100	0.200	
2024-032	38	ROCHE E		51	0.200	0.000	0.00	0.200	0.200	
2024-032	44	BECK.COUL.		53	0.194	0.023	12.00	0.100	0.200	
2024-032	50	ARC		22	0.100	0.000	0.00	0.100	0.100	
2024-032	57	S. EXL 200		64	0.151	0.053	35.20	0.100	0.200	
2024-032	58	APELLICA		11	0.164	0.048	29.40	0.100	0.200	
2024-033	29	VITROS		47	4.232	0.150	3.55	3.800	4.700	
2024-033	36	TOSOH AIA		10	5.160	0.326	6.32	4.200	6.100	
2024-033	38	ROCHE E		51	8.051	0.508	6.31	6.500	9.600	
2024-033	44	BECK.COUL.		53	8.057	0.495	6.15	6.600	9.500	
2024-033	50	ARC		22	6.432	0.328	5.10	5.400	7.400	
2024-033	57	S. EXL 200		64	7.819	0.364	4.65	6.700	8.900	
2024-033	58	APELLICA		11	6.882	0.225	3.27	6.200	7.600	
2024-034	29	VITROS		47	7.968	0.281	3.52	7.100	8.800	
2024-034	36	TOSOH AIA		10	9.820	0.572	5.83	8.100	11.500	
2024-034	38	ROCHE E		51	15.594	0.985	6.31	12.600	18.500	
2024-034	44	BECK.COUL.		53	15.636	0.976	6.24	12.700	18.600	
2024-034	50	ARC		22	12.582	0.516	4.10	11.000	14.100	
2024-034	57	S. EXL 200		64	15.437	0.721	4.67	13.300	17.600	
2024-034	58	APELLICA		11	13.391	0.466	3.48	12.000	14.800	
2024-035	29	VITROS		47	3.630	0.150	4.14	3.200	4.100	
2024-035	36	TOSOH AIA		10	4.310	0.301	7.00	3.400	5.200	

**Participant Summary**  
**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 90 SPECIAL TEST							
ANALYTE						NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH		
2024-035	38	ROCHE E		51	6.782	0.384	5.66	5.600	7.900		
2024-035	44	BECK.COUL.		53	6.829	0.350	5.12	5.800	7.900		
2024-035	50	ARC		22	5.409	0.313	5.79	4.500	6.300		
2024-035	57	S. EXL 200		64	6.594	0.288	4.37	5.700	7.500		
2024-035	58	ATELLICA		11	5.773	0.222	3.84	5.100	6.400		
071 VITAMIN B 12			CLIA TEST ID #: 0		EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}						
2024-031	29	VITROS		29	807.586	50.155	6.21	657.000	958.000		
2024-031	38	ROCHE E		33	1031.212	59.902	5.81	852.000	1211.000		
2024-031	44	BECK.COUL.		29	725.500	43.035	5.93	596.000	855.000		
2024-031	50	ARC		21	896.190	52.183	5.82	740.000	1053.000		
2024-031	57	S. EXL 200		22	906.909	45.029	4.97	772.000	1042.000		
2024-032	29	VITROS		29	195.103	8.023	4.11	171.000	219.000		
2024-032	38	ROCHE E		33	185.000	27.899	15.08	139.000	231.000		
2024-032	44	BECK.COUL.		29	131.286	9.039	6.89	104.000	158.000		
2024-032	50	ARC		21	183.857	26.068	14.18	138.000	230.000		
2024-032	57	S. EXL 200		22	206.455	18.836	9.12	155.000	258.000		
2024-033	29	VITROS		29	427.276	16.870	3.95	377.000	478.000		
2024-033	38	ROCHE E		33	466.485	29.084	6.23	379.000	554.000		
2024-033	44	BECK.COUL.		29	338.897	16.606	4.90	289.000	389.000		
2024-033	50	ARC		21	417.667	33.832	8.10	316.000	519.000		
2024-033	57	S. EXL 200		22	444.318	27.300	6.14	362.000	526.000		
2024-034	29	VITROS		29	713.828	42.140	5.90	587.000	840.000		
2024-034	38	ROCHE E		33	769.152	44.633	5.80	635.000	903.000		
2024-034	44	BECK.COUL.		29	561.483	31.530	5.62	467.000	656.000		
2024-034	50	ARC		21	667.429	24.371	3.65	594.000	741.000		
2024-034	57	S. EXL 200		22	685.955	32.013	4.67	590.000	782.000		



**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY                      SUB: 60 SPECIAL TESTS                      GRP: 90 SPECIAL TEST

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
071 VITAMIN B 12		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}						
2024-035	29 VITROS			29	382.172	13.646	3.57	341.000	423.000
2024-035	38 ROCHE E			33	421.758	28.662	6.80	336.000	508.000
2024-035	44 BECK.COUL.			29	311.621	22.587	7.25	244.000	379.000
2024-035	50 ARC			21	380.250	23.117	6.08	311.000	450.000
2024-035	57 S. EXL 200			22	411.500	25.280	6.14	336.000	487.000

SPEC: 10 CHEMISTRY                      SUB: 60 SPECIAL TESTS                      GRP: 95 GLYCOHEMOGLOBINE

ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
146 GLYCOHEMOGLOBIN									
2024-041	12 COBAS/INT.			27	4.959	0.279	5.63	4.100	5.800
2024-041	14 IMMUNOTUR.			17	5.094	0.155	3.05	4.600	5.600
2024-041	22 VITROS			53	4.867	0.080	1.65	4.600	5.100
2024-041	31 IMMUNOTURB			44	4.877	0.219	4.48	4.200	5.500
2024-041	40 SIEMENS DI			82	5.000	0.170	3.41	4.500	5.500
2024-041	46 ARCHITECT			19	4.916	0.127	2.58	4.500	5.300
2024-041	48 ATELLICA			12	4.817	0.114	2.37	4.500	5.200
2024-042	12 COBAS/INT.			27	5.812	0.137	2.35	5.400	6.200
2024-042	14 IMMUNOTUR.			17	6.000	0.211	3.52	5.400	6.600
2024-042	22 VITROS			53	5.728	0.094	1.64	5.400	6.000
2024-042	31 IMMUNOTURB			44	5.818	0.160	2.75	5.300	6.300
2024-042	40 SIEMENS DI			82	5.794	0.128	2.21	5.400	6.200
2024-042	46 ARCHITECT			19	5.626	0.129	2.30	5.200	6.000
2024-042	48 ATELLICA			12	5.583	0.128	2.29	5.200	6.000
2024-043	12 COBAS/INT.			27	8.526	0.296	3.48	7.600	9.400
2024-043	14 IMMUNOTUR.			17	8.906	0.392	4.40	7.700	10.100

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 95 GLYCOHEMOGLOBINE					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
2024-043	22	VITROS		53	8.408	0.216	2.57	7.800	9.100		
2024-043	31	IMMUNOTURB		44	8.541	0.308	3.61	7.600	9.500		
2024-043	40	SIEMENS DI		82	8.758	0.203	2.32	8.100	9.400		
2024-043	46	ARCHITECT		19	8.205	0.242	2.95	7.500	8.900		
2024-043	48	APELLICA		12	8.083	0.172	2.13	7.600	8.600		
146	GLYCOHEMOGLOBIN		CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 3 SD OR 25 % {LOWER}							
2024-044	12	COBAS/INT.		27	5.807	0.207	3.57	5.200	6.400		
2024-044	14	IMMUNOTUR.		17	5.947	0.168	2.83	5.400	6.500		
2024-044	22	VITROS		53	5.723	0.096	1.69	5.400	6.000		
2024-044	31	IMMUNOTURB		44	5.814	0.187	3.21	5.300	6.400		
2024-044	40	SIEMENS DI		82	5.806	0.137	2.36	5.400	6.200		
2024-044	46	ARCHITECT		19	5.626	0.129	2.30	5.200	6.000		
2024-044	48	APELLICA		12	5.567	0.143	2.58	5.100	6.000		
2024-045	12	COBAS/INT.		27	8.535	0.240	2.81	7.800	9.300		
2024-045	14	IMMUNOTUR.		17	8.841	0.324	3.66	7.900	9.800		
2024-045	22	VITROS		53	8.402	0.199	2.36	7.800	9.000		
2024-045	31	IMMUNOTURB		44	8.542	0.317	3.71	7.600	9.500		
2024-045	40	SIEMENS DI		82	8.770	0.230	2.62	8.100	9.500		
2024-045	46	ARCHITECT		19	8.200	0.243	2.96	7.500	8.900		
2024-045	48	APELLICA		12	8.075	0.179	2.21	7.500	8.600		

SPEC: 10 CHEMISTRY			SUB: 60 SPECIAL TESTS			GRP: 99 Vitamin D					
ANALYTE											
SAMPLE	METHOD	SYST/INST	REAGENTS	NO. PART LABS	TARGET VALUE	STANDARD DEVIATION	% CV	ACCEPTABLE LOW	RANGE HIGH		
178	Vitamin D		EVALUATION CRITERIA: TARGET VALUE 20 %								
2024-261	3	VITROS		47	20.553	3.407	16.58	16.000	25.000		
2024-261	5	ROCHE E		35	6.000	0.000	0.00	5.000	7.000		
2024-261	9	BECK.COUL.		50	14.061	1.921	13.66	11.000	17.000		

**Participant Summary**

**MONTH 2 OF YEAR 2024**

SPEC: 10 CHEMISTRY		SUB: 60 SPECIAL TESTS		GRP: 99 Vitamin D						
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE	
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH	
2024-261	11	ARC		18	8.667	0.667	7.69	7.000	10.000	
2024-261	25	S. DIME		35	10.559	1.718	16.27	8.000	13.000	
2024-261	27	APELLICA		10	13.500	2.202	16.31	11.000	16.000	
178 Vitamin D			CLIA TEST ID #: 0	EVALUATION CRITERIA: TARGET VALUE 20 %						
2024-262	3	VITROS		47	120.319	5.344	4.44	96.000	144.000	
2024-262	5	ROCHE E		35	78.000	5.684	7.29	62.000	94.000	
2024-262	9	BECK.COUL.		50	88.286	7.685	8.70	71.000	106.000	
2024-262	11	ARC		18	73.056	4.453	6.10	58.000	88.000	
2024-262	25	S. DIME		35	68.059	3.918	5.76	54.000	82.000	
2024-262	27	APELLICA		10	125.400	5.426	4.33	100.000	150.000	
2024-263	3	VITROS		47	106.128	7.070	6.66	85.000	127.000	
2024-263	5	ROCHE E		35	56.829	3.806	6.70	45.000	68.000	
2024-263	9	BECK.COUL.		50	76.265	6.666	8.74	61.000	92.000	
2024-263	11	ARC		18	58.471	2.893	4.95	47.000	70.000	
2024-263	25	S. DIME		35	56.176	4.011	7.14	45.000	67.000	
2024-263	27	APELLICA		10	105.900	3.300	3.12	85.000	127.000	
2024-264	3	VITROS		47	54.413	5.157	9.48	44.000	65.000	
2024-264	5	ROCHE E		35	16.829	2.535	15.07	13.000	20.000	
2024-264	9	BECK.COUL.		50	38.429	3.338	8.69	31.000	46.000	
2024-264	11	ARC		18	24.944	0.848	3.40	20.000	30.000	
2024-264	25	S. DIME		35	25.647	2.699	10.53	21.000	31.000	
2024-264	27	APELLICA		10	51.700	12.546	24.27	41.000	62.000	
2024-265	3	VITROS		47	83.391	6.876	8.25	67.000	100.000	
2024-265	5	ROCHE E		35	35.286	4.075	11.55	28.000	42.000	
2024-265	9	BECK.COUL.		50	59.469	5.245	8.82	48.000	71.000	
2024-265	11	ARC		18	42.944	1.810	4.21	34.000	52.000	
2024-265	25	S. DIME		35	41.735	3.673	8.80	33.000	50.000	

### Participant Summary

MONTH 2 OF YEAR 2024

---

SPEC: 10 CHEMISTRY	SUB: 60 SPECIAL TESTS	GRP: 99 Vitamin D							
ANALYTE				NO. PART	TARGET	STANDARD	%	ACCEPTABLE	RANGE
SAMPLE	METHOD	SYST/INST	REAGENTS	LABS	VALUE	DEVIATION	CV	LOW	HIGH
2024-265	27 ATELLICA			10	80.700	10.070	12.48	65.000	97.000

---